<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:ird="http://opusgtx.com/20251231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ird-20251231.xsd" xlink:type="simple"/>
    <context id="c20250101to20251231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c20260305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
        </entity>
        <period>
            <instant>2026-03-05</instant>
        </period>
    </context>
    <context id="c20251231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_StatementClassOfStockAxis_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20251231_StatementClassOfStockAxis_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20231231_StatementClassOfStockAxis_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_StatementClassOfStockAxis_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_StatementClassOfStockAxis_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20241231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20251231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20241231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20251231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251001to20251231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20241231_RestatementAxis_RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20260201to20260218_SubsequentEventTypeAxis_SubsequentEventMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-02-18</endDate>
        </period>
    </context>
    <context id="c20241231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20251231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20251231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_DerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_DerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_DerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_OtherDerivativeLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ird:OtherDerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_OtherDerivativeLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ird:OtherDerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_OtherDerivativeLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ird:OtherDerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_DerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_OtherDerivativeLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ird:OtherDerivativeLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20250101to20251231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_OtherDerivativeLiabilitiesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ird:OtherDerivativeLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_OtherDerivativeLiabilitiesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ird:OtherDerivativeLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_OtherDerivativeLiabilitiesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ird:OtherDerivativeLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_OtherDerivativeLiabilitiesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ird:OtherDerivativeLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_OtherDerivativeLiabilitiesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ird:OtherDerivativeLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20251231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20241022to20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ird:OpusGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-22</startDate>
            <endDate>2024-10-22</endDate>
        </period>
    </context>
    <context id="c20241022to20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember_StatementClassOfStockAxis_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ird:OpusGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-22</startDate>
            <endDate>2024-10-22</endDate>
        </period>
    </context>
    <context id="c20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember_StatementClassOfStockAxis_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ird:OpusGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-22</instant>
        </period>
    </context>
    <context id="c20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ird:OpusGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-22</instant>
        </period>
    </context>
    <context id="c20241022to20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ird:OpusGeneticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-22</startDate>
            <endDate>2024-10-22</endDate>
        </period>
    </context>
    <context id="c20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ird:OpusGeneticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-22</instant>
        </period>
    </context>
    <context id="c20241022to20241022_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-22</startDate>
            <endDate>2024-10-22</endDate>
        </period>
    </context>
    <context id="c20241022to20241022_StatementClassOfStockAxis_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-22</startDate>
            <endDate>2024-10-22</endDate>
        </period>
    </context>
    <context id="c20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ird:OpusGeneticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-22</instant>
        </period>
    </context>
    <context id="c20201105_BusinessAcquisitionAxis_RexahnStockholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ird:RexahnStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-05</instant>
        </period>
    </context>
    <context id="c20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c20220615to20220615_HealthCareOrganizationRevenueSourcesAxis_DevelopmentRegulatoryAndCommercialMilestoneMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_UniversityOfPennsylvaniaLCA5RDH12LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">ird:DevelopmentRegulatoryAndCommercialMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:UniversityOfPennsylvaniaLCA5RDH12LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="c20180606to20180606_HealthCareOrganizationRevenueSourcesAxis_DevelopmentRegulatoryAndCommercialMilestoneMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_PennAndUFRHOLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">ird:DevelopmentRegulatoryAndCommercialMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:PennAndUFRHOLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-06</startDate>
            <endDate>2018-06-06</endDate>
        </period>
    </context>
    <context id="c20190410to20190410_HealthCareOrganizationRevenueSourcesAxis_CommercialMilestonesMember_ProductOrServiceAxis_FirstLicensedProductMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_PennAndUniversityOfFloridaBEST1LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ird:FirstLicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">ird:CommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:PennAndUniversityOfFloridaBEST1LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-10</startDate>
            <endDate>2019-04-10</endDate>
        </period>
    </context>
    <context id="c20221223to20221223_HealthCareOrganizationRevenueSourcesAxis_CommercialMilestonesMember_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_BEST1ProgramMember_TypeOfArrangementAxis_IvericAssetPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">ird:CommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:BEST1ProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:IvericAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-23</startDate>
            <endDate>2022-12-23</endDate>
        </period>
    </context>
    <context id="c20211109to20211109_HealthCareOrganizationRevenueSourcesAxis_DevelopmentRegulatoryAndCommercialMilestoneMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_MassachusettsEyeAndEarInfirmaryLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">ird:DevelopmentRegulatoryAndCommercialMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:MassachusettsEyeAndEarInfirmaryLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-09</startDate>
            <endDate>2021-11-09</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_HealthCareOrganizationRevenueSourcesAxis_DevelopmentRegulatoryAndCommercialMilestoneMember_TypeOfArrangementAxis_UniversityOfPennsylvaniaLCA5RDH12LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">ird:DevelopmentRegulatoryAndCommercialMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:UniversityOfPennsylvaniaLCA5RDH12LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_HealthCareOrganizationRevenueSourcesAxis_CommercialMilestonesMember_SubsidiarySaleOfStockAxis_BEST1ProgramMember_TypeOfArrangementAxis_IvericAssetPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">ird:CommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:BEST1ProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:IvericAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_HealthCareOrganizationRevenueSourcesAxis_CommercialMilestonesMember_ProductOrServiceAxis_FirstLicensedProductMember_TypeOfArrangementAxis_PennAndUniversityOfFloridaBEST1LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ird:FirstLicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">ird:CommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:PennAndUniversityOfFloridaBEST1LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250701to20250701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-07-01</endDate>
        </period>
    </context>
    <context id="c20240411to20240411_AwardTypeAxis_RestrictedStockUnitsRSUMember_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-11</startDate>
            <endDate>2024-04-11</endDate>
        </period>
    </context>
    <context id="c20240411to20240411_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-11</startDate>
            <endDate>2024-04-11</endDate>
        </period>
    </context>
    <context id="c20241022to20241022_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_BoardMemberMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ird:BoardMemberMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-22</startDate>
            <endDate>2024-10-22</endDate>
        </period>
    </context>
    <context id="c20240511to20240511_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-11</startDate>
            <endDate>2024-05-11</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_TitleOfIndividualAxis_BoardMemberMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ird:BoardMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_TitleOfIndividualAxis_BoardMemberMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ird:BoardMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20251231_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20241231_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20250321to20250321_SubsidiarySaleOfStockAxis_March2025PrivatePlacementMember_TitleOfIndividualAxis_ChairmanOfTheBoardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ird:ChairmanOfTheBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:March2025PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-21</startDate>
            <endDate>2025-03-21</endDate>
        </period>
    </context>
    <context id="c20250321to20250321_SubsidiarySaleOfStockAxis_March2025PrivatePlacementMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:March2025PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-21</startDate>
            <endDate>2025-03-21</endDate>
        </period>
    </context>
    <context id="c20250825to20250825_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-25</startDate>
            <endDate>2025-08-25</endDate>
        </period>
    </context>
    <context id="c20250825to20250825_RelatedPartyTransactionsByRelatedPartyAxis_SeanAinsworthMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ird:SeanAinsworthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-25</startDate>
            <endDate>2025-08-25</endDate>
        </period>
    </context>
    <context id="c20250825to20250825_RelatedPartyTransactionsByRelatedPartyAxis_CamGallagherMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ird:CamGallagherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-25</startDate>
            <endDate>2025-08-25</endDate>
        </period>
    </context>
    <context id="c20220825_RelatedPartyTransactionAxis_BindingLetterAgreement2022Member_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ird:BindingLetterAgreement2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ird:FoundationFightingBlindnessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-25</instant>
        </period>
    </context>
    <context id="c20250527_RelatedPartyTransactionAxis_LetterAgreement2025Member_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ird:LetterAgreement2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ird:FoundationFightingBlindnessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-27</instant>
        </period>
    </context>
    <context id="c20220825to20220825_RelatedPartyTransactionAxis_BindingLetterAgreement2022Member_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ird:BindingLetterAgreement2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ird:FoundationFightingBlindnessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-25</startDate>
            <endDate>2022-08-25</endDate>
        </period>
    </context>
    <context id="c20250527to20250527_RelatedPartyTransactionAxis_LetterAgreement2025Member_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ird:LetterAgreement2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ird:FoundationFightingBlindnessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-27</startDate>
            <endDate>2025-05-27</endDate>
        </period>
    </context>
    <context id="c20250527to20250527_RelatedPartyTransactionAxis_BindingLetterAgreement2022Member_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ird:BindingLetterAgreement2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ird:FoundationFightingBlindnessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-27</startDate>
            <endDate>2025-05-27</endDate>
        </period>
    </context>
    <context id="c20250527_RelatedPartyTransactionAxis_BindingLetterAgreement2022Member_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ird:BindingLetterAgreement2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ird:FoundationFightingBlindnessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-27</instant>
        </period>
    </context>
    <context id="c20250101to20251231_RelatedPartyTransactionAxis_LetterAgreement2025Member_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ird:LetterAgreement2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ird:FoundationFightingBlindnessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250630_RelatedPartyTransactionAxis_LetterAgreement2025Member_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ird:LetterAgreement2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ird:FoundationFightingBlindnessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c20250613_RelatedPartyTransactionAxis_FoundationFightingBlindnessRetinalDegenerationFundAgreementMember_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ird:FoundationFightingBlindnessRetinalDegenerationFundAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ird:FoundationFightingBlindnessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-13</instant>
        </period>
    </context>
    <context id="c20250630_RelatedPartyTransactionAxis_FoundationFightingBlindnessRetinalDegenerationFundAgreementMember_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ird:FoundationFightingBlindnessRetinalDegenerationFundAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ird:FoundationFightingBlindnessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c20251231_RelatedPartyTransactionAxis_FoundationFightingBlindnessRetinalDegenerationFundAgreementMember_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ird:FoundationFightingBlindnessRetinalDegenerationFundAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ird:FoundationFightingBlindnessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20250613to20250613_RelatedPartyTransactionAxis_FoundationFightingBlindnessRetinalDegenerationFundAgreementMember_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ird:FoundationFightingBlindnessRetinalDegenerationFundAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ird:FoundationFightingBlindnessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-13</startDate>
            <endDate>2025-06-13</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_RelatedPartyTransactionAxis_FoundationFightingBlindnessRetinalDegenerationFundAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ird:FoundationFightingBlindnessRetinalDegenerationFundAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20251231_RelatedPartyTransactionAxis_FoundationFightingBlindnessRetinalDegenerationFundAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ird:FoundationFightingBlindnessRetinalDegenerationFundAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20241022_StatementClassOfStockAxis_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-22</instant>
        </period>
    </context>
    <context id="c20250430_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="c20250505_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-05</instant>
        </period>
    </context>
    <context id="c20251106to20251106_SubsidiarySaleOfStockAxis_November2025RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:November2025RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-06</startDate>
            <endDate>2025-11-06</endDate>
        </period>
    </context>
    <context id="c20251106to20251106_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_November2025RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:November2025RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-06</startDate>
            <endDate>2025-11-06</endDate>
        </period>
    </context>
    <context id="c20251106_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_November2025RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:November2025RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-06</instant>
        </period>
    </context>
    <context id="c20251106_FinancialInstrumentAxis_PreFundedRDOWarrantsMember_SubsidiarySaleOfStockAxis_November2025RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ird:PreFundedRDOWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:November2025RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-06</instant>
        </period>
    </context>
    <context id="c20250321to20250321_SubsidiarySaleOfStockAxis_PrivateOfferingMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:PrivateOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-21</startDate>
            <endDate>2025-03-21</endDate>
        </period>
    </context>
    <context id="c20250321to20250321_SubsidiarySaleOfStockAxis_PrivateOfferingMember_TitleOfIndividualAxis_ChairmanOfTheBoardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ird:ChairmanOfTheBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:PrivateOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-21</startDate>
            <endDate>2025-03-21</endDate>
        </period>
    </context>
    <context id="c20250321to20250321_SubsidiarySaleOfStockAxis_UnderwrittenPublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-21</startDate>
            <endDate>2025-03-21</endDate>
        </period>
    </context>
    <context id="c20250321_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:March2025PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-21</instant>
        </period>
    </context>
    <context id="c20250321_ClassOfWarrantOrRightAxis_March2025WarrantsMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:March2025WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-21</instant>
        </period>
    </context>
    <context id="c20250321_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-21</instant>
        </period>
    </context>
    <context id="c20250321_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember_TitleOfIndividualAxis_ChairmanOfTheBoardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ird:ChairmanOfTheBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:March2025PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-21</instant>
        </period>
    </context>
    <context id="c20250321_ClassOfWarrantOrRightAxis_March2025WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:March2025WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-21</instant>
        </period>
    </context>
    <context id="c20250321_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:March2025PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-21</instant>
        </period>
    </context>
    <context id="c20251231_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:March2025PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20250101to20251231_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:March2025PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250324to20250324_SubsidiarySaleOfStockAxis_March2025FinancingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:March2025FinancingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-24</startDate>
            <endDate>2025-03-24</endDate>
        </period>
    </context>
    <context id="c20251231_ClassOfWarrantOrRightAxis_March2025WarrantsMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:March2025WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20250321_ClassOfWarrantOrRightAxis_March2025WarrantsMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:March2025WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-21</instant>
        </period>
    </context>
    <context id="c20250324_ClassOfWarrantOrRightAxis_March2025WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:March2025WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-24</instant>
        </period>
    </context>
    <context id="c20251231_ClassOfWarrantOrRightAxis_March2025WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:March2025WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20250101to20251231_ClassOfWarrantOrRightAxis_March2025WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:March2025WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_ClassOfWarrantOrRightAxis_March2025WarrantsMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:March2025WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250324to20250324_ClassOfWarrantOrRightAxis_March2025WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:March2025WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-24</startDate>
            <endDate>2025-03-24</endDate>
        </period>
    </context>
    <context id="c20251231_ClassOfWarrantOrRightAxis_March2025WarrantsMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:March2025WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20250324_ClassOfWarrantOrRightAxis_March2025WarrantsMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:March2025WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-24</instant>
        </period>
    </context>
    <context id="c20250321_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:March2025PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-21</instant>
        </period>
    </context>
    <context id="c20251231_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:March2025PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20250324_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:March2025PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-24</instant>
        </period>
    </context>
    <context id="c20251231_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:March2025PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20250101to20251231_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:March2025PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250324to20250324_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:March2025PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-24</startDate>
            <endDate>2025-03-24</endDate>
        </period>
    </context>
    <context id="c20251231_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember_RangeAxis_MinimumMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:March2025PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20250324_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:March2025PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-24</instant>
        </period>
    </context>
    <context id="c20250113to20250113_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:AtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-13</startDate>
            <endDate>2025-01-13</endDate>
        </period>
    </context>
    <context id="c20250311to20250311_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:AtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-11</startDate>
            <endDate>2025-03-11</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:AtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20210311to20251231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:AtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-11</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:AtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20230810_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-10</instant>
        </period>
    </context>
    <context id="c20250101to20251231_SubsidiarySaleOfStockAxis_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_SubsidiarySaleOfStockAxis_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230811to20250402_SubsidiarySaleOfStockAxis_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-11</startDate>
            <endDate>2025-04-02</endDate>
        </period>
    </context>
    <context id="c20230801to20230810_SubsidiarySaleOfStockAxis_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-10</endDate>
        </period>
    </context>
    <context id="c20210608to20210608_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="c20210608_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-08</instant>
        </period>
    </context>
    <context id="c20210608_FinancialInstrumentAxis_RDOWarrantsMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ird:RDOWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-08</instant>
        </period>
    </context>
    <context id="c20251231_FinancialInstrumentAxis_RDOWarrantsMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ird:RDOWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20250101to20251231_FinancialInstrumentAxis_RDOWarrantsMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ird:RDOWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20200629to20200629_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-06-29</endDate>
        </period>
    </context>
    <context id="c20200629to20200629_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-06-29</endDate>
        </period>
    </context>
    <context id="c20200629to20200629_BusinessAcquisitionAxis_RexahnStockholdersMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ird:RexahnStockholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-06-29</endDate>
        </period>
    </context>
    <context id="c20200629to20200629_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-06-29</endDate>
        </period>
    </context>
    <context id="c20201119_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-19</instant>
        </period>
    </context>
    <context id="c20251231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20241231_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20250101to20251231_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20251231_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_ClassOfWarrantOrRightAxis_WarrantExercisePriceThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:WarrantExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_ClassOfWarrantOrRightAxis_WarrantExercisePriceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:WarrantExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_ClassOfWarrantOrRightAxis_WarrantExercisePriceOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:WarrantExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_SubsidiarySaleOfStockAxis_November2025RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:November2025RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20250321_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_SubsidiarySaleOfStockAxis_March2025FinancingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ird:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:March2025FinancingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-21</instant>
        </period>
    </context>
    <context id="c20250101to20251231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20250522_PlanNameAxis_InducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-22</instant>
        </period>
    </context>
    <context id="c20250808_PlanNameAxis_InducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-08</instant>
        </period>
    </context>
    <context id="c20191231_PlanNameAxis_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20201130_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="c20201130_PlanNameAxis_EquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="c20201105_PlanNameAxis_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-05</instant>
        </period>
    </context>
    <context id="c20250101to20251231_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_PlanNameAxis_EquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250101_PlanNameAxis_EvergreenProvisionPlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:EvergreenProvisionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_PlanNameAxis_EquityIncentivePlan2018Member_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_PlanNameAxis_EquityIncentivePlan2018Member_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20231231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20251231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20241231_PlanNameAxis_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20251231_PlanNameAxis_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20250101to20251231_PlanNameAxis_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_PlanNameAxis_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20251231_PlanNameAxis_InducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_PlanNameAxis_EvergreenProvisionPlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ird:EvergreenProvisionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20200101to20201231_RelatedPartyTransactionAxis_ApexianSublicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ird:ApexianSublicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_HealthCareOrganizationRevenueSourcesAxis_SalesMilestonesMember_RangeAxis_MaximumMember_RelatedPartyTransactionAxis_ApexianSublicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">ird:SalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ird:ApexianSublicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_HealthCareOrganizationRevenueSourcesAxis_DevelopmentAndRegulatoryMilestonesMember_RangeAxis_MaximumMember_RelatedPartyTransactionAxis_ApexianSublicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">ird:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ird:ApexianSublicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20221106to20221106_TypeOfArrangementAxis_ViatrisLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:ViatrisLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-06</startDate>
            <endDate>2022-11-06</endDate>
        </period>
    </context>
    <context id="c20221101to20221130_TypeOfArrangementAxis_ViatrisLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:ViatrisLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="c20221106_TypeOfArrangementAxis_ViatrisLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:ViatrisLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-06</instant>
        </period>
    </context>
    <context id="c20251231_TypeOfArrangementAxis_ViatrisLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:ViatrisLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20250101to20251231_TypeOfArrangementAxis_ViatrisLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:ViatrisLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20230930_HealthCareOrganizationRevenueSourcesAxis_SalesMilestonesMember_TypeOfArrangementAxis_ViatrisLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">ird:SalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:ViatrisLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c20231231_TypeOfArrangementAxis_ViatrisLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:ViatrisLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_TypeOfArrangementAxis_ViatrisLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:ViatrisLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_TypeOfArrangementAxis_ViatrisLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:ViatrisLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_HealthCareOrganizationRevenueSourcesAxis_SalesMilestonesMember_TypeOfArrangementAxis_ViatrisLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">ird:SalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:ViatrisLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ProductOrServiceAxis_LicenseTransferFeeMember_TypeOfArrangementAxis_ViatrisLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ird:LicenseTransferFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:ViatrisLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_ProductOrServiceAxis_LicenseTransferFeeMember_TypeOfArrangementAxis_ViatrisLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ird:LicenseTransferFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:ViatrisLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_TypeOfArrangementAxis_BioSenseLicenseAndAssignmentsAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:BioSenseLicenseAndAssignmentsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_TypeOfArrangementAxis_ProcessaLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:ProcessaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20240901to20240930_TypeOfArrangementAxis_SBIRGrantAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:SBIRGrantAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20250722_TypeOfArrangementAxis_RDH12AgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:RDH12AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-22</instant>
        </period>
    </context>
    <context id="c20250101to20251231_TypeOfArrangementAxis_SBIRGrantAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:SBIRGrantAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_TypeOfArrangementAxis_SBIRGrantAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ird:SBIRGrantAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20251231_BusinessAcquisitionAxis_RexahnStockholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ird:RexahnStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_BusinessAcquisitionAxis_OpusGeneticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ird:OpusGeneticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20211001to20211001_RetirementPlanNameAxis_RetirementPlan401KMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">ird:RetirementPlan401KMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_RetirementPlanNameAxis_RetirementPlan401KMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">ird:RetirementPlan401KMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_RetirementPlanNameAxis_RetirementPlan401KMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">ird:RetirementPlan401KMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20260312to20260312_SubsequentEventTypeAxis_SubsequentEventMember_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ird:AtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-12</startDate>
            <endDate>2026-03-12</endDate>
        </period>
    </context>
    <context id="c20260213to20260213_SubsequentEventTypeAxis_SubsequentEventMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-13</startDate>
            <endDate>2026-02-13</endDate>
        </period>
    </context>
    <context id="c20260213_StatementClassOfStockAxis_SeriesBPreferredStockMember_SubsequentEventTypeAxis_SubsequentEventMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-13</instant>
        </period>
    </context>
    <context id="c20260213_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-13</instant>
        </period>
    </context>
    <unit id="U001">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U002">
        <measure>shares</measure>
    </unit>
    <unit id="U003">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U004">
        <measure>ird:Segment</measure>
    </unit>
    <unit id="U005">
        <measure>ird:Asset</measure>
    </unit>
    <unit id="U006">
        <measure>pure</measure>
    </unit>
    <unit id="U007">
        <measure>ird:Right</measure>
    </unit>
    <unit id="U008">
        <measure>ird:Milestone</measure>
    </unit>
    <unit id="U009">
        <measure>ird:Installment</measure>
    </unit>
    <unit id="U010">
        <measure>ird:Director</measure>
    </unit>
    <unit id="U011">
        <measure>ird:Performanceobligation</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="c20250101to20251231"
      id="Fact_0974605e0bc94cba975265ce8678e7aa">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="c20250101to20251231"
      id="Fact_17a485ecbf2f4ee68ee1d0a149806e0e">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="c20250101to20251231"
      id="Fact_f39d5c7b3fe8496ebd2b180017680e97">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="c20250101to20251231"
      id="Fact_7f7ebc5d1fc7421f8d443d013b107fbf">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="c20250101to20251231"
      id="Fact_7145a8e389ef4f3d96178626f6738b86">0001228627</dei:EntityCentralIndexKey>
    <ird:NumberOfRDOWarrantsSoldAtOfferingPrice
      contextRef="c20210608_FinancialInstrumentAxis_RDOWarrantsMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"
      decimals="2"
      id="Fact_d090cab10f4f4fabacc37ae2d3b591d3"
      unitRef="U002">0.50</ird:NumberOfRDOWarrantsSoldAtOfferingPrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="c20250101to20251231_PlanNameAxis_EquityIncentivePlan2018Member_RangeAxis_MinimumMember"
      id="Fact_5ad805ae5165416189740367b2bde6bb">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MinimumMember"
      id="Fact_058d91f000234303b1e7e8999ccc8b9c">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MinimumMember"
      id="Fact_1ef3378be6904988a15aead682a873b1">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231_TypeOfArrangementAxis_SBIRGrantAgreementMember"
      decimals="-6"
      id="Fact_75a0e2cc0bbd464db646ff9437462081"
      unitRef="U001">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration
      contextRef="c20250101to20251231"
      id="Fact_61ebfbf864f6406981d1e8914baf9657">http://xbrl.sec.gov/stpr/2025#NC</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalJurisdictionContributionGreaterThan50PercentTaxEffectExtensibleEnumeration>
    <us-gaap:TaxJurisdictionOfDomicileExtensibleEnumeration
      contextRef="c20250101to20251231"
      id="Fact_7b3f3f4f97694e3e8c468e749298a8ce">http://xbrl.sec.gov/country/2025#US</us-gaap:TaxJurisdictionOfDomicileExtensibleEnumeration>
    <dei:AuditorFirmId
      contextRef="c20250101to20251231"
      id="Fact_81e57d914bf24bcf8cf39bb8013284ec">42</dei:AuditorFirmId>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c20251231"
      id="Fact_7d1ed90daac6412988e06e18a3d1a35c"
      unitRef="U001"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c20241231"
      id="Fact_30352ae9a45242548bba788b48f7b431"
      unitRef="U001"
      xsi:nil="true"/>
    <us-gaap:LeaseExpirationDate1
      contextRef="c20250101to20251231"
      id="Fact_a289e5cb1ce143a0827898c97406573a">2025-07-31</us-gaap:LeaseExpirationDate1>
    <dei:DocumentType
      contextRef="c20250101to20251231"
      id="Fact_2feb9e38a5ed4af0ac44df600666aeab">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="c20250101to20251231"
      id="Fact_ae5ab4afe1dd46778109c120a0cf0909">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="c20250101to20251231"
      id="Fact_0a4ebffc1f874132866fcd23bacd82b8">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="c20250101to20251231"
      id="Fact_a1c623a0fdd04c1f8191ed6d902ef4fe">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="c20250101to20251231"
      id="Fact_2d6fe56c55004e5a8132f4af81fd2343">001-34079</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="c20250101to20251231"
      id="Fact_3080f8b903b843148567900a4b8a0d9c">Opus Genetics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20250101to20251231"
      id="Fact_e4d2c40aa00e48b385b346f4c2d1d288">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20250101to20251231"
      id="Fact_19139caa0bbe40319b02d8ec6f7b99c7">11-3516358</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20250101to20251231"
      id="Fact_bc315b80192544db885ea0a5a5c41802">8 Davis Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20250101to20251231"
      id="Fact_0821d80d9e314bd58e4754a3ed709f97">Suite 220</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20250101to20251231"
      id="Fact_8ff5f51a4a4f4e0386613dd959bc6919">Durham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20250101to20251231"
      id="Fact_5ae536366ff94b648568b8e0206b643a">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20250101to20251231"
      id="Fact_de25797ffa0c4ab5b08ae1bb4364ad8e">27713</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20250101to20251231"
      id="Fact_ef0c9c9371b74c59a9ac10d688aa28f8">984</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20250101to20251231"
      id="Fact_2044d77adb7f46459b7f3de8639bc3df">884-6030</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="c20250101to20251231"
      id="Fact_16c367093e2d49d1950e5114e0a8bfb8">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20250101to20251231"
      id="Fact_d2179a5b40e9475cb440effecd3ece01">IRD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20250101to20251231"
      id="Fact_3bb7530b54414281b91bed0a9708d8b0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="c20250101to20251231"
      id="Fact_92427b40b0344a11833d7ca1adfb2c3c">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="c20250101to20251231"
      id="Fact_27ff3ed0656645c4ae10eb0e6ac1d53f">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="c20250101to20251231"
      id="Fact_4cfbfe69aac84b16a01b48ec1c943590">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="c20250101to20251231"
      id="Fact_d6f3616b818b4ef0aca958c58d007d05">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="c20250101to20251231"
      id="Fact_f59e0fe631b244a7bbeb826ac30d009d">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="c20250101to20251231"
      id="Fact_0a69127d488e4b389b0c380906612196">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20250101to20251231"
      id="Fact_73d6e7973910492b8379cf26f4b3ac9f">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="c20250101to20251231"
      id="Fact_ff170871a18f41f1a199c2a70d73e72a">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="c20250101to20251231"
      id="Fact_ab74660aba434453a7ec9b747e405430">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="c20250101to20251231"
      id="Fact_0b0e960a8e164fafa3e2e2247642dcfa">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="c20250630"
      decimals="-5"
      id="Fact_20a5a07ece5e4522a3b177208d19b159"
      unitRef="U001">45900000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c20260305"
      decimals="INF"
      id="Fact_c55d36006ecb4cadaf378e997faca894"
      unitRef="U002">71149045</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="c20250101to20251231"
      id="Text_06ce9b7766bf430fb576ef6e94cf60f0">
&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Risk Management and Strategy&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 27pt;"&gt;The Company has adopted a cybersecurity risk management program that includes processes designed to identify, assess, manage, and monitor risks from
      cybersecurity threats. We have integrated cybersecurity risk management into our broader risk management framework to promote a
      company-wide culture of cybersecurity awareness and risk management. &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"&gt;These processes include conducting an assessment of internal and external threats to the security, confidentiality, integrity and availability of
      Company data and systems along with other material risks to Company operations, at least annually and whenever there are material changes to the Company&#x2019;s systems or operations, and responding to risks identified. The Company&#x2019;s cybersecurity and risk
      management program is based on National Institute of Standards and Technology (NIST) frameworks. As part of our risk management process, the Company also engages outside providers to conduct periodic security assessments. As part of our third-party risk management program, we conduct assessments of vendor cybersecurity risks, including risks associated with our cloud vendors and other third parties.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;&lt;br/&gt;
      &lt;br/&gt;
    &lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Cybersecurity Threats&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 27pt;"&gt;As of the date of this report, we have not identified any risks from a cybersecurity threat or incident that we believe has or is reasonably likely to have a material effect on our business strategy, results of operations, or financial condition. Despite our continuing efforts, we cannot
      guarantee that our cybersecurity safeguards will prevent breaches or breakdowns of our or our third-party service providers&#x2019; information technology systems, particularly in the face of continually evolving cybersecurity threats and increasingly
      sophisticated threat actors. For more information, see Item 1A Risk Factors, &#x201c;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt;Our business and operations would suffer in the event of system failures or unplanned
        events, including cyber incidents, network security breaches, service interruptions, or data corruption&lt;/span&gt;.&#x201d;&lt;/div&gt;
</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="c20250101to20251231"
      id="Fact_a95353a8f9734f9c973fc7d2c2a73498">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="c20250101to20251231"
      id="Text_a3fea0f9c8b841608c34eac2254f8a2b">&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"&gt;These processes include conducting an assessment of internal and external threats to the security, confidentiality, integrity and availability of
      Company data and systems along with other material risks to Company operations, at least annually and whenever there are material changes to the Company&#x2019;s systems or operations, and responding to risks identified. The Company&#x2019;s cybersecurity and risk
      management program is based on National Institute of Standards and Technology (NIST) frameworks. As part of our risk management process, the Company also engages outside providers to conduct periodic security assessments. As part of our third-party risk management program, we conduct assessments of vendor cybersecurity risks, including risks associated with our cloud vendors and other third parties.&lt;/span&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="c20250101to20251231"
      id="Fact_65bc9a9eef4c44118054a82800b86e40">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="c20250101to20251231"
      id="Fact_c4b1116a6d9c4e73b71f4f410e3926f7">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock
      contextRef="c20250101to20251231"
      id="Text_a30b1a1289ec4555a28f9646aa3b9616">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 27pt;"&gt;As of the date of this report, we have not identified any risks from a cybersecurity threat or incident that we believe has or is reasonably likely to have a material effect on our business strategy, results of operations, or financial condition. Despite our continuing efforts, we cannot
      guarantee that our cybersecurity safeguards will prevent breaches or breakdowns of our or our third-party service providers&#x2019; information technology systems, particularly in the face of continually evolving cybersecurity threats and increasingly
      sophisticated threat actors. For more information, see Item 1A Risk Factors, &#x201c;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"&gt;Our business and operations would suffer in the event of system failures or unplanned
        events, including cyber incidents, network security breaches, service interruptions, or data corruption&lt;/span&gt;.&#x201d;&lt;/div&gt;
</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="c20250101to20251231"
      id="Fact_4c3d8cd7016645f38263651af2954eb9">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="c20250101to20251231"
      id="Text_ea04e940afdc41fabcd2eb2d377fd5e6">
&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt; &lt;br/&gt;
    &lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Governance&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 27pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The cybersecurity risk management program, including the prevention, detection, mitigation, and remediation of cybersecurity incidents, is led by the
      Company&#x2019;s Chief Operating Officer and VP of Accounting in coordination with the Company&#x2019;s IT managed service provider. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt; Both of these
      individuals have experience in overseeing our cybersecurity and information technology programs and have held similar oversight functions in prior roles. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"&gt;We rely heavily on information technology
      consultants for advice and expertise on monitoring evolving industry standards and to monitor our compliance with applicable policies.&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The VP of Accounting reports on cybersecurity matters to the Company&#x2019;s Audit Committee at least annually, as well as any time there are material changes to the Company&#x2019;s systems or operations and material updates are shared at each regular meeting of the full Board.&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"&gt;
      &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The VP of Accounting also reports to the Company&#x2019;s Chief Financial Officer and other members of our senior management as appropriate.&lt;/span&gt; These reports may feature an overall assessment of the Company&#x2019;s compliance with the Company&#x2019;s cybersecurity policies and include topics such as risk assessment, risk management and control decisions, service
      provider arrangements, test results, security incidents and responses, and recommendations for changes and updates to policies and procedures. In addition, the results of any external reviews on our cybersecurity program are reported to senior
      management and the Audit Committee.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="c20250101to20251231"
      id="Text_92965dc0af4d4cc7a316a58d7d124b75">&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The cybersecurity risk management program, including the prevention, detection, mitigation, and remediation of cybersecurity incidents, is led by the
      Company&#x2019;s Chief Operating Officer and VP of Accounting in coordination with the Company&#x2019;s IT managed service provider. &lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="c20250101to20251231"
      id="Text_390d6f99dee5477caf07aacc729f622c">&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The cybersecurity risk management program, including the prevention, detection, mitigation, and remediation of cybersecurity incidents, is led by the
      Company&#x2019;s Chief Operating Officer and VP of Accounting in coordination with the Company&#x2019;s IT managed service provider. &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt; Both of these
      individuals have experience in overseeing our cybersecurity and information technology programs and have held similar oversight functions in prior roles. &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"&gt;We rely heavily on information technology
      consultants for advice and expertise on monitoring evolving industry standards and to monitor our compliance with applicable policies.&#160;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The VP of Accounting reports on cybersecurity matters to the Company&#x2019;s Audit Committee at least annually, as well as any time there are material changes to the Company&#x2019;s systems or operations and material updates are shared at each regular meeting of the full Board.&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The VP of Accounting also reports to the Company&#x2019;s Chief Financial Officer and other members of our senior management as appropriate.&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="c20250101to20251231"
      id="Text_80ae71573c804e6a8e1d62d55d82036c">&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt; Both of these
      individuals have experience in overseeing our cybersecurity and information technology programs and have held similar oversight functions in prior roles. &lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="c20250101to20251231"
      id="Text_0eb8300a9f34485bb6cf8d72d0a33378">&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The VP of Accounting reports on cybersecurity matters to the Company&#x2019;s Audit Committee at least annually, as well as any time there are material changes to the Company&#x2019;s systems or operations and material updates are shared at each regular meeting of the full Board.&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="c20250101to20251231"
      id="Fact_4664c0a2eccf46d4a1c0d66ef06eed4d">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="c20250101to20251231"
      id="Text_e88931594269468da8cc09fbeb57fd5f">&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"&gt;
      &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The VP of Accounting also reports to the Company&#x2019;s Chief Financial Officer and other members of our senior management as appropriate.&lt;/span&gt; These reports may feature an overall assessment of the Company&#x2019;s compliance with the Company&#x2019;s cybersecurity policies and include topics such as risk assessment, risk management and control decisions, service
      provider arrangements, test results, security incidents and responses, and recommendations for changes and updates to policies and procedures. In addition, the results of any external reviews on our cybersecurity program are reported to senior
      management and the Audit Committee.&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="c20250101to20251231"
      id="Text_37331e9b3f0948669a02dffd2deeb9ca">&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The VP of Accounting also reports to the Company&#x2019;s Chief Financial Officer and other members of our senior management as appropriate.&lt;/span&gt; These reports may feature an overall assessment of the Company&#x2019;s compliance with the Company&#x2019;s cybersecurity policies and include topics such as risk assessment, risk management and control decisions, service
      provider arrangements, test results, security incidents and responses, and recommendations for changes and updates to policies and procedures. In addition, the results of any external reviews on our cybersecurity program are reported to senior
      management and the Audit Committee.&lt;/span&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="c20250101to20251231"
      id="Fact_6f4e7e79f07942de8fb303684490c888">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="c20251001to20251231"
      id="Fact_c34141f741f846dd9e010a8c9f22c83d">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="c20251001to20251231"
      id="Fact_0a3e3538166148a2a040a97f4cd9b831">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="c20251001to20251231"
      id="Fact_aab6e9de81344c16950b639d41e68852">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="c20251001to20251231"
      id="Fact_7fd426607caa45468186527a6d526473">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="c20251001to20251231"
      id="Fact_0ff3572a676443b9ad8816402ed340dd">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorName
      contextRef="c20250101to20251231"
      id="Fact_0904f1b8730b482fa6dd4abab9c54373">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="c20250101to20251231"
      id="Fact_ee0bb091765e4044984d86b6cb9994ee">Detroit, Michigan</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20251231"
      decimals="-3"
      id="Fact_ece36568ef2042218f42ee835bf9414e"
      unitRef="U001">45091000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20241231"
      decimals="-3"
      id="Fact_16938cb5f33b432d909cd8767b311e91"
      unitRef="U001">30321000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_0eb91702ba1e4a47b1e64267d532f0b6"
      unitRef="U001">1995000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_5bd7860ef3a1468790436d3b188e0759"
      unitRef="U001">3563000</us-gaap:AccountsReceivableNetCurrent>
    <ird:ContractAssetsAndUnbilledReceivablesCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_58f4c7806f8243978aadfc4130f07a99"
      unitRef="U001">1170000</ird:ContractAssetsAndUnbilledReceivablesCurrent>
    <ird:ContractAssetsAndUnbilledReceivablesCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_5f03c2ba69594e0785aa6a0d407518db"
      unitRef="U001">2209000</ird:ContractAssetsAndUnbilledReceivablesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_542d90459cd747379c9e16f696834334"
      unitRef="U001">1788000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_7c18d20a953f468997e47110c39a1f27"
      unitRef="U001">515000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ShortTermInvestments
      contextRef="c20251231"
      decimals="-3"
      id="Fact_f3761c753b504af2a508f55a0685003f"
      unitRef="U001">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="c20241231"
      decimals="-3"
      id="Fact_7b81df4fb4444886884a59045fe3762b"
      unitRef="U001">2000</us-gaap:ShortTermInvestments>
    <us-gaap:AssetsCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_289bb981ec8c413395e0a43e0e048cf5"
      unitRef="U001">50044000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_f6c29efaeb454e80989cd2545133f6be"
      unitRef="U001">36610000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20251231"
      decimals="-3"
      id="Fact_f79b14b2abf94f4fbbe4d1504f59ec83"
      unitRef="U001">199000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20241231"
      decimals="-3"
      id="Fact_771d6a140ed8427eacc01e47878b9018"
      unitRef="U001">252000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets
      contextRef="c20251231"
      decimals="-3"
      id="Fact_e5a3aea16fe14237a52f656b9163c4b6"
      unitRef="U001">50243000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20241231"
      decimals="-3"
      id="Fact_91df733e1e9448b2a25fb6579ca10db1"
      unitRef="U001">36862000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_399545756ba2433cbf998a2bb2cfded3"
      unitRef="U001">3293000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_9fe7666aa49743a2a9edf1d929533f40"
      unitRef="U001">3148000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="c20251231"
      decimals="-3"
      id="Fact_b9da263cacba4dabb121b237a57b0651"
      unitRef="U001">4488000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="c20241231"
      decimals="-3"
      id="Fact_31425c1803da42c997c8f9d142596337"
      unitRef="U001">8147000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_b421575432284ac09bfa3b3341fa5c59"
      unitRef="U001">7781000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_21d566e453c94a78bb73c1a6a6886a4f"
      unitRef="U001">11295000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_13525b2f24704e9c8be29f7721a09202"
      unitRef="U001">25985000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_e048b20ce48d4ca5b46c5cc17ed26dff"
      unitRef="U001">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_049beed6f1f64a01a147429dc97086a2"
      unitRef="U001">1129000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_ed8d0e3231fe4a3bb8fb1c9b4b035880"
      unitRef="U001">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:Liabilities
      contextRef="c20251231"
      decimals="-3"
      id="Fact_51e0b8955a384c3a80b75ff841da6124"
      unitRef="U001">34895000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="c20241231"
      decimals="-3"
      id="Fact_6cc5c93a2e62421baea5594ba936704b"
      unitRef="U001">11295000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c20251231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="4"
      id="Fact_c1257f51760847a8bc5fbe4bb6b85ede"
      unitRef="U003">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c20241231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="4"
      id="Fact_b4ce78cc8ccb4abcaa01033265bcb12f"
      unitRef="U003">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c20251231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact_d6d774162b694ce8b9251b2ffd8667c3"
      unitRef="U002">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c20241231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact_2afd32f32f1e41899d83f6f4855f7bda"
      unitRef="U002">14146</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c20251231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact_dce08716507e48668b6c58db17e922f3"
      unitRef="U002">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c20251231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact_7b02dc54543f4afdbc0616fea7d042f6"
      unitRef="U002">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c20241231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="3"
      id="Fact_d1bebdc0fe38436c84f951937a7be291"
      unitRef="U002">14145.374</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c20241231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="3"
      id="Fact_4492d506ee40444b9dbd4b0b9965ecc6"
      unitRef="U002">14145.374</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_4a0b3d14c4b94240b5ab3fd947c72d44"
      unitRef="U001">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_da8e24af2f4b4538bbeb124eafbe2b3e"
      unitRef="U001">18843000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20251231"
      decimals="4"
      id="Fact_c17909f4ee60464e9ec39d9fc729bfbc"
      unitRef="U003">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20241231"
      decimals="4"
      id="Fact_a6f68c721f5c4f3b88bb7b7e4942c81f"
      unitRef="U003">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20251231"
      decimals="0"
      id="Fact_dd4f1ae568fa4c2dacb9a5d223c700ab"
      unitRef="U002">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20241231"
      decimals="0"
      id="Fact_477e11452c834db5828e48bb22dc08f6"
      unitRef="U002">9985854</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20251231"
      decimals="INF"
      id="Fact_8f62e791fae0463094cfbd15e66b731e"
      unitRef="U002">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20241231"
      decimals="INF"
      id="Fact_823b6d47fad149e5857f2c349bab01cb"
      unitRef="U002">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c20251231"
      decimals="INF"
      id="Fact_4a4c8e3e1b0a45ae864a84fa7ef7ba27"
      unitRef="U002">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c20241231"
      decimals="INF"
      id="Fact_01e35418e9504b9993eaf6bbc70755a5"
      unitRef="U002">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="c20251231"
      decimals="-3"
      id="Fact_6af5f13004654c3bbc94c78a71d3167a"
      unitRef="U001">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="c20241231"
      decimals="-3"
      id="Fact_463ff44572a84d2ba080d2151fabd9e0"
      unitRef="U001">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20251231"
      decimals="4"
      id="Fact_7470c79fb12a46c188c3af8e0a4e74b3"
      unitRef="U003">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20241231"
      decimals="4"
      id="Fact_1aae4862c79d4889a71ae99391fe86bc"
      unitRef="U003">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20241231"
      decimals="0"
      id="Fact_3eed9b1a96bd4cac81041b40cd565cb8"
      unitRef="U002">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20251231"
      decimals="0"
      id="Fact_0e77ad46d2014075bd098546df87ba8f"
      unitRef="U002">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20251231"
      decimals="0"
      id="Fact_9cbc6422683a4eb2814fdf28b21e062d"
      unitRef="U002">69894507</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20251231"
      decimals="0"
      id="Fact_727c4494e3ee466781f6e6bd78c7f115"
      unitRef="U002">69894507</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20241231"
      decimals="0"
      id="Fact_62ed43b60dc14f259a2ca56110e9c8b2"
      unitRef="U002">31574657</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20241231"
      decimals="0"
      id="Fact_222e9288b86844ffa06545f17480adad"
      unitRef="U002">31574657</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="c20251231"
      decimals="-3"
      id="Fact_63f26c8f183b442bb18ed65909b60e46"
      unitRef="U001">7000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="c20241231"
      decimals="-3"
      id="Fact_b77cf58c117a4e27ba30b098e56b346e"
      unitRef="U001">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20251231"
      decimals="-3"
      id="Fact_4ef921d6534f41b7b59221863a9b6772"
      unitRef="U001">203930000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20241231"
      decimals="-3"
      id="Fact_c0f754fcf38249c7a96d8caf5cc268ab"
      unitRef="U001">145719000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20251231"
      decimals="-3"
      id="Fact_c77f690c1e46467eb959b0f5d34e756e"
      unitRef="U001">-188589000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20241231"
      decimals="-3"
      id="Fact_fdd3880e7bf44bd48377d6959670b04e"
      unitRef="U001">-138998000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="c20251231"
      decimals="-3"
      id="Fact_b4e12e99782e43f18ebe45a9091878d0"
      unitRef="U001">15348000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20241231"
      decimals="-3"
      id="Fact_bff3e214d68a4394b391ab4145aa62db"
      unitRef="U001">6724000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20251231"
      decimals="-3"
      id="Fact_6f044e6244724f3cb5fc6f0cac33ec93"
      unitRef="U001">50243000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20241231"
      decimals="-3"
      id="Fact_da3c91d8d4ce4f149e66631597710cac"
      unitRef="U001">36862000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_d807e2cdd1c64813933ffba4d153dbeb"
      unitRef="U001">14196000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_7e80085fd34340349977fc474c1b7cf6"
      unitRef="U001">10992000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_003db6ffaa0b4726b6ef9e73e8f04089"
      unitRef="U001">30812000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_66dcc1406ba74c9b83349cc607b933ac"
      unitRef="U001">26851000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_c063d41d336949b083fd901355e40065"
      unitRef="U001">21983000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_a056c6ee0e374645bb1d70753b3500bf"
      unitRef="U001">18215000</us-gaap:GeneralAndAdministrativeExpense>
    <ird:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_11e0d1b453084cc594417106a54fc7bb"
      unitRef="U001">0</ird:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost>
    <ird:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_4b969d361b3f45179da06b73f1df321b"
      unitRef="U001">28000000</ird:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost>
    <us-gaap:OperatingExpenses
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_d266408ae24c471b9bd40f02b4e51ad5"
      unitRef="U001">52795000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_17fd1ab29c6c4c28b419b52d15c43c91"
      unitRef="U001">73066000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_12716b0c6c9a4dce996b556e07206723"
      unitRef="U001">-38599000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_079cf7b16e2f4228aaceeeecb817d610"
      unitRef="U001">-62074000</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_0ebac092122547d194f05eba05bbfc5a"
      unitRef="U001">-11515000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_38e63d9db77441c38925dfee8e0aaa30"
      unitRef="U001">72000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <ird:FinancingCosts
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_ef3ae8115d77432d91b30be8e62f077a"
      unitRef="U001">1337000</ird:FinancingCosts>
    <ird:FinancingCosts
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_3d7a97b89b8c4eb5899e931b491bdcb0"
      unitRef="U001">0</ird:FinancingCosts>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_8f5a8302e2ab41eab2674a1e0ca14dbd"
      unitRef="U001">129000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_852e64c025254e03bca30e4dfca65fdf"
      unitRef="U001">0</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_07aa5940577543c1940ef96b0dc0e7cf"
      unitRef="U001">1989000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_250af61e7fbf4b2fb28877048d448560"
      unitRef="U001">4470000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_9a12e68a579e40a8b252af61d36907d2"
      unitRef="U001">-49591000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_39cb6c6d190c49719ddb57c63054371f"
      unitRef="U001">-57532000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_fb27275d44fa4760810bda0061351a2d"
      unitRef="U001">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_7aae0a8c59584a90991080a7d52d7d2c"
      unitRef="U001">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_7db7725c893d451a96f955d955b63937"
      unitRef="U001">-49591000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_5d36d4d86fa745bab6eb6b069d3f2e72"
      unitRef="U001">-57532000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_e4edf586bc094ed4a12cb237e753df09"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_74a5f5389022467a81bbbe4f6c44dd86"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_2ce8a0e6d4674bc8b6b965cfee75ef34"
      unitRef="U001">-49591000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_e9960eeda18f40d29e293485e2f7ee57"
      unitRef="U001">-57532000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20250101to20251231"
      decimals="2"
      id="Fact_a596d791acd1485bb3cc4e85d97deb65"
      unitRef="U003">-0.8</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20250101to20251231"
      decimals="2"
      id="Fact_a3c12f88588a4033a6fca98d977ea6a5"
      unitRef="U003">-0.8</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_f447a53319764306a6619511dc7b34f1"
      unitRef="U003">-2.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_5730c151867f47ab9340e64b96af7e3e"
      unitRef="U003">-2.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20250101to20251231"
      decimals="0"
      id="Fact_918dcf0607904c4a835531f7d1aa2269"
      unitRef="U002">62221901</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20250101to20251231"
      decimals="0"
      id="Fact_7fad1fde8eac4cae89a8f864cca0be08"
      unitRef="U002">62221901</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20240101to20241231"
      decimals="0"
      id="Fact_a68a9efc7b5547ee8856523a9576cfc2"
      unitRef="U002">26715526</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20240101to20241231"
      decimals="0"
      id="Fact_10afdfbb54fc4cf2b67a56b41cd411c7"
      unitRef="U002">26715526</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c20231231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact_5690081d3fb947eca782b70760d13c33"
      unitRef="U002">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c20231231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="-3"
      id="Fact_4ef40f95a4d04bad8d5d5bd390facd8d"
      unitRef="U001">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_bee01bbad4d845b2928de6bf9131dd52"
      unitRef="U002">23977491</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_3312aed419e7446d882b8d56e315b500"
      unitRef="U001">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_a697771f689247b4975a80a1aadb9b36"
      unitRef="U001">131370000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_a319c57c6385455f8e404c4d4b514aad"
      unitRef="U001">-81466000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20231231"
      decimals="-3"
      id="Fact_228c885f646f481783c46e5c3bb8dfa0"
      unitRef="U001">49906000</us-gaap:StockholdersEquity>
    <ird:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="c20240101to20241231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="3"
      id="Fact_83af5f95ea6d4d3280aca9791ddbe232"
      unitRef="U002">14145.374</ird:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="c20240101to20241231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="-3"
      id="Fact_558c8709ddf74239850b721c5e420b55"
      unitRef="U001">18843000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_863b08338a464d668bd38f0c664871f6"
      unitRef="U002">5237063</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_e02cdc09dffb4074b1c6f5754ef59782"
      unitRef="U001">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_236a3910fc464b629d046cf7dc601f10"
      unitRef="U001">6964000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_0ea046f437744f39b95018452fe3aa80"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_4978d39b057544aaa962eda6e979c69a"
      unitRef="U001">6965000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <ird:StockIssuedDuringPeriodSharesAtTheMarketProgramAndPurchaseAgreement
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_07db0f8382044e46a781bd5c115155ba"
      unitRef="U002">2008522</ird:StockIssuedDuringPeriodSharesAtTheMarketProgramAndPurchaseAgreement>
    <ird:StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_e89af900f0a7433bb9c3c0341bc0034c"
      unitRef="U001">0</ird:StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement>
    <ird:StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_181e7cd6be1d4690a50a08cd1e1fc6d9"
      unitRef="U001">4497000</ird:StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement>
    <ird:StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_00f28be1b05c411e91578823a3119852"
      unitRef="U001">0</ird:StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement>
    <ird:StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_51ae310e59d74e018a1c792b99f39b8f"
      unitRef="U001">4497000</ird:StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement>
    <ird:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_65018d53334149ce84946b8be23b4668"
      unitRef="U001">0</ird:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing>
    <ird:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_469dbbd4815d4bb7a493050ccf785a3f"
      unitRef="U001">395000</ird:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing>
    <ird:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_22f23381ac54436fa3d9ce0aab0ed4fa"
      unitRef="U001">0</ird:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing>
    <ird:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_c58b2b768d014f389c1b49ff72fff7b3"
      unitRef="U001">395000</ird:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_b6e351dbd5534173ae748bf1d162b1c3"
      unitRef="U002">395396</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_8f209df5608f4fbd9d9be53bf0e290ed"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_420a9b43de68425289b8ced1ce0a0aea"
      unitRef="U001">3362000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_1c295bf3e03741e69825e148d7bcb00f"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_90e8443038fa486681c4394358fb2c99"
      unitRef="U001">3362000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ird:StockRepurchasesForPaymentOfEmployeeTaxesShares
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_d4b75aa8b2314e3e89e7796cb9626f54"
      unitRef="U002">43815</ird:StockRepurchasesForPaymentOfEmployeeTaxesShares>
    <ird:AdjustmentsToAdditionalPaidInCapitalShareRepurchasesForPaymentOfEmployeeTaxes
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_eb3fde9fd37b43b096f3f09fbadd1866"
      unitRef="U001">0</ird:AdjustmentsToAdditionalPaidInCapitalShareRepurchasesForPaymentOfEmployeeTaxes>
    <ird:AdjustmentsToAdditionalPaidInCapitalShareRepurchasesForPaymentOfEmployeeTaxes
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_5df95cc3977f40cfa744d3c648028e9a"
      unitRef="U001">79000</ird:AdjustmentsToAdditionalPaidInCapitalShareRepurchasesForPaymentOfEmployeeTaxes>
    <ird:AdjustmentsToAdditionalPaidInCapitalShareRepurchasesForPaymentOfEmployeeTaxes
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_9092e3363f1644b7aa54b6d70382f80d"
      unitRef="U001">0</ird:AdjustmentsToAdditionalPaidInCapitalShareRepurchasesForPaymentOfEmployeeTaxes>
    <ird:AdjustmentsToAdditionalPaidInCapitalShareRepurchasesForPaymentOfEmployeeTaxes
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_dde3335a2c174921b9983d449c39b3a6"
      unitRef="U001">79000</ird:AdjustmentsToAdditionalPaidInCapitalShareRepurchasesForPaymentOfEmployeeTaxes>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_b1b695d1a9da496c8e61cccbb76e0c02"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_cfd19a2037eb4713ac6d82689357bbb9"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_f1476b96df16428a8560284beac07da5"
      unitRef="U001">-57532000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_83e5c7e2e8a84454ae7a7697c8c94c09"
      unitRef="U001">-57532000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c20241231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="3"
      id="Fact_b91caff5baa94aa3a2c43bacb5d155b0"
      unitRef="U002">14145.374</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c20241231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="-3"
      id="Fact_52c168abe979443a8155ab0f9eacc898"
      unitRef="U001">18843000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="c20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_af0a79eb45b64cd695cd8cdbf142414b"
      unitRef="U002">31574657</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_a372cc0e727b460fae6fddf735b97b27"
      unitRef="U001">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_59487a1e7eb64178960e6a2455d025f1"
      unitRef="U001">145719000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20241231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_43a93bffab5d4186b80d64c013c2b249"
      unitRef="U001">-138998000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20241231"
      decimals="-3"
      id="Fact_e7ee2a70977a4f42a137ed762ef3975f"
      unitRef="U001">6724000</us-gaap:StockholdersEquity>
    <ird:TemporaryEquityStockConversionShares
      contextRef="c20250101to20251231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="3"
      id="Fact_300c8c29e0ac48c19afd1d67323830e4"
      unitRef="U002">14145.374</ird:TemporaryEquityStockConversionShares>
    <ird:TemporaryEquityStockConversionValue
      contextRef="c20250101to20251231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="-3"
      id="Fact_2460b821e4cf40d59332046293ec4930"
      unitRef="U001">18843000</ird:TemporaryEquityStockConversionValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_fdd8d0439b9e4b7291344a8476921861"
      unitRef="U002">14145374</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_c5d4841d9ff04542b3a054ffbfad10ba"
      unitRef="U001">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_f94a3cb2500549768e64ebfc744ee953"
      unitRef="U001">18842000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_ebaf1cfee9e7462780c0b075c812a8b2"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_841bbddfe5504a3980d14c3c0dac6eb6"
      unitRef="U001">18843000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <ird:StockIssuedDuringPeriodSharesOfPrivateOfferingAndPrivatePlacement
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_d27328da67784fb29bd76bfdb57ea30c"
      unitRef="U002">13396207</ird:StockIssuedDuringPeriodSharesOfPrivateOfferingAndPrivatePlacement>
    <ird:StockIssuedDuringPeriodValueOfPrivateOfferingAndPrivatePlacement
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_ee373fe671e74f8abbb8ea9c4e9fdff6"
      unitRef="U001">1000</ird:StockIssuedDuringPeriodValueOfPrivateOfferingAndPrivatePlacement>
    <ird:StockIssuedDuringPeriodValueOfPrivateOfferingAndPrivatePlacement
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_ed68bf7935fd4f0d8686437a9bc207ee"
      unitRef="U001">5979000</ird:StockIssuedDuringPeriodValueOfPrivateOfferingAndPrivatePlacement>
    <ird:StockIssuedDuringPeriodValueOfPrivateOfferingAndPrivatePlacement
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_22fbb7912974426ebf22f0bc1e6f0a31"
      unitRef="U001">0</ird:StockIssuedDuringPeriodValueOfPrivateOfferingAndPrivatePlacement>
    <ird:StockIssuedDuringPeriodValueOfPrivateOfferingAndPrivatePlacement
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_cc00b1ba2fb043b5971adf480785d9c0"
      unitRef="U001">5980000</ird:StockIssuedDuringPeriodValueOfPrivateOfferingAndPrivatePlacement>
    <ird:StockIssuedDuringPeriodSharesRegisteredDirectOffering
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_f7765a7c64c645fd98e0f43bd922580b"
      unitRef="U002">3827751</ird:StockIssuedDuringPeriodSharesRegisteredDirectOffering>
    <ird:StockIssuedDuringPeriodValueRegisteredDirectOffering
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_a8ffc63dbe2b426593e78a2d877ff688"
      unitRef="U001">1000</ird:StockIssuedDuringPeriodValueRegisteredDirectOffering>
    <ird:StockIssuedDuringPeriodValueRegisteredDirectOffering
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_2b6f7673e0fb4406ada3df547601681a"
      unitRef="U001">22998000</ird:StockIssuedDuringPeriodValueRegisteredDirectOffering>
    <ird:StockIssuedDuringPeriodValueRegisteredDirectOffering
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_b6fd5c23e65e49059b9b5ec98db59a0e"
      unitRef="U001">0</ird:StockIssuedDuringPeriodValueRegisteredDirectOffering>
    <ird:StockIssuedDuringPeriodValueRegisteredDirectOffering
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_f02e998c8b814f038fe73ca7ef267150"
      unitRef="U001">22999000</ird:StockIssuedDuringPeriodValueRegisteredDirectOffering>
    <ird:StockIssuedDuringPeriodSharesAtTheMarketProgramAndPurchaseAgreement
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_2ae79fbecbf543408e3a69472fb79294"
      unitRef="U002">5057750</ird:StockIssuedDuringPeriodSharesAtTheMarketProgramAndPurchaseAgreement>
    <ird:StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_a16d6efeebde423ea3fc5745b86eb1b9"
      unitRef="U001">1000</ird:StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement>
    <ird:StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_44bbe91acce049f3933942fa6e3c53d1"
      unitRef="U001">5804000</ird:StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement>
    <ird:StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_bbed248b42ef461e91a1658e9e959350"
      unitRef="U001">0</ird:StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement>
    <ird:StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_dad6e94b0ffd4e5c9b239aa9e0a7e404"
      unitRef="U001">5805000</ird:StockIssuedDuringPeriodValueAtTheMarketProgramAndPurchaseAgreement>
    <ird:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_e1bac57aa5af4f4fb068fa2568d55846"
      unitRef="U001">0</ird:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing>
    <ird:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_7251c08c576e4ae9bbfcb0daaa471462"
      unitRef="U001">940000</ird:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing>
    <ird:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_a82f62ee1da84beab271e01a46ec09af"
      unitRef="U001">0</ird:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing>
    <ird:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_42d1675a3067441790ab97577d874d46"
      unitRef="U001">940000</ird:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_d49459e53f0e40a095613b23cf98f7e9"
      unitRef="U002">748977</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_ee21f05fa1b24ff697abfeea309805f8"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_9847947f23c6417e9794227493ee058d"
      unitRef="U001">3399000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_f23566c9b5a0498f8b78100c3d4ec3e8"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_5c0bbbd25656424bb32f59edd30d54f0"
      unitRef="U001">3399000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ird:StockRepurchasesForPaymentOfEmployeeTaxesShares
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_ab28eec21a2b407aab5ade117ecf5b42"
      unitRef="U002">86058</ird:StockRepurchasesForPaymentOfEmployeeTaxesShares>
    <ird:AdjustmentsToAdditionalPaidInCapitalShareRepurchasesForPaymentOfEmployeeTaxes
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_8bef706ca7cf4b04ba37396813f7f81b"
      unitRef="U001">0</ird:AdjustmentsToAdditionalPaidInCapitalShareRepurchasesForPaymentOfEmployeeTaxes>
    <ird:AdjustmentsToAdditionalPaidInCapitalShareRepurchasesForPaymentOfEmployeeTaxes
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_f7f54d6e184d45e3923ecd005eb0b6be"
      unitRef="U001">152000</ird:AdjustmentsToAdditionalPaidInCapitalShareRepurchasesForPaymentOfEmployeeTaxes>
    <ird:AdjustmentsToAdditionalPaidInCapitalShareRepurchasesForPaymentOfEmployeeTaxes
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_e74a88daa6984e2592ec417b178fd52f"
      unitRef="U001">0</ird:AdjustmentsToAdditionalPaidInCapitalShareRepurchasesForPaymentOfEmployeeTaxes>
    <ird:AdjustmentsToAdditionalPaidInCapitalShareRepurchasesForPaymentOfEmployeeTaxes
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_44e5a42187b6455caf3506d3f1ac48a3"
      unitRef="U001">152000</ird:AdjustmentsToAdditionalPaidInCapitalShareRepurchasesForPaymentOfEmployeeTaxes>
    <ird:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_919aca590ea14eafb46e7205442a1062"
      unitRef="U002">862684</ird:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <ird:StockIssuedDuringPeriodValueStockExerciseOfWarrants
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_5b16f7b920bb4f94811f512e4f726213"
      unitRef="U001">0</ird:StockIssuedDuringPeriodValueStockExerciseOfWarrants>
    <ird:StockIssuedDuringPeriodValueStockExerciseOfWarrants
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_23e87ea4ce7c4f7c9b61319ae733f2bc"
      unitRef="U001">1872000</ird:StockIssuedDuringPeriodValueStockExerciseOfWarrants>
    <ird:StockIssuedDuringPeriodValueStockExerciseOfWarrants
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_8b3226ec593341f4b06f00535b4e488b"
      unitRef="U001">0</ird:StockIssuedDuringPeriodValueStockExerciseOfWarrants>
    <ird:StockIssuedDuringPeriodValueStockExerciseOfWarrants
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_7b5dde63d5404586ac3873571a5043b8"
      unitRef="U001">1872000</ird:StockIssuedDuringPeriodValueStockExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_507a69ae8050415fa821104e5cba0a26"
      unitRef="U002">336759</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_0e980fa4981540ea83dada78de7d97c1"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_65458e691d4f4c79a7c4a80ab22922b9"
      unitRef="U001">352000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_ebcdbe479b6f4aef81290bbed7e7289c"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_f3ff698cdadc4cdcb7c8710f480af9b9"
      unitRef="U001">352000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_d344b6095fe0438f9c5c992b54d5931b"
      unitRef="U002">30406</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_a530d78563334529b099d6430366965f"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_165ef70f4e7445c19a3fc31cb4647193"
      unitRef="U001">57000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_293d4064fec143888c33ef6f117d437c"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_bba4a39c56df4321af25ead2031664de"
      unitRef="U001">57000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_37974e4eda3145b6bbb67414f69ffc20"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_68f5438c2cb5433ba0ef59cf35060b80"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_4fd0359ff85e40289c5ce2afa47ba36d"
      unitRef="U001">-49591000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_93beb1a39e864175b41c2fcf02f913e9"
      unitRef="U001">-49591000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c20251231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact_4b2b55f0df5f4ae3892c6751840f3cb4"
      unitRef="U002">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c20251231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="-3"
      id="Fact_1f36507c977940fdb7800eb88eeeafaa"
      unitRef="U001">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="c20251231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_705fc24c5aa64f1fb9045a52525dbe63"
      unitRef="U002">69894507</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20251231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_02ceea54c41b4435bd4abb1037cb3303"
      unitRef="U001">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20251231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_173c5ebf0382416fa8baf1ca39e94f88"
      unitRef="U001">203930000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20251231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_24b59662580448efb6860206b7229cb1"
      unitRef="U001">-188589000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20251231"
      decimals="-3"
      id="Fact_9bb7cf8bde494cf8ab65cfcf03fb5f96"
      unitRef="U001">15348000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_cb655ee1feca439082db839212b06b05"
      unitRef="U001">-49591000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_b1caa1b1c63f4fe59b0fe1d8eeba46cf"
      unitRef="U001">-57532000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_ce30d0cdef8a4f24a89683fb85133eb3"
      unitRef="U001">3399000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_9b669c36d2da43d391184bc9a97ae0f1"
      unitRef="U001">3362000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_7fdd4fa08e4e46368eaa06228984faca"
      unitRef="U001">53000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_67e3abe76eed42e5822a2d11ebd34294"
      unitRef="U001">10000</us-gaap:Depreciation>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_45c90aa8c9df4cb18b757615f71e71e3"
      unitRef="U001">-11515000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_96cfbf2fa5a0442c9e4e6a5fab0f2f33"
      unitRef="U001">72000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <ird:WarrantFinancingCostsReclassifiedToFinancingActivities
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_d2f5153d432845e591145e8698528b6e"
      unitRef="U001">1337000</ird:WarrantFinancingCostsReclassifiedToFinancingActivities>
    <ird:WarrantFinancingCostsReclassifiedToFinancingActivities
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_8fd039e53254446d998a90d980cc5cc2"
      unitRef="U001">0</ird:WarrantFinancingCostsReclassifiedToFinancingActivities>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_a6b60d57bf9a4bb7baa547e35881784e"
      unitRef="U001">129000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_31839fc36e4443b190c2496873fea8a4"
      unitRef="U001">0</us-gaap:InterestExpenseNonoperating>
    <ird:NonCashShareIssuances
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_1ec8315cbcb1431b841c9fa942d4605e"
      unitRef="U001">57000</ird:NonCashShareIssuances>
    <ird:NonCashShareIssuances
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_d4c608a0a0cf4ace80b416e473c121d0"
      unitRef="U001">0</ird:NonCashShareIssuances>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_8ab10526bc7e4ce6bea24d146e254520"
      unitRef="U001">-2000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_3fe062e0a03e451ca5bdd7c24c810d73"
      unitRef="U001">-13000</us-gaap:UnrealizedGainLossOnInvestments>
    <ird:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_519263532b324dcb87621d1f7d80545c"
      unitRef="U001">0</ird:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost>
    <ird:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_3fcda2bbcebb48fe9e6e04a22ec13beb"
      unitRef="U001">28000000</ird:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost>
    <ird:AssetAcquisitionGainLossOnAcquisitionOfBusiness
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_33c81f6bd0c14af4a3abf17c050fec66"
      unitRef="U001">0</ird:AssetAcquisitionGainLossOnAcquisitionOfBusiness>
    <ird:AssetAcquisitionGainLossOnAcquisitionOfBusiness
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_c40b297c567541cd825e0fbfa211578d"
      unitRef="U001">2447000</ird:AssetAcquisitionGainLossOnAcquisitionOfBusiness>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_5afe07e37a904083b7b9ff1785d59628"
      unitRef="U001">-1568000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_4ff98596d976495ab320415d49b79318"
      unitRef="U001">2637000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <ird:IncreaseDecreaseInContractAssetsAndUnbilledReceivables
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_035a9c5e2971476a94bdebfbc8b5f136"
      unitRef="U001">-1039000</ird:IncreaseDecreaseInContractAssetsAndUnbilledReceivables>
    <ird:IncreaseDecreaseInContractAssetsAndUnbilledReceivables
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_633acd95f79c48428c8e1c0166668d26"
      unitRef="U001">802000</ird:IncreaseDecreaseInContractAssetsAndUnbilledReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_a0d99426e7894d69b36ee71cadc9c794"
      unitRef="U001">1273000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_15235ba9262b4cbebc92de33f3c568e0"
      unitRef="U001">-634000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_747f659145514d6fb6fce3c855a5dc36"
      unitRef="U001">7000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_bc6ea25ec03a46c2bbd1ed3883420552"
      unitRef="U001">220000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_f6b4d7a7d3854b80a86a64b97e5f1b9b"
      unitRef="U001">-3495000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_de58f0fdb74543bb843171553dffa901"
      unitRef="U001">5675000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_8e0a746c245c46e89c80ddc2077f9314"
      unitRef="U001">-35253000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_5709c5e4fb55427f883015659aef7030"
      unitRef="U001">-25576000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAcquiredInExcessOfPaymentsToAcquireBusiness
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_dee3425235e942168a9ddc3124059c08"
      unitRef="U001">0</us-gaap:CashAcquiredInExcessOfPaymentsToAcquireBusiness>
    <us-gaap:CashAcquiredInExcessOfPaymentsToAcquireBusiness
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_1b778f6ad3d24b40a2e2274f207308df"
      unitRef="U001">1210000</us-gaap:CashAcquiredInExcessOfPaymentsToAcquireBusiness>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_a49afdf96619427cb72ccc97b2f80235"
      unitRef="U001">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_d139fc96973444569ede17f39c3dd6c6"
      unitRef="U001">1210000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <ird:ProceedsFromIssuanceInConnectionWithRegisteredDirectOffering
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_b09f783f45304fee842ea78967c63c07"
      unitRef="U001">22999000</ird:ProceedsFromIssuanceInConnectionWithRegisteredDirectOffering>
    <ird:ProceedsFromIssuanceInConnectionWithRegisteredDirectOffering
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_725c6e4c68fa46e6ad41fd747c4a3047"
      unitRef="U001">0</ird:ProceedsFromIssuanceInConnectionWithRegisteredDirectOffering>
    <ird:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInConnectionWithPrivateOfferingAndPrivatePlacement
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_2f17300f7903444f9e844775678a17c0"
      unitRef="U001">5980000</ird:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInConnectionWithPrivateOfferingAndPrivatePlacement>
    <ird:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInConnectionWithPrivateOfferingAndPrivatePlacement
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_0411a516f321472eb4fd900efb323ea9"
      unitRef="U001">0</ird:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInConnectionWithPrivateOfferingAndPrivatePlacement>
    <ird:ProceedsFromIssuanceOfWarrantsInConnectionWithPrivateOfferingAndPrivatePlacement
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_cdc2834398724e5292e9b3bf09d9974f"
      unitRef="U001">15520000</ird:ProceedsFromIssuanceOfWarrantsInConnectionWithPrivateOfferingAndPrivatePlacement>
    <ird:ProceedsFromIssuanceOfWarrantsInConnectionWithPrivateOfferingAndPrivatePlacement
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_eca2c2410ee6471c81d7e51e0b9568b0"
      unitRef="U001">0</ird:ProceedsFromIssuanceOfWarrantsInConnectionWithPrivateOfferingAndPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_69239214b5bf4781b43daa5a3941a8f3"
      unitRef="U001">5805000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_bfad90193e084cc7b9c603cd5e4cbfe2"
      unitRef="U001">4497000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_ff70abd1748c4d27b808c7f0addc96dd"
      unitRef="U001">2301000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_5e09a042fe9b40fd970561bf90df64ff"
      unitRef="U001">232000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_04b421eec58840369a0eff85c5523e47"
      unitRef="U001">1000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_a6d0636b39c34d2591f8f33f57e62e91"
      unitRef="U001">0</us-gaap:ProceedsFromRelatedPartyDebt>
    <ird:ShareRepurchasesForPaymentOfEmployeeTaxes
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_502c6993778b4ed09bddf87d9bc369f2"
      unitRef="U001">152000</ird:ShareRepurchasesForPaymentOfEmployeeTaxes>
    <ird:ShareRepurchasesForPaymentOfEmployeeTaxes
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_5d4585a21aa74c05a54630b728d6b98a"
      unitRef="U001">79000</ird:ShareRepurchasesForPaymentOfEmployeeTaxes>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_cb94869e648d4b7281ff50bbbd24264f"
      unitRef="U001">820000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_cf265fe3a9a44c56a02101cc8832b5aa"
      unitRef="U001">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_17784eee3e964b02b6585c4a787fbaf8"
      unitRef="U001">352000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_3421d6b5dc554ec2beef4f46db3f3eaa"
      unitRef="U001">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_7f2354ba97904670b6e984da23c0a059"
      unitRef="U001">50023000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_31f1270d8b874015b93f52396cafcace"
      unitRef="U001">4186000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_e731b551e2be43a88ffb2f934efa9811"
      unitRef="U001">14770000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_a42dd57dc8194e28884d17e7a4ddccfa"
      unitRef="U001">-20180000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20241231"
      decimals="-3"
      id="Fact_f35ebbfbc29c4077ab6fca632f3dee20"
      unitRef="U001">30321000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20231231"
      decimals="-3"
      id="Fact_88fa410257af491ebcddc2cae793dc11"
      unitRef="U001">50501000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20251231"
      decimals="-3"
      id="Fact_2ee63610ac1c469db37193f9ff714c9b"
      unitRef="U001">45091000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20241231"
      decimals="-3"
      id="Fact_f7d61e2120694f109efa1a4c56bd487c"
      unitRef="U001">30321000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_38ee8ad27c854d7f917e161c71fe2c69"
      unitRef="U001">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_780918e9426547358d524809f5bff03e"
      unitRef="U001">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_12cb4f88a0734af1a21eec327881b09a"
      unitRef="U001">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_123ccf787b73443295f1dd94ce7f58a2"
      unitRef="U001">0</us-gaap:InterestPaidNet>
    <ird:CommonStockAndSeriesAPreferredStockIssuedInConnectionWithAssetAcquisition
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_49196af547bb45af996ff471d6ab3e2d"
      unitRef="U001">0</ird:CommonStockAndSeriesAPreferredStockIssuedInConnectionWithAssetAcquisition>
    <ird:CommonStockAndSeriesAPreferredStockIssuedInConnectionWithAssetAcquisition
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_b6a5ef002d6f45c2aa541d3994bd7396"
      unitRef="U001">25808000</ird:CommonStockAndSeriesAPreferredStockIssuedInConnectionWithAssetAcquisition>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_b747e63ad2544ce3877728242267f257"
      unitRef="U001">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_b622c08560284a99942215ae979e15f7"
      unitRef="U001">955000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_00667fb3a82a466a86543b57615bc010"
      unitRef="U001">18843000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_b421a4e33088453d915146f31757236a"
      unitRef="U001">0</us-gaap:ConversionOfStockAmountConverted1>
    <ird:ReclassificationOfWarrantLiabilitiesToEquityUponExercise
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_0574d67ffcfc49829a83d533a8f1523e"
      unitRef="U001">1052000</ird:ReclassificationOfWarrantLiabilitiesToEquityUponExercise>
    <ird:ReclassificationOfWarrantLiabilitiesToEquityUponExercise
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_dbb2fa89236447ea82a011cdf69db00a"
      unitRef="U001">0</ird:ReclassificationOfWarrantLiabilitiesToEquityUponExercise>
    <ird:UnpaidIssuanceCosts
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_1d71efd68a984e79b14ccdf48512bdd3"
      unitRef="U001">24000</ird:UnpaidIssuanceCosts>
    <ird:UnpaidIssuanceCosts
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_f743bf53968b455bb71caaf479a6d5b1"
      unitRef="U001">163000</ird:UnpaidIssuanceCosts>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="c20250101to20251231"
      id="Text_f1dbbe8dce714ee3a93360c4ebafcce6">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold;"&gt;1.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold;"&gt;Company Description and Summary of Significant Accounting Policies&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Nature of Business and Basis of Presentation&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none; text-align: justify;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Opus Genetics, Inc. (the &#x201c;Company&#x201d; or &#x201c;Opus&#x201d;), a Delaware corporation formerly known as Ocuphire Pharma, Inc. (the &#x201c;Company&#x201d; or
              &#x201c;Opus&#x201d;), is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (&#x201c;IRDs&#x201d;) and small molecule therapies for other ophthalmic disorders. The Company&#x2019;s headquarters is located in
              Durham, North Carolina.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none; text-align: justify;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none; text-align: justify;"&gt;On October 22, 2024, the Company acquired a private corporation then operating under the name of
            &#x201c;Opus Genetics, Inc.&#x201d; (&#x201c;Private Opus&#x201d;) pursuant to the terms of an Agreement and Plan of Merger, dated as of October 22, 2024 (such agreement, the &#x201c;Merger Agreement&#x201d; and the transaction consummated via the Merger Agreement, the &#x201c;Opus
            Acquisition&#x201d;), by and among the Company, Private Opus, and certain merger subsidiaries party thereto.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none; text-align: justify;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none; text-align: justify;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company&#x2019;s pipeline features a portfolio of adeno-associated virus (&#x201c;AAV&#x201d;) based gene therapies that address mutations in
              genes that cause different forms of Leber congenital amaurosis (&#x201c;LCA&#x201d;), bestrophinopathy, and retinitis pigmentosa. The Company&#x2019;s most advanced gene therapy program is designed to address mutations in the LCA5 gene, which encodes the
              lebercilin protein. More specifically, we are developing OPGx-LCA5 to treat LCA5-associated inherited retinal disease (&#x201c;IRD&#x201d;), an early-onset retinal degeneration, and an open-label, dose-escalation Phase 1/2 clinical trial is ongoing.
              OPGx-BEST1 is another gene therapy candidate in the Company&#x2019;s portfolio. This asset is being developed for the treatment of IRDs associated with mutations in the BEST1 gene, which can lead to legal blindness. Apart from gene therapies, the
              Company&#x2019;s pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a relatively non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size as well as APX3330, a novel small-molecule inhibitor of Ref-1 designed
              to slow the progression of non-proliferative diabetic retinopathy.&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none; text-align: justify;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none; text-align: justify;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;In November 2022, the Company entered into a license and collaboration agreement (as amended, the &#x201c;Viatris License Agreement&#x201d;)
              with Viatris, Inc. (&#x201c;Viatris&#x201d;), pursuant to which it granted Viatris an exclusive license to develop, manufacture, import, export and commercialize its refractive product candidate Phentolamine Ophthalmic Solution 0.75% (&#x201c;PS&#x201d;). PS is a
              once-daily eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. PS was approved by the FDA for the treatment of pharmacologically induced mydriasis produced by adrenergic agonists (e.g.,
              phenylephrine) or parasympatholytic (e.g., tropicamide) agents, or a combination thereof under the brand name RYZUMVI&#xae; in September 2023 and was launched commercially in April 2024. Additionally, the Company is currently developing PS for
              decreased vision under mesopic (low) light conditions following keratorefractive surgery, pursuant to a received FDA agreement under Special Protocol Assessment (&#x201c;SPA&#x201d;).&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;

        &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Basis of Presentation&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting
            standards generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and include the accounts of the Company&#x2019;s subsidiary, the former Private Opus entity (&#x201c;OPUSTX, LLC&#x201d;). All intercompany transactions and balances have been eliminated in
            consolidation. The Company&#x2019;s fiscal year begins on January 1 and ends on December 31.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            The derivative liability line item reflected on the December 31, 2024 consolidated balance sheet in the prior year was reclassified to the accrued expenses and other liabilities line item in the amount of $2,000.&lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; font-weight: bold; text-align: justify; text-transform: none;"&gt;&lt;span style="font-weight: bold; font-style: italic;"&gt;Liquidity&lt;/span&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none; font-weight: bold; font-style: italic;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: bold; font-style: italic;"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none; font-weight: normal; font-size: 10pt; font-style: normal;"&gt;Since its inception, the Company has devoted
            substantially all of its resources to drug development and clinical trials.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none; font-weight: normal; font-style: normal;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;As of
                December 31, 2025, the Company had $45.1 million in cash and cash equivalents and, as disclosed in Note 14 &#x2013; Subsequent events,
                the Company received gross proceeds of approximately $25.0 million from its February 2026 private placement which closed on
                February 18, 2026. The Company believes its current available cash and cash equivalents will be sufficient to fund its operations for at least the next 12 months from the date of issuance of these financial statements.&lt;/span&gt;&lt;span style="color: #000000;"&gt;&lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-size: 10pt; font-weight: normal; font-style: normal;"&gt;&lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
             &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-size: 10pt; font-weight: normal; font-style: normal;"&gt; &lt;span style="font-weight: normal; font-size: 10pt; font-style: normal;"&gt;In the future, the Company may need to raise additional funds until it is able to generate sufficient revenues to fund its development activities. The Company&#x2019;s future
                  operating activities, coupled with its plans to raise capital or issue debt financing, may provide additional liquidity in the future, however these actions are not solely within the control of the Company, and the Company is unable to
                  predict the outcome of these actions to generate the liquidity ultimately required.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Use of Estimates&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the
          consolidated financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Segment Information&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company&#x2019;s chief operating
          decision maker in deciding how to allocate resources and assessing performance. The Company&#x2019;s chief operating decision maker is its Chief Executive Officer. The Company&#x2019;s Chief Executive Officer views the Company&#x2019;s operations and manages its
          business in one operating segment, which is the business of development of products related to vision performance and health.
          Accordingly, the consolidated financial statements and accompanying notes contained herein include the measure of profit or loss&lt;span style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;, categories of expenses and other financial information that is evaluated by the Company&#x2019;s Chief Executive Officer&lt;/span&gt;.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Cash and Cash Equivalents&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company considers all highly liquid investments with an original maturity of 90 days or less at the time of deposit to be cash equivalents.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;Concentration of Credit Risk&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Financial


































































































































                  instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. Management follows approved policies established by the Company&#x2019;s Board of Directors (the &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#x201c;&lt;/span&gt;Board&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#x201d;&lt;/span&gt;) to reduce credit risk associated with the Company&#x2019;s cash deposit and investment accounts. Pursuant to these policies,
                  the Company limits its exposure through the kind, quality and concentration of its investments. The Company&#x2019;s cash and cash equivalents are held or managed by three financial institutions in the United States. As of December 31, 2025, the
                  Company had cash equivalents of $44.8 million that were not eligible for coverage by Federal Deposit Insurance Corporation.
                  These balances are invested in funds whose assets consist almost entirely of securities issued by the U.S. Treasury or guaranteed by the U.S. government.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Short-term Investments&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and records them on a settlement
                date basis. The Company&#x2019;s short-term investments are comprised of equity securities, which in accordance with the fair value hierarchy described below are recorded at fair value using Level l inputs on the balance sheets. Subsequent changes
                in fair values are recorded in other income, net on the consolidated statements of comprehensive loss. The Company classifies investments available to fund current operations as current assets on its consolidated balance sheets. The Company
                did not recognize any impairments on its investments to date through December 31, 2025.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Revenue Recognition&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt; &lt;br/&gt;
              &lt;/div&gt;

&lt;div style="text-align: justify;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company follows the provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) 606, &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;. The guidance provides a five-step model to determine how revenue is recognized. The Company
                  has entered into license agreements which have revenue recognition implications (See Note 10 &#x2013; License and Collaboration Revenue and Other Funding Agreements).&lt;/span&gt; &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;In determining the appropriate amount of revenue to be recognized, the Company performs the following steps: (i) identification of the contracts with a
                customer; (ii) determination of the performance obligations in the contract; (iii) measurement of the transaction price, including potential constraints on variable consideration; (iv) allocation of the transaction price to the performance
                obligations based on estimated stand-alone selling prices; and (v) recognition of revenue when (or as) the Company satisfies a performance obligation.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to
                  the customer and is the unit of account in ASC 606. Performance obligations may include license rights, development and other services. Significant management judgment is required to determine the level of effort required under an
                  arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations are either completed or become
                  inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each
                performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount
                rates and probabilities of technical and regulatory success. The Company allocates the total transaction price to each performance obligation based on the relative standalone selling prices of the promised goods or service underlying each
                performance obligation.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&lt;span style="font-weight: normal; font-style: italic;"&gt;Licenses of intellectual property and research and development services:&lt;/span&gt; If the license to the
                Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license
                is transferred to the customer, and the customer can use and benefit from the license. For licenses that are bundled with other obligations, such as research and development services, the Company utilizes judgment to assess the nature of
                the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue
                from non-refundable, up-front fees. For research and development services that are distinct from a license transfer obligation, the Company determines whether the services are satisfied over time or at a point in time and, if over time, the
                appropriate method of measuring progress for purposes of recognizing revenue from such services. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue
                recognition.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;span style="font-style: italic; font-weight: normal;"&gt;Milestone payments:&lt;/span&gt; &lt;/span&gt;At the inception of each arrangement
                that includes milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
                that a significant revenue reversal will not occur, the value of the associated milestone (such as a regulatory submission) is included in the transaction price. Milestone payments that are not within the control of the Company, such as
                approvals from regulators, are not considered probable of being achieved until such contingency occurs (such as receipt of those approvals).&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&lt;span style="font-weight: normal; font-style: italic;"&gt;Royalties:&lt;/span&gt; For arrangements that include sales-based royalties, including milestone payments
                based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to
                which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
              &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none;"&gt;Contract
                  Assets and Unbilled Receivables&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;br/&gt;
                &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; The Company recognizes contract assets and unbilled receivables when goods or services are transferred to the customer before the customer pays or before reimbursement for payment is billed or due, excluding any
                  amounts presented as an account receivable. The Company recorded contract assets &lt;span style="font-weight: normal; font-style: normal;"&gt;and unbilled receivables &lt;/span&gt;in connection with a license and collaboration agreement (See Note
                  10 &#x2013; License and Collaboration Revenue and Other Funding Agreements).&lt;/span&gt;&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0); font-style: italic; font-variant: normal; text-transform: none;"&gt;Accounts Receivable and Allowances for Credit Losses&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt; &lt;br/&gt;
                      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-size: 10.0pt; color: #000000;"&gt;The Company records a provision for credit losses, when
                          appropriate, based on historical experience, current conditions and reasonable supportable forecasts. The Company estimates credit losses over the remaining expected life of an asset by, among other things&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-size: 10.0pt; color: #000000;"&gt;,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; primarily using historical experience and current economic conditions that could affect the collectability of the balances in the future. Account balances are written
                          off against the allowance when the Company believes that it is probable that the receivable will not be recovered. Actual write-offs may be in excess of the Company&#x2019;s estimated allowance.&lt;/span&gt; The Company has not incurred any bad debt expense to date and no allowance for credit losses has been recorded during the periods presented.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
              &lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-weight: bold; font-style: italic; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Research and Development&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Research and development expenses consist of costs incurred in
            performing research and development activities, including compensation, benefits and stock-based compensation costs for research and development employees and costs for consultants, costs associated with nonclinical studies and clinical trials,
            regulatory activities, manufacturing activities to support clinical activities, license fees, nonlegal patent costs, fees paid to external service providers that conduct certain research and development, and an allocation of overhead expenses.
            Research and development expenses include costs that are reimbursed under the Viatris License Agreement (See Note 10 &#x2013; License and Collaboration Revenue and Other Funding Agreements).&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
        &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-style: italic; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;General
            and Administrative Expenses&lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;br/&gt;
            General and administrative expenses consist primarily of personnel-related costs, including salaries, benefits and stock-based compensation costs, for personnel in functions not directly associated with research and development activities.
            Other significant costs include insurance coverage for directors and officers and other property and liability exposures, legal fees relating to intellectual property and corporate matters, business development costs, professional fees for
            accounting and tax services, and other consulting costs.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; font-weight: bold; font-style: italic;"&gt;Acquired In-Process Research and Development Expenses&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; font-weight: bold; font-style: italic;"&gt;-&lt;/span&gt;Process Research and Development Expenses&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-style: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt; &lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company includes costs to acquire or in-license product candidates as acquired
              in-process research and development expenses (&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#x201c;&lt;/span&gt;&lt;/span&gt;IPR&amp;amp;D&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#x201d;&lt;/span&gt;&lt;/span&gt;). These costs are immediately
              expensed provided that the payments do not also represent processes or activities that would constitute a &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#x201c;business&#x201d; as defined under GAAP or provided that the product candidate has not
                  achieved regulatory approval for marketing&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;, and absent obtaining such approval, has no
              alternative future use. Royalties owed on future sales of any licensed product will be expensed in the period the related revenues are recognized (See Note 2 &lt;/span&gt;&#x2013;&lt;span style="font-style: italic;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-style: normal;"&gt;Mergers).&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;
           &lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Other Income, net&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Other income, net includes interest earned from cash and
          cash equivalent investments, realized and unrealized gains (losses) from equity investments, the gain in connection with Opus Acquisition, and reimbursements in connection with grants and other sources when they occur.&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Stock-Based Compensation&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;The Company accounts for stock-based compensation in accordance with the provisions of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 718, &lt;span style="font-style: italic;"&gt;Compensation &#x2014; Stock Compensation&lt;/span&gt;. Accordingly, compensation costs related to equity instruments granted are recognized at the grant date fair value. The Company records forfeitures when they occur.
            Stock-based compensation arrangements to non-employees are accounted for in accordance with the applicable provisions of ASC 718.&lt;/div&gt;

&lt;div&gt;&#160;
            &lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt; Warrant liabilities&lt;br/&gt;
          &lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;br/&gt;
            &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company issued warrants to
              purchase equity securities in connection with the March 2025 financings and are recorded under the warrant liabilities line item in the accompanying consolidated balance sheets (See Note 7 &#x2013; Financings). The Company accounts for these
              warrants as a liability at fair value when the valuation inputs are not fixed and determinable. Additionally, issuance costs associated with the warrant liability were expensed as incurred and reflected as financing costs in the accompanying
              consolidated statements of comprehensive loss. The Company adjusts the liability for changes in fair value until the earlier of the exercise or expiration of the warrants. Any future change in fair value of the warrant liabilities, when
              outstanding, is recognized in the consolidated statements of comprehensive loss under the fair value change in warrant and other derivative liabilities line item.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Other Derivative Liabilities&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="letter-spacing: normal; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company evaluates all features contained in financing agreements to determine if there are any embedded derivatives that require
              separation from the underlying agreement under ASC 815 &#x2013; Derivatives and Hedging. An embedded derivative that requires separation is accounted for as a separate liability from the host agreement. The separated embedded derivative is accounted
              for separately on a fair market value basis. The Company records the fair value change of a separated embedded derivative at each reporting period in the consolidated statements of comprehensive loss under the fair value change in derivative
              liability line item. The Company determined that certain features under an equity line financing collectively qualified as an embedded derivative (See Note 7 &#x2014; Financings). The derivative was accounted for separately from the underlying
              equity line financing agreement.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Fair Value Measurements&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company follows accounting guidance that emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Fair value is defined as
          &#x201c;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#x201d; Fair value measurements are defined on a three-level hierarchy:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                &lt;div&gt;Level 1 inputs: Unadjusted quoted prices for identical assets or liabilities in active markets;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                &lt;div&gt;Level 2 inputs: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, whether directly or indirectly, for substantially the full term of the
                  asset or liability; and&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                &lt;div&gt;Level 3 inputs: Unobservable inputs in which there is little or no market data available, which requires management to develop its own assumptions in pricing the asset or liability.&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;As of December 31, 2025 and 2024, the fair
              values of cash and cash equivalents, accounts receivable, contract assets and unbilled receivables, prepaid and other assets, accounts payable, and accrued expenses approximated their carrying values because of the short-term nature of these
              assets or liabilities. The fair value of the short-term investments were based on observable Level 1 inputs in the form of quoted market prices from a major stock exchange. The fair value of the warrant liabilities and derivative liability
              associated with the equity line financing facility was based on cash flow models discounted at current implied market rates representing expected returns by market participants for similar instruments and are based on Level 3 inputs as well
              the Company&#x2019;s underlying stock price and associated volatility, expected term of the financing and market interest rates. There were no
              transfers between fair value hierarchy levels during the years ended December 31, 2025 and 2024&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;.&lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;As of December 31, 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;" valign="bottom"&gt;
                  &lt;div&gt;Description&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;Level 1&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;Level 2&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;Level 3&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-weight: bold; font-style: italic;" valign="bottom"&gt;
                  &lt;div&gt;Assets:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;Short-term investments&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;* &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;* &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div&gt;Total assets at fair value&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;* &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;* &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Liabilities:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Warrant liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;$ &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;25,985&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;$ &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;$ &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;25,985&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Total liabilities at fair value&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$ &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;25,985&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$ &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;25,985&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&#160; *De minimis value&lt;br/&gt;
        &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 52.02%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="14" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;As of December 31, 2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 52.02%;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;Description&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Level 1&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Level 2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Level 3&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%;" valign="bottom"&gt;
                &lt;div style="font-weight: bold; font-style: italic;"&gt;Assets:&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;Short-term investments&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;Total assets at fair value&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52.02%; padding-bottom: 4px; background-color: rgb(204, 238, 255);"&gt;&lt;span style="font-style: italic; font-weight: bold;"&gt;Liabilities:&lt;/span&gt; &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 9.01%; text-align: right; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.01%; padding: 0px 0px 4px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 9.01%; text-align: right; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.01%; padding: 0px 0px 4px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 9.01%; text-align: right; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.01%; padding: 0px 0px 4px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 9.01%; text-align: right; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.01%; padding: 0px 0px 4px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52.02%; padding-bottom: 4px;"&gt;Derivative liability &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="border-bottom: 2px solid #000000; vertical-align: bottom; width: 1.01%;"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="border-bottom: 2px solid #000000; vertical-align: bottom; width: 9.01%; text-align: right;"&gt;2&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.01%; padding: 0px 0px 4px;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="border-bottom: 2px solid #000000; vertical-align: bottom; width: 1.01%;"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="border-bottom: 2px solid #000000; vertical-align: bottom; width: 9.01%; text-align: right;"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.01%; padding: 0px 0px 4px;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="border-bottom: 2px solid #000000; vertical-align: bottom; width: 1.01%;"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="border-bottom: 2px solid #000000; vertical-align: bottom; width: 9.01%; text-align: right;"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.01%; padding: 0px 0px 4px;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="border-bottom: 2px solid #000000; vertical-align: bottom; width: 1.01%;"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="border-bottom: 2px solid #000000; vertical-align: bottom; width: 9.01%; text-align: right;"&gt;&#160;2&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.01%; padding: 0px 0px 4px;"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52.02%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;Total liabilities at fair value &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;2&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;2&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following tables provides a roll-forward of short-term investments, warrant liabilities, and derivative liabilities measured at fair value on a recurring basis
            using observable Level 1 and Level 3 inputs, as applicable, for the years ended December 31, 2025 and 2024 (in thousands):&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;2025&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;2024&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Short-term investments&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance as of beginning of period&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;15&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Unrealized loss&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(2&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(13&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance as of end of period&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="margin-left: 5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;2025&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;2024&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; orphans: 2; text-align: left; text-indent: -9.6px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Warrant liabilities&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Issuance of March 2025 Warrants and March 2025 Private Placement Warrants&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;15,520&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: middle; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;Exercises &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(1,052&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Change





                      in fair value&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;11,517&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Balance as of end of period&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;25,985&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
              &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                      &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                      &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt; 2025&lt;br/&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                      &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;2024&lt;br/&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
                      &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; orphans: 2; text-align: left; text-indent: -9.6px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Other derivative liabilities&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;74&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%;" valign="bottom"&gt;
                      &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Change in fair value&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(2&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(72&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Balance as of end of period&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
            &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;There were no financial instruments measured on a
          non-recurring basis for any of the periods presented.&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt;Recent Accounting Pronouncements&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;span style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;In December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2023-09 Income Taxes (Topic 740):
              Improvements to Income Tax Disclosures, which enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance also includes certain other amendments to improve the effectiveness of
              income tax disclosures. This ASU is effective for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years and should be applied on a prospective basis, with retrospective application permitted. The
              Company adopted this standard and applied the disclosure requirements on a prospective basis effective for the year ended December 31, 2025. The adoption did not have a material impact on our consolidated financial position or results of
              operations. See Note 12 &#x2013; Income Taxes, for our updated income tax disclosure.&lt;br/&gt;
              &lt;br/&gt;
              In November 2024, the FASB issued ASU 2024-03 Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU is intended to improve the
              disclosures related to expenses and provide investors more detailed information about certain types of expenses. This ASU is effective for annual periods beginning after December 15, 2026, and interim reporting periods beginning after
              December 15, 2027, with early adoption permitted. The Company is currently evaluating the potential impact that this new standard will have on our consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <ird:NatureOfBusinessPolicyTextBlock
      contextRef="c20250101to20251231"
      id="Text_68f5c12775f248cfacda58b1a27b3d97">
&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Nature of Business and Basis of Presentation&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none; text-align: justify;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Opus Genetics, Inc. (the &#x201c;Company&#x201d; or &#x201c;Opus&#x201d;), a Delaware corporation formerly known as Ocuphire Pharma, Inc. (the &#x201c;Company&#x201d; or
              &#x201c;Opus&#x201d;), is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (&#x201c;IRDs&#x201d;) and small molecule therapies for other ophthalmic disorders. The Company&#x2019;s headquarters is located in
              Durham, North Carolina.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none; text-align: justify;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none; text-align: justify;"&gt;On October 22, 2024, the Company acquired a private corporation then operating under the name of
            &#x201c;Opus Genetics, Inc.&#x201d; (&#x201c;Private Opus&#x201d;) pursuant to the terms of an Agreement and Plan of Merger, dated as of October 22, 2024 (such agreement, the &#x201c;Merger Agreement&#x201d; and the transaction consummated via the Merger Agreement, the &#x201c;Opus
            Acquisition&#x201d;), by and among the Company, Private Opus, and certain merger subsidiaries party thereto.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none; text-align: justify;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none; text-align: justify;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company&#x2019;s pipeline features a portfolio of adeno-associated virus (&#x201c;AAV&#x201d;) based gene therapies that address mutations in
              genes that cause different forms of Leber congenital amaurosis (&#x201c;LCA&#x201d;), bestrophinopathy, and retinitis pigmentosa. The Company&#x2019;s most advanced gene therapy program is designed to address mutations in the LCA5 gene, which encodes the
              lebercilin protein. More specifically, we are developing OPGx-LCA5 to treat LCA5-associated inherited retinal disease (&#x201c;IRD&#x201d;), an early-onset retinal degeneration, and an open-label, dose-escalation Phase 1/2 clinical trial is ongoing.
              OPGx-BEST1 is another gene therapy candidate in the Company&#x2019;s portfolio. This asset is being developed for the treatment of IRDs associated with mutations in the BEST1 gene, which can lead to legal blindness. Apart from gene therapies, the
              Company&#x2019;s pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a relatively non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size as well as APX3330, a novel small-molecule inhibitor of Ref-1 designed
              to slow the progression of non-proliferative diabetic retinopathy.&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none; text-align: justify;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none; text-align: justify;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;In November 2022, the Company entered into a license and collaboration agreement (as amended, the &#x201c;Viatris License Agreement&#x201d;)
              with Viatris, Inc. (&#x201c;Viatris&#x201d;), pursuant to which it granted Viatris an exclusive license to develop, manufacture, import, export and commercialize its refractive product candidate Phentolamine Ophthalmic Solution 0.75% (&#x201c;PS&#x201d;). PS is a
              once-daily eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. PS was approved by the FDA for the treatment of pharmacologically induced mydriasis produced by adrenergic agonists (e.g.,
              phenylephrine) or parasympatholytic (e.g., tropicamide) agents, or a combination thereof under the brand name RYZUMVI&#xae; in September 2023 and was launched commercially in April 2024. Additionally, the Company is currently developing PS for
              decreased vision under mesopic (low) light conditions following keratorefractive surgery, pursuant to a received FDA agreement under Special Protocol Assessment (&#x201c;SPA&#x201d;).&lt;/span&gt;&lt;/div&gt;
</ird:NatureOfBusinessPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="c20250101to20251231"
      id="Text_e2d30901866545bca4cdd5a077080d92">
&lt;div&gt;

        &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Basis of Presentation&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting
            standards generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and include the accounts of the Company&#x2019;s subsidiary, the former Private Opus entity (&#x201c;OPUSTX, LLC&#x201d;). All intercompany transactions and balances have been eliminated in
            consolidation. The Company&#x2019;s fiscal year begins on January 1 and ends on December 31.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            The derivative liability line item reflected on the December 31, 2024 consolidated balance sheet in the prior year was reclassified to the accrued expenses and other liabilities line item in the amount of $2,000.&lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;
</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="c20241231_RestatementAxis_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="-3"
      id="Fact_dff36e10f5874c70bf3ae2f63fe8da8b"
      unitRef="U001">2000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="c20241231_RestatementAxis_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="-3"
      id="Fact_6ac48f8c65dd4d9ea2a3c8e7f687616d"
      unitRef="U001">2000000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <ird:LiquidityPolicyTextBlock
      contextRef="c20250101to20251231"
      id="Text_eaffe4c1d53c4a4690543b0acdb5e796">
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; font-weight: bold; text-align: justify; text-transform: none;"&gt;&lt;span style="font-weight: bold; font-style: italic;"&gt;Liquidity&lt;/span&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none; font-weight: bold; font-style: italic;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: bold; font-style: italic;"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none; font-weight: normal; font-size: 10pt; font-style: normal;"&gt;Since its inception, the Company has devoted
            substantially all of its resources to drug development and clinical trials.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none; font-weight: normal; font-style: normal;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;As of
                December 31, 2025, the Company had $45.1 million in cash and cash equivalents and, as disclosed in Note 14 &#x2013; Subsequent events,
                the Company received gross proceeds of approximately $25.0 million from its February 2026 private placement which closed on
                February 18, 2026. The Company believes its current available cash and cash equivalents will be sufficient to fund its operations for at least the next 12 months from the date of issuance of these financial statements.&lt;/span&gt;&lt;span style="color: #000000;"&gt;&lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-size: 10pt; font-weight: normal; font-style: normal;"&gt;&lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
             &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-size: 10pt; font-weight: normal; font-style: normal;"&gt; &lt;span style="font-weight: normal; font-size: 10pt; font-style: normal;"&gt;In the future, the Company may need to raise additional funds until it is able to generate sufficient revenues to fund its development activities. The Company&#x2019;s future
                  operating activities, coupled with its plans to raise capital or issue debt financing, may provide additional liquidity in the future, however these actions are not solely within the control of the Company, and the Company is unable to
                  predict the outcome of these actions to generate the liquidity ultimately required.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
</ird:LiquidityPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20251231"
      decimals="-5"
      id="Fact_7aad3acd082a47eab2cf237c92175f48"
      unitRef="U001">45100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20260201to20260218_SubsequentEventTypeAxis_SubsequentEventMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember"
      decimals="-5"
      id="Fact_b6d0ab16e7ad44baae27b59e7cfdea50"
      unitRef="U001">25000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:UseOfEstimates
      contextRef="c20250101to20251231"
      id="Text_d631c76888554c638da934f5c3017694">
&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Use of Estimates&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the
          consolidated financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/div&gt;
</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="c20250101to20251231"
      id="Text_fc20d4026e33408c9d950b2383011b29">
&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Segment Information&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company&#x2019;s chief operating
          decision maker in deciding how to allocate resources and assessing performance. The Company&#x2019;s chief operating decision maker is its Chief Executive Officer. The Company&#x2019;s Chief Executive Officer views the Company&#x2019;s operations and manages its
          business in one operating segment, which is the business of development of products related to vision performance and health.
          Accordingly, the consolidated financial statements and accompanying notes contained herein include the measure of profit or loss&lt;span style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;, categories of expenses and other financial information that is evaluated by the Company&#x2019;s Chief Executive Officer&lt;/span&gt;.&lt;/div&gt;
</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c20250101to20251231"
      decimals="INF"
      id="Fact_3e23fc8ddc904f8eacfd6575bb531cf1"
      unitRef="U004">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="c20250101to20251231"
      id="Text_fffa5701510144218e097a4d10b4df8b">
&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Cash and Cash Equivalents&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company considers all highly liquid investments with an original maturity of 90 days or less at the time of deposit to be cash equivalents.&lt;/div&gt;
</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="c20250101to20251231"
      id="Text_5caaf684a68345f99084758bbe2b7437">
&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;Concentration of Credit Risk&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Financial


































































































































                  instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. Management follows approved policies established by the Company&#x2019;s Board of Directors (the &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#x201c;&lt;/span&gt;Board&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#x201d;&lt;/span&gt;) to reduce credit risk associated with the Company&#x2019;s cash deposit and investment accounts. Pursuant to these policies,
                  the Company limits its exposure through the kind, quality and concentration of its investments. The Company&#x2019;s cash and cash equivalents are held or managed by three financial institutions in the United States. As of December 31, 2025, the
                  Company had cash equivalents of $44.8 million that were not eligible for coverage by Federal Deposit Insurance Corporation.
                  These balances are invested in funds whose assets consist almost entirely of securities issued by the U.S. Treasury or guaranteed by the U.S. government.&lt;/span&gt;&lt;/div&gt;
</us-gaap:ConcentrationRiskCreditRisk>
    <ird:CashEquivalentsNotEligibleForFDICCoverage
      contextRef="c20251231"
      decimals="-5"
      id="Fact_3206ea2e566f4432a99dbb59d50bec3a"
      unitRef="U001">44800000</ird:CashEquivalentsNotEligibleForFDICCoverage>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="c20250101to20251231"
      id="Text_617e973009fd4c2ebcc2315c407db08d">
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Short-term Investments&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and records them on a settlement
                date basis. The Company&#x2019;s short-term investments are comprised of equity securities, which in accordance with the fair value hierarchy described below are recorded at fair value using Level l inputs on the balance sheets. Subsequent changes
                in fair values are recorded in other income, net on the consolidated statements of comprehensive loss. The Company classifies investments available to fund current operations as current assets on its consolidated balance sheets. The Company
                did not recognize any impairments on its investments to date through December 31, 2025.&lt;/div&gt;
</us-gaap:InvestmentPolicyTextBlock>
    <ird:ImpairmentOnInvestment
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_6cbf2898be9b4d2c8c10157715002d24"
      unitRef="U001">0</ird:ImpairmentOnInvestment>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="c20250101to20251231"
      id="Text_38ef849f5ae24df4afc422e341c81547">
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Revenue Recognition&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt; &lt;br/&gt;
              &lt;/div&gt;

&lt;div style="text-align: justify;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company follows the provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) 606, &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;. The guidance provides a five-step model to determine how revenue is recognized. The Company
                  has entered into license agreements which have revenue recognition implications (See Note 10 &#x2013; License and Collaboration Revenue and Other Funding Agreements).&lt;/span&gt; &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;In determining the appropriate amount of revenue to be recognized, the Company performs the following steps: (i) identification of the contracts with a
                customer; (ii) determination of the performance obligations in the contract; (iii) measurement of the transaction price, including potential constraints on variable consideration; (iv) allocation of the transaction price to the performance
                obligations based on estimated stand-alone selling prices; and (v) recognition of revenue when (or as) the Company satisfies a performance obligation.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to
                  the customer and is the unit of account in ASC 606. Performance obligations may include license rights, development and other services. Significant management judgment is required to determine the level of effort required under an
                  arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations are either completed or become
                  inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each
                performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount
                rates and probabilities of technical and regulatory success. The Company allocates the total transaction price to each performance obligation based on the relative standalone selling prices of the promised goods or service underlying each
                performance obligation.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&lt;span style="font-weight: normal; font-style: italic;"&gt;Licenses of intellectual property and research and development services:&lt;/span&gt; If the license to the
                Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license
                is transferred to the customer, and the customer can use and benefit from the license. For licenses that are bundled with other obligations, such as research and development services, the Company utilizes judgment to assess the nature of
                the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue
                from non-refundable, up-front fees. For research and development services that are distinct from a license transfer obligation, the Company determines whether the services are satisfied over time or at a point in time and, if over time, the
                appropriate method of measuring progress for purposes of recognizing revenue from such services. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue
                recognition.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;span style="font-style: italic; font-weight: normal;"&gt;Milestone payments:&lt;/span&gt; &lt;/span&gt;At the inception of each arrangement
                that includes milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable
                that a significant revenue reversal will not occur, the value of the associated milestone (such as a regulatory submission) is included in the transaction price. Milestone payments that are not within the control of the Company, such as
                approvals from regulators, are not considered probable of being achieved until such contingency occurs (such as receipt of those approvals).&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&lt;span style="font-weight: normal; font-style: italic;"&gt;Royalties:&lt;/span&gt; For arrangements that include sales-based royalties, including milestone payments
                based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to
                which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/div&gt;
</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <ird:ContractAssetsAndUnbilledReceivablesPolicyTextBlock
      contextRef="c20250101to20251231"
      id="Text_0a22b1bed034426096d4f579a3d1d09a">
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none;"&gt;Contract
                  Assets and Unbilled Receivables&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;br/&gt;
                &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; The Company recognizes contract assets and unbilled receivables when goods or services are transferred to the customer before the customer pays or before reimbursement for payment is billed or due, excluding any
                  amounts presented as an account receivable. The Company recorded contract assets &lt;span style="font-weight: normal; font-style: normal;"&gt;and unbilled receivables &lt;/span&gt;in connection with a license and collaboration agreement (See Note
                  10 &#x2013; License and Collaboration Revenue and Other Funding Agreements).&lt;/span&gt;&lt;br/&gt;
              &lt;/div&gt;
</ird:ContractAssetsAndUnbilledReceivablesPolicyTextBlock>
    <us-gaap:CreditLossFinancialInstrumentPolicyTextBlock
      contextRef="c20250101to20251231"
      id="Text_e0378714dfbb4168bf1f8b8b24247308">
&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0); font-style: italic; font-variant: normal; text-transform: none;"&gt;Accounts Receivable and Allowances for Credit Losses&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt; &lt;br/&gt;
                      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-size: 10.0pt; color: #000000;"&gt;The Company records a provision for credit losses, when
                          appropriate, based on historical experience, current conditions and reasonable supportable forecasts. The Company estimates credit losses over the remaining expected life of an asset by, among other things&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-size: 10.0pt; color: #000000;"&gt;,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; primarily using historical experience and current economic conditions that could affect the collectability of the balances in the future. Account balances are written
                          off against the allowance when the Company believes that it is probable that the receivable will not be recovered. Actual write-offs may be in excess of the Company&#x2019;s estimated allowance.&lt;/span&gt; The Company has not incurred any bad debt expense to date and no allowance for credit losses has been recorded during the periods presented.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
</us-gaap:CreditLossFinancialInstrumentPolicyTextBlock>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_e2502870140748ebb5dc14a36d89d2d9"
      unitRef="U001">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_98a26319ddfc442d9d06bfab394edd05"
      unitRef="U001">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_5dac7d91b3db4afcb40ffdc11363aabc"
      unitRef="U001">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="c20250101to20251231"
      id="Text_99d496e0fd6247c18634c2d01b8aac26">
&lt;div style="text-align: justify;"&gt;&lt;span style="font-weight: bold; font-style: italic; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Research and Development&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Research and development expenses consist of costs incurred in
            performing research and development activities, including compensation, benefits and stock-based compensation costs for research and development employees and costs for consultants, costs associated with nonclinical studies and clinical trials,
            regulatory activities, manufacturing activities to support clinical activities, license fees, nonlegal patent costs, fees paid to external service providers that conduct certain research and development, and an allocation of overhead expenses.
            Research and development expenses include costs that are reimbursed under the Viatris License Agreement (See Note 10 &#x2013; License and Collaboration Revenue and Other Funding Agreements).&lt;/span&gt;&lt;/div&gt;
</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="c20250101to20251231"
      id="Text_9643c1787cf44eca99bc9745f6bb784c">
&lt;div style="text-align: justify;"&gt;&lt;span style="font-style: italic; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;General
            and Administrative Expenses&lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;br/&gt;
            General and administrative expenses consist primarily of personnel-related costs, including salaries, benefits and stock-based compensation costs, for personnel in functions not directly associated with research and development activities.
            Other significant costs include insurance coverage for directors and officers and other property and liability exposures, legal fees relating to intellectual property and corporate matters, business development costs, professional fees for
            accounting and tax services, and other consulting costs.&lt;/span&gt;&lt;/div&gt;
</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="c20250101to20251231"
      id="Text_bce9c4feb689447b9723189271568f0f">
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; font-weight: bold; font-style: italic;"&gt;Acquired In-Process Research and Development Expenses&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; font-weight: bold; font-style: italic;"&gt;-&lt;/span&gt;Process Research and Development Expenses&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-style: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt; &lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company includes costs to acquire or in-license product candidates as acquired
              in-process research and development expenses (&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#x201c;&lt;/span&gt;&lt;/span&gt;IPR&amp;amp;D&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#x201d;&lt;/span&gt;&lt;/span&gt;). These costs are immediately
              expensed provided that the payments do not also represent processes or activities that would constitute a &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#x201c;business&#x201d; as defined under GAAP or provided that the product candidate has not
                  achieved regulatory approval for marketing&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;, and absent obtaining such approval, has no
              alternative future use. Royalties owed on future sales of any licensed product will be expensed in the period the related revenues are recognized (See Note 2 &lt;/span&gt;&#x2013;&lt;span style="font-style: italic;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-style: normal;"&gt;Mergers).&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;
</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <ird:OtherIncomeExpenseNetPolicyTextBlock
      contextRef="c20250101to20251231"
      id="Text_e1df800b48924c1e8bb1915674ef31b4">
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Other Income, net&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Other income, net includes interest earned from cash and
          cash equivalent investments, realized and unrealized gains (losses) from equity investments, the gain in connection with Opus Acquisition, and reimbursements in connection with grants and other sources when they occur.&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;
</ird:OtherIncomeExpenseNetPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="c20250101to20251231"
      id="Text_33c799f4f8954cea87024db2d024952c">
&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Stock-Based Compensation&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;The Company accounts for stock-based compensation in accordance with the provisions of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 718, &lt;span style="font-style: italic;"&gt;Compensation &#x2014; Stock Compensation&lt;/span&gt;. Accordingly, compensation costs related to equity instruments granted are recognized at the grant date fair value. The Company records forfeitures when they occur.
            Stock-based compensation arrangements to non-employees are accounted for in accordance with the applicable provisions of ASC 718.&lt;/div&gt;
</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:DerivativesMethodsOfAccountingNonhedgingDerivatives
      contextRef="c20250101to20251231"
      id="Text_28428333b045411294d9429aadfb4a5f">
&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt; Warrant liabilities&lt;br/&gt;
          &lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;br/&gt;
            &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company issued warrants to
              purchase equity securities in connection with the March 2025 financings and are recorded under the warrant liabilities line item in the accompanying consolidated balance sheets (See Note 7 &#x2013; Financings). The Company accounts for these
              warrants as a liability at fair value when the valuation inputs are not fixed and determinable. Additionally, issuance costs associated with the warrant liability were expensed as incurred and reflected as financing costs in the accompanying
              consolidated statements of comprehensive loss. The Company adjusts the liability for changes in fair value until the earlier of the exercise or expiration of the warrants. Any future change in fair value of the warrant liabilities, when
              outstanding, is recognized in the consolidated statements of comprehensive loss under the fair value change in warrant and other derivative liabilities line item.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;
</us-gaap:DerivativesMethodsOfAccountingNonhedgingDerivatives>
    <us-gaap:DerivativesEmbeddedDerivatives
      contextRef="c20250101to20251231"
      id="Text_3451c390e6f64f02af165dee0017e0bf">
&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Other Derivative Liabilities&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="letter-spacing: normal; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company evaluates all features contained in financing agreements to determine if there are any embedded derivatives that require
              separation from the underlying agreement under ASC 815 &#x2013; Derivatives and Hedging. An embedded derivative that requires separation is accounted for as a separate liability from the host agreement. The separated embedded derivative is accounted
              for separately on a fair market value basis. The Company records the fair value change of a separated embedded derivative at each reporting period in the consolidated statements of comprehensive loss under the fair value change in derivative
              liability line item. The Company determined that certain features under an equity line financing collectively qualified as an embedded derivative (See Note 7 &#x2014; Financings). The derivative was accounted for separately from the underlying
              equity line financing agreement.&lt;/span&gt;&lt;/div&gt;
</us-gaap:DerivativesEmbeddedDerivatives>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="c20250101to20251231"
      id="Text_b414ac34fc9c45ffa88fd7f8a11f6432">
&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Fair Value Measurements&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company follows accounting guidance that emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Fair value is defined as
          &#x201c;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#x201d; Fair value measurements are defined on a three-level hierarchy:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                &lt;div&gt;Level 1 inputs: Unadjusted quoted prices for identical assets or liabilities in active markets;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                &lt;div&gt;Level 2 inputs: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, whether directly or indirectly, for substantially the full term of the
                  asset or liability; and&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                &lt;div&gt;Level 3 inputs: Unobservable inputs in which there is little or no market data available, which requires management to develop its own assumptions in pricing the asset or liability.&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;As of December 31, 2025 and 2024, the fair
              values of cash and cash equivalents, accounts receivable, contract assets and unbilled receivables, prepaid and other assets, accounts payable, and accrued expenses approximated their carrying values because of the short-term nature of these
              assets or liabilities. The fair value of the short-term investments were based on observable Level 1 inputs in the form of quoted market prices from a major stock exchange. The fair value of the warrant liabilities and derivative liability
              associated with the equity line financing facility was based on cash flow models discounted at current implied market rates representing expected returns by market participants for similar instruments and are based on Level 3 inputs as well
              the Company&#x2019;s underlying stock price and associated volatility, expected term of the financing and market interest rates. There were no
              transfers between fair value hierarchy levels during the years ended December 31, 2025 and 2024&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;.&lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;As of December 31, 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;" valign="bottom"&gt;
                  &lt;div&gt;Description&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;Level 1&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;Level 2&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;Level 3&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-weight: bold; font-style: italic;" valign="bottom"&gt;
                  &lt;div&gt;Assets:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;Short-term investments&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;* &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;* &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div&gt;Total assets at fair value&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;* &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;* &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Liabilities:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Warrant liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;$ &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;25,985&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;$ &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;$ &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;25,985&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Total liabilities at fair value&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$ &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;25,985&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$ &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;25,985&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&#160; *De minimis value&lt;br/&gt;
        &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 52.02%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="14" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;As of December 31, 2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 52.02%;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;Description&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Level 1&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Level 2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Level 3&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%;" valign="bottom"&gt;
                &lt;div style="font-weight: bold; font-style: italic;"&gt;Assets:&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;Short-term investments&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;Total assets at fair value&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52.02%; padding-bottom: 4px; background-color: rgb(204, 238, 255);"&gt;&lt;span style="font-style: italic; font-weight: bold;"&gt;Liabilities:&lt;/span&gt; &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 9.01%; text-align: right; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.01%; padding: 0px 0px 4px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 9.01%; text-align: right; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.01%; padding: 0px 0px 4px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 9.01%; text-align: right; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.01%; padding: 0px 0px 4px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 9.01%; text-align: right; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.01%; padding: 0px 0px 4px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52.02%; padding-bottom: 4px;"&gt;Derivative liability &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="border-bottom: 2px solid #000000; vertical-align: bottom; width: 1.01%;"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="border-bottom: 2px solid #000000; vertical-align: bottom; width: 9.01%; text-align: right;"&gt;2&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.01%; padding: 0px 0px 4px;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="border-bottom: 2px solid #000000; vertical-align: bottom; width: 1.01%;"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="border-bottom: 2px solid #000000; vertical-align: bottom; width: 9.01%; text-align: right;"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.01%; padding: 0px 0px 4px;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="border-bottom: 2px solid #000000; vertical-align: bottom; width: 1.01%;"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="border-bottom: 2px solid #000000; vertical-align: bottom; width: 9.01%; text-align: right;"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.01%; padding: 0px 0px 4px;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="border-bottom: 2px solid #000000; vertical-align: bottom; width: 1.01%;"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="border-bottom: 2px solid #000000; vertical-align: bottom; width: 9.01%; text-align: right;"&gt;&#160;2&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.01%; padding: 0px 0px 4px;"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52.02%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;Total liabilities at fair value &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;2&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;2&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following tables provides a roll-forward of short-term investments, warrant liabilities, and derivative liabilities measured at fair value on a recurring basis
            using observable Level 1 and Level 3 inputs, as applicable, for the years ended December 31, 2025 and 2024 (in thousands):&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;2025&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;2024&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Short-term investments&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance as of beginning of period&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;15&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Unrealized loss&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(2&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(13&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance as of end of period&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="margin-left: 5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;2025&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;2024&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; orphans: 2; text-align: left; text-indent: -9.6px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Warrant liabilities&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Issuance of March 2025 Warrants and March 2025 Private Placement Warrants&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;15,520&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: middle; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;Exercises &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(1,052&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Change





                      in fair value&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;11,517&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Balance as of end of period&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;25,985&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
              &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                      &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                      &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt; 2025&lt;br/&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                      &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;2024&lt;br/&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
                      &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; orphans: 2; text-align: left; text-indent: -9.6px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Other derivative liabilities&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;74&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%;" valign="bottom"&gt;
                      &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Change in fair value&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(2&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(72&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Balance as of end of period&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
            &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;There were no financial instruments measured on a
          non-recurring basis for any of the periods presented.&lt;br/&gt;
        &lt;/div&gt;
</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_85be1a329880484e9f758a339f9078ab"
      unitRef="U001">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_5a4e8060c772430c94a91e60be8c6786"
      unitRef="U001">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_5417f39ea6324f788eadad1e51418b19"
      unitRef="U001">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_24e13f23312a428497203baf0bdd93c4"
      unitRef="U001">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="c20250101to20251231"
      id="Text_7650f1381721419d9c52d6c18d2a805e">
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;
          &lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;As of December 31, 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;" valign="bottom"&gt;
                  &lt;div&gt;Description&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;Level 1&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;Level 2&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;Level 3&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-weight: bold; font-style: italic;" valign="bottom"&gt;
                  &lt;div&gt;Assets:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;Short-term investments&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;* &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;* &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div&gt;Total assets at fair value&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;* &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;* &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Liabilities:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Warrant liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;$ &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;25,985&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;$ &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;$ &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;25,985&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Total liabilities at fair value&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$ &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;25,985&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$ &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;25,985&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&#160; *De minimis value&lt;br/&gt;
        &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 52.02%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="14" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;As of December 31, 2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 52.02%;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;Description&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Level 1&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Level 2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Level 3&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%;" valign="bottom"&gt;
                &lt;div style="font-weight: bold; font-style: italic;"&gt;Assets:&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;Short-term investments&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;Total assets at fair value&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52.02%; padding-bottom: 4px; background-color: rgb(204, 238, 255);"&gt;&lt;span style="font-style: italic; font-weight: bold;"&gt;Liabilities:&lt;/span&gt; &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 9.01%; text-align: right; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.01%; padding: 0px 0px 4px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 9.01%; text-align: right; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.01%; padding: 0px 0px 4px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 9.01%; text-align: right; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.01%; padding: 0px 0px 4px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 9.01%; text-align: right; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.01%; padding: 0px 0px 4px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52.02%; padding-bottom: 4px;"&gt;Derivative liability &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="border-bottom: 2px solid #000000; vertical-align: bottom; width: 1.01%;"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="border-bottom: 2px solid #000000; vertical-align: bottom; width: 9.01%; text-align: right;"&gt;2&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.01%; padding: 0px 0px 4px;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="border-bottom: 2px solid #000000; vertical-align: bottom; width: 1.01%;"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="border-bottom: 2px solid #000000; vertical-align: bottom; width: 9.01%; text-align: right;"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.01%; padding: 0px 0px 4px;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="border-bottom: 2px solid #000000; vertical-align: bottom; width: 1.01%;"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="border-bottom: 2px solid #000000; vertical-align: bottom; width: 9.01%; text-align: right;"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.01%; padding: 0px 0px 4px;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="border-bottom: 2px solid #000000; vertical-align: bottom; width: 1.01%;"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="border-bottom: 2px solid #000000; vertical-align: bottom; width: 9.01%; text-align: right;"&gt;&#160;2&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.01%; padding: 0px 0px 4px;"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52.02%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;Total liabilities at fair value &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;2&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;2&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20251231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_57024ca792b84d5695790322cb307405"
      unitRef="U001">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20251231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_50fabaf66e0b4b968d0afc4baef8fade"
      unitRef="U001">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20251231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_069c0786f8054ee99f53be8f0a23c409"
      unitRef="U001">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20251231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_99067d2ffbad48da926d28d06297afbc"
      unitRef="U001">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20251231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_9e4a671901244d3dbc772db49292d188"
      unitRef="U001">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_9e00fa25816b49b3b3a94f5ba3c78eaa"
      unitRef="U001">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_356da4b15b1b4aeabe9a5b5153a5a759"
      unitRef="U001">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_20bf5917d9834f6ab3f67d89b7d4aee7"
      unitRef="U001">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20251231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_DerivativeMember"
      decimals="-3"
      id="Fact_80a84d6fff25433db993492e8119134b"
      unitRef="U001">25985000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_DerivativeMember"
      decimals="-3"
      id="Fact_9b5b7b07e90e44ada9dffd948bc79169"
      unitRef="U001">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_DerivativeMember"
      decimals="-3"
      id="Fact_eef267e109a541d2a66f458022c8c05c"
      unitRef="U001">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_DerivativeMember"
      decimals="-3"
      id="Fact_9d651ee06bfd4659b09143a59ef1db0c"
      unitRef="U001">25985000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20251231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_41ecbef79e974a52b37fc7cfb8fcf3e1"
      unitRef="U001">25985000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_d59a3cb95feb4b60bd69df8c832ddc60"
      unitRef="U001">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_b34415de505b486ab80fbd58564449ae"
      unitRef="U001">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_d761fc0369ae457c869479cfdd7867d7"
      unitRef="U001">25985000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20241231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_a07b86bd37234092a1ca6001b90e40a1"
      unitRef="U001">2000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20241231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_68400f59fa30499284b16c0aaa794a82"
      unitRef="U001">2000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20241231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_1ff6aa4dc60741569d2137bbf0800d9d"
      unitRef="U001">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20241231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_535a9b90c2db461bb831d8844ec27e32"
      unitRef="U001">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20241231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_29dff9f1446b45878295b2ec6ac57032"
      unitRef="U001">2000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_8e562fa3126c4fcba5114ae677e56fb5"
      unitRef="U001">2000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_2b753e84e1c543cd906bd3182832f565"
      unitRef="U001">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_5afc2ca1bb18481ea071f324e81d4605"
      unitRef="U001">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20241231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_OtherDerivativeLiabilitiesMember"
      decimals="-3"
      id="Fact_67418cf23bd84fc6b3a3c437faf3c325"
      unitRef="U001">2000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_OtherDerivativeLiabilitiesMember"
      decimals="-3"
      id="Fact_6a57e8c2b82c4de0a1807e38edade294"
      unitRef="U001">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_OtherDerivativeLiabilitiesMember"
      decimals="-3"
      id="Fact_4b335bcf96fe472e8065ae3a1f6cbc16"
      unitRef="U001">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_OtherDerivativeLiabilitiesMember"
      decimals="-3"
      id="Fact_3d025e6007c54a99a1f9c4662876c8ee"
      unitRef="U001">2000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20241231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_0ef51fb85d80448fa369ce572b80048d"
      unitRef="U001">2000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_f3de25384426446ab5b4dac424566ca1"
      unitRef="U001">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_ae63d84775574df18916dd91abbbdfcc"
      unitRef="U001">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_6af6dc0472414aec9ab69adf4098e0b4"
      unitRef="U001">2000</us-gaap:LiabilitiesFairValueDisclosure>
    <ird:ScheduleOfFairValueInvestmentsWarrantLiabilitiesAndDerivativeLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="c20250101to20251231"
      id="Text_d65ff2eeae3d4e1b9b11505c635ca1e3">
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following tables provides a roll-forward of short-term investments, warrant liabilities, and derivative liabilities measured at fair value on a recurring basis
            using observable Level 1 and Level 3 inputs, as applicable, for the years ended December 31, 2025 and 2024 (in thousands):&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;2025&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;2024&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Short-term investments&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance as of beginning of period&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;15&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Unrealized loss&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(2&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(13&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance as of end of period&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="margin-left: 5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;2025&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;2024&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; orphans: 2; text-align: left; text-indent: -9.6px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Warrant liabilities&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Issuance of March 2025 Warrants and March 2025 Private Placement Warrants&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;15,520&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: middle; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;Exercises &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(1,052&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Change





                      in fair value&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;11,517&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Balance as of end of period&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;25,985&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
              &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                      &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                      &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt; 2025&lt;br/&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                      &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;2024&lt;br/&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
                      &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; orphans: 2; text-align: left; text-indent: -9.6px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Other derivative liabilities&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;74&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%;" valign="bottom"&gt;
                      &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Change in fair value&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(2&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(72&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Balance as of end of period&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                      &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
            &lt;/div&gt;
</ird:ScheduleOfFairValueInvestmentsWarrantLiabilitiesAndDerivativeLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20241231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_9744c0b166f04464b956af9623d028d2"
      unitRef="U001">2000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20231231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_a3fc36c7cc634e019aa23d72cfcd48d5"
      unitRef="U001">15000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="c20250101to20251231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_1aaf41a99e624cf4a950c77ec78f76ef"
      unitRef="U001">-2000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="c20240101to20241231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_66100b750086456d99fcd1490ebc613a"
      unitRef="U001">-13000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20251231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_48a729580e474c0b9ab4af5b752843e0"
      unitRef="U001">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20241231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_80a48102b15a487ea7c679cf7e344a59"
      unitRef="U001">2000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_633366268db14980b2b35a077a690da0"
      unitRef="U001">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_0eba4e4c4c4d41fa84f122042c1bc20e"
      unitRef="U001">0</us-gaap:DerivativeLiabilitiesCurrent>
    <ird:DerivativeLiabilityIssuanceOfWarrantsAndPrivatePlacementWarrants
      contextRef="c20250101to20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_abbe1258698244f6ae707700679f8efd"
      unitRef="U001">15520000</ird:DerivativeLiabilityIssuanceOfWarrantsAndPrivatePlacementWarrants>
    <ird:DerivativeLiabilityIssuanceOfWarrantsAndPrivatePlacementWarrants
      contextRef="c20240101to20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_9077044d79cb4c3a81089669945855f6"
      unitRef="U001">0</ird:DerivativeLiabilityIssuanceOfWarrantsAndPrivatePlacementWarrants>
    <ird:DerivativeLiabilityExcercisesCurrent
      contextRef="c20250101to20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_1e5cde32ac304efea7c6dd9ecd850b78"
      unitRef="U001">1052000</ird:DerivativeLiabilityExcercisesCurrent>
    <ird:DerivativeLiabilityExcercisesCurrent
      contextRef="c20240101to20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_9c6d97e5774c4cd3b50daad34a6c1fc4"
      unitRef="U001">0</ird:DerivativeLiabilityExcercisesCurrent>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c20250101to20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_d2df7560e8b743cf81225396139f16f5"
      unitRef="U001">11517000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c20240101to20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_df19c772aee2491ebae092a98d85b2d3"
      unitRef="U001">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_a6f11233f9fd494da58ac5abc05b491b"
      unitRef="U001">25985000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_DerivativeFinancialInstrumentsLiabilitiesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_27b40949507942b49ef708136b8fab06"
      unitRef="U001">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_OtherDerivativeLiabilitiesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_899e105def554c8984aad502b685af75"
      unitRef="U001">2000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="c20231231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_OtherDerivativeLiabilitiesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_1526de02730947fbbada170c0b7faa4c"
      unitRef="U001">74000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c20250101to20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_OtherDerivativeLiabilitiesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_d2e580d35dde4a2f84df1ad6470c6b91"
      unitRef="U001">-2000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c20240101to20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_OtherDerivativeLiabilitiesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_31ef28ec48614f5cb6d853b02233768c"
      unitRef="U001">-72000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_OtherDerivativeLiabilitiesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_1f55d65297674c1b90ab49b57947b537"
      unitRef="U001">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_OtherDerivativeLiabilitiesMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_dcbdd6ebf50a411b8b8fecf6a31f0a4a"
      unitRef="U001">2000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="c20241231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember"
      decimals="-3"
      id="Fact_de03bbb586104a909ea403e625d0e6b8"
      unitRef="U001">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="c20251231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember"
      decimals="-3"
      id="Fact_ce3cbcfe9b054185a4097edc8b692cde"
      unitRef="U001">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="c20250101to20251231"
      id="Text_75d122433aa740f2a2c8dc3fe0b0ac37">
&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt;Recent Accounting Pronouncements&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;span style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;In December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2023-09 Income Taxes (Topic 740):
              Improvements to Income Tax Disclosures, which enhances income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance also includes certain other amendments to improve the effectiveness of
              income tax disclosures. This ASU is effective for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years and should be applied on a prospective basis, with retrospective application permitted. The
              Company adopted this standard and applied the disclosure requirements on a prospective basis effective for the year ended December 31, 2025. The adoption did not have a material impact on our consolidated financial position or results of
              operations. See Note 12 &#x2013; Income Taxes, for our updated income tax disclosure.&lt;br/&gt;
              &lt;br/&gt;
              In November 2024, the FASB issued ASU 2024-03 Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU is intended to improve the
              disclosures related to expenses and provide investors more detailed information about certain types of expenses. This ASU is effective for annual periods beginning after December 15, 2026, and interim reporting periods beginning after
              December 15, 2027, with early adoption permitted. The Company is currently evaluating the potential impact that this new standard will have on our consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="c20250101to20251231"
      id="Text_0f80218aa1404bf1bcf82c50f1661e71">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold;"&gt;2.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold;"&gt;Mergers&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&#160;&#160;
          &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold; font-size: 10pt; background-color: rgb(255, 255, 255); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;Acquisition of Opus Genetics&lt;/div&gt;

&lt;div style="font-size: 10pt;"&gt;&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;Summary of Transaction&lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"&gt;As described in
                Note 1 &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#x2013; Company Description and
                  Summary of Significant Accounting Policies,&lt;/span&gt; on October 22, 2024, the Company completed the stock purchase of Private Opus. Under the terms of the Merger Agreement, at the closing of the Opus Acquisition, the Company issued to the
                security holders of Private Opus 5,237,063 shares of the Company&#x2019;s common stock, par value $0.0001 per share, and 14,145.374
                shares of the Company&#x2019;s preferred stock, par value $0.0001 per share, designated as Series A Non-Voting Convertible Preferred
                Stock (&#x201c;Series A Preferred Stock&#x201d;), each share of which was converted into 1,000 shares of common stock on May 5, 2025 upon
                stockholder approval that occurred on April 30, 2025.&lt;br/&gt;
              &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; background-color: rgb(255, 255, 255);"&gt;The total consideration in connection with the Opus Acquisition was $25.8 million. The transaction was accounted for as an asset acquisition in accordance with ASC 805, &lt;span style="font-style: italic;"&gt;Business Combinations&lt;/span&gt;, as one asset, the underlying intellectual property associated with the IRD therapies, comprised more than 90% of Private Opus&#x2019;s assets.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; background-color: rgb(255, 255, 255);"&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; background-color: rgb(255, 255, 255);"&gt;Under this method of accounting, the Company was the accounting acquirer for financial reporting purposes.
              This determination was primarily based on the facts that, immediately following the Opus Acquisition: (i) legacy Ocuphire&#x2019;s stockholders held the majority of the voting rights in the combined company based on their ownership, (ii) Private
              Opus held only three out of the nine board of director seats of the combined company, and (iii) Private Opus senior management held only one of the five key positions in the senior management of the combined company. &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; background-color: rgb(255, 255, 255);"&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; background-color: rgb(255, 255, 255);"&gt;Private Opus was determined to be a variable interest entity (&#x201c;VIE&#x201d;) as it was insufficiently capitalized to
              fund future operations. As such, the acquisition costs of $2.8 million were expensed and not capitalized as part of the purchase
              price in accordance with ASC 805.&#160; In addition, the fair value of the net assets and IPR&amp;amp;D acquired in excess of the purchase price was recorded as an asset acquisition gain and was included in the other income, net line item in the
              consolidated statements of comprehensive loss. The reported operating results prior to the Opus Acquisition are those of legacy Ocuphire.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-align: justify; background-color: rgb(255, 255, 255);"&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: #FFFFFF; margin: 0px 0px 0px; letter-spacing: normal; white-space: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 0px; text-transform: none;"&gt;The following summarizes the purchase price paid in the Opus Acquisition&#160;(in thousands, except share and per share amounts):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: #FFFFFF; margin: 0px 0px 0px; letter-spacing: normal; white-space: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 0px; text-transform: none;"&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;"&gt;Number of common shares of the combined organization owned by the Company&#x2019;s Pre-acquisition Private Opus stockholders&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;5,237,063&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;Multiplied by the fair value per share of the Company&#x2019;s common stock (1)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;1.33&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;Fair value of common stock issued to affect the Opus Acquisition&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;6,965&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 88%;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;"&gt;Number of Series A preferred shares of the combined organization owned by the Company&#x2019;s Pre-acquisition Private Opus stockholders&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;14,145.374&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;Multiplied by the fair value per share of the Company&#x2019;s Series A preferred stock (2)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;1.3321&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;Fair value of preferred stock issued to affect the Opus Acquisition&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;18,843&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;Purchase price&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;25,808&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
                        &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-size: 10pt;"&gt;(1)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                        &lt;div style="color: rgb(0, 0, 0); text-align: justify; font-size: 10pt;"&gt;
                          &lt;div&gt;Based on the last reported sale price of the Company&#x2019;s common stock on the Nasdaq Capital Market on October 22, 2024, the
                            closing date of the Opus Acquisition.&lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
                &lt;div&gt; &lt;br/&gt;
                &lt;/div&gt;

              &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
                      &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-size: 10pt;"&gt;(2)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                      &lt;div style="color: rgb(0, 0, 0); text-align: justify; font-size: 10pt;"&gt;
                        &lt;div&gt;Based on the fair market valuation of the Series A preferred stock that considered the reported sale price of the Company&#x2019;s
                          common stock on the Nasdaq Capital Market on October 22, 2024 on an as converted basis (1,000 shares of common stock
                          for 1 share of preferred stock), the closing date of the Opus Acquisition, as well as the underlying dividend
                          provisions on a discounted cash flow basis.&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt; &lt;br/&gt;
              &lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The fair value of the net assets and IPR&amp;amp;D acquired was as follows
                (in thousands):&lt;/span&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="letter-spacing: normal; width: 100%; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;Cash acquired&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;1,210&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 88%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;Net liabilities assumed&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;(955&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;IPR&amp;amp;D (3)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;28,000&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; font-size: 10pt; width: 88%; padding-bottom: 4px;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;Net assets and IPR&amp;amp;D acquired&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;28,255&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;  &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
                      &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-size: 10pt; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;(3)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
                      &lt;div style="color: rgb(0, 0, 0); text-align: justify; font-size: 10pt;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
                        &lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
                          &lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';"&gt;Represents the Private Opus Acquisition research and development projects which were in-process, but not yet completed, and which the Company may advance post the Opus
                              Acquisition. This includes the development of gene therapies for IRDs.&#160;Current accounting standards require that the fair value of IPR&amp;amp;D projects acquired in an asset acquisition with no alternative future use be charged
                              to expense on the acquisition date. The acquired IPR&amp;amp;D did not have outputs or employees. The fair value of the&lt;span style="letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; IPR&amp;amp;D was recorded at fair value using Level 3 inputs. A Multi-Period Excess Earnings Method (&#x201c;MPEEM&#x201d;)
                                model was applied which incorporates assumptions such as future earnings and margins in connection with the further development and commercialization of IRD therapies, and a discount rate of &lt;span style="text-indent: 0pt;"&gt;20&lt;/span&gt;%.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
                        &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
                      &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
              &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-bottom: 12pt;"&gt;The gain recorded upon the close of the Opus Acquisition is recapped below (in
              thousands):&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;Purchase Price&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;25,808&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;Net assets and IPR&amp;amp;D acquired&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;28,255&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; font-size: 10pt; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;Gain recorded upon close of Opus Acquisition&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;2,447&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;
             &lt;br class="Apple-interchange-newline"/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-weight: bold; font-style: italic; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; Merger with Rexahn&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;On November 5, 2020, the Company completed a merger transaction with Rexahn Pharmaceuticals, Inc. (&#x201c;Rexahn). In connection with the merger (&#x201c;Rexahn Merger&#x201d;), the
            Company, Shareholder Representatives Services LLC, as representative of the Rexahn stockholders prior to the Merger, and Olde Monmouth Stock Transfer Co., Inc., as the rights agent, entered into the Contingent Value Rights Agreement (the &#x201c;CVR
            Agreement&#x201d;).&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Pursuant to the terms of the Rexahn Merger and the CVR Agreement, Rexahn stockholders of record as of immediately prior to the effective time of the Rexahn Merger
            received one contingent value right (&#x201c;CVR&#x201d;) for each share of Rexahn common stock held.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"&gt; &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;The CVRs are not transferable, except in certain limited circumstances, will not be certificated or evidenced by any instrument, will not accrue interest and will not be registered with the SEC or listed for trading on any exchange.
                The CVR Agreement will continue in effect until the later of the end of the CVR Term (as defined in the CVR Agreement) and the payment of all amounts payable thereunder. &lt;/span&gt;As of December 31, 2025, no payments subject to the CVR Agreement had been received beyond those previously reported in the second and third quarters of calendar year
              2021. In addition, no milestones had been accrued as of December 31, 2025, as there were no potential milestones yet considered probable beyond those previously reported.&lt;/div&gt;
</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c20241022to20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_a6e1aa763951428da7ea9b6c6a7f0ef0"
      unitRef="U002">5237063</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="4"
      id="Fact_2794c7b101e5430a8f7bcb2c80d0437d"
      unitRef="U003">0.0001</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c20241022to20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="3"
      id="Fact_2c18d2cda1ba4f86a787111ba08949b1"
      unitRef="U002">14145.374</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="4"
      id="Fact_a96bfd3d68f64915bb8b367b07bdd91a"
      unitRef="U003">0.0001</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact_df238f9003ab43b0b4fc68f3d51e201d"
      unitRef="U002">1000</us-gaap:PreferredStockConvertibleSharesIssuable>
    <ird:AssetAcquisitionPurchasePriceConsiderationTransferred
      contextRef="c20241022to20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember"
      decimals="-5"
      id="Fact_6620e6aea7c64db29d0540edc97ff66e"
      unitRef="U001">25800000</ird:AssetAcquisitionPurchasePriceConsiderationTransferred>
    <ird:NumberOfAssetAcquired
      contextRef="c20241022to20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember"
      decimals="INF"
      id="Fact_cd3a5d553e8240c7ac06eb1ed2db0cdd"
      unitRef="U005">1</ird:NumberOfAssetAcquired>
    <ird:PercentageOfUnderlyingIntellectualPropertyAssociatedWithIRDTherapiesInAcquisition
      contextRef="c20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember_RangeAxis_MaximumMember"
      decimals="2"
      id="Fact_37e9b2ce05954d26a2201b4923592ff8"
      unitRef="U006">0.90</ird:PercentageOfUnderlyingIntellectualPropertyAssociatedWithIRDTherapiesInAcquisition>
    <ird:AssetAcquisitionAcquisitionRelatedCosts
      contextRef="c20241022to20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember"
      decimals="-5"
      id="Fact_c391427370834007aef873c423913284"
      unitRef="U001">2800000</ird:AssetAcquisitionAcquisitionRelatedCosts>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="c20250101to20251231"
      id="Text_e47589ba2b9b41afb94ffff8229f6311">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: #FFFFFF; margin: 0px 0px 0px; letter-spacing: normal; white-space: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 0px; text-transform: none;"&gt;The following summarizes the purchase price paid in the Opus Acquisition&#160;(in thousands, except share and per share amounts):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: #FFFFFF; margin: 0px 0px 0px; letter-spacing: normal; white-space: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-indent: 0px; text-transform: none;"&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 88%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;"&gt;Number of common shares of the combined organization owned by the Company&#x2019;s Pre-acquisition Private Opus stockholders&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;5,237,063&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;Multiplied by the fair value per share of the Company&#x2019;s common stock (1)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;1.33&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;Fair value of common stock issued to affect the Opus Acquisition&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;6,965&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 88%;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;"&gt;Number of Series A preferred shares of the combined organization owned by the Company&#x2019;s Pre-acquisition Private Opus stockholders&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;14,145.374&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;Multiplied by the fair value per share of the Company&#x2019;s Series A preferred stock (2)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;1.3321&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;Fair value of preferred stock issued to affect the Opus Acquisition&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;18,843&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 88%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;Purchase price&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;25,808&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div&gt;
                &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
                        &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-size: 10pt;"&gt;(1)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                        &lt;div style="color: rgb(0, 0, 0); text-align: justify; font-size: 10pt;"&gt;
                          &lt;div&gt;Based on the last reported sale price of the Company&#x2019;s common stock on the Nasdaq Capital Market on October 22, 2024, the
                            closing date of the Opus Acquisition.&lt;/div&gt;
                        &lt;/div&gt;
                      &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
                &lt;div&gt; &lt;br/&gt;
                &lt;/div&gt;

              &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
                      &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-size: 10pt;"&gt;(2)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                      &lt;div style="color: rgb(0, 0, 0); text-align: justify; font-size: 10pt;"&gt;
                        &lt;div&gt;Based on the fair market valuation of the Series A preferred stock that considered the reported sale price of the Company&#x2019;s
                          common stock on the Nasdaq Capital Market on October 22, 2024 on an as converted basis (1,000 shares of common stock
                          for 1 share of preferred stock), the closing date of the Opus Acquisition, as well as the underlying dividend
                          provisions on a discounted cash flow basis.&lt;/div&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c20241022to20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_add6038d53c64808b3601415d4b2a8ec"
      unitRef="U002">5237063</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <ird:AssetAcquisitionSharePrice
      contextRef="c20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="INF"
      id="Fact_834b0fc015cb442180a8d6a9001f9919"
      unitRef="U003">1.33</ird:AssetAcquisitionSharePrice>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c20241022to20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_11cde8474d7045b8adb27b72e59b6495"
      unitRef="U001">6965000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c20241022to20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="3"
      id="Fact_10220c673ebd46dbaa7f5429018d4722"
      unitRef="U002">14145.374</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <ird:AssetAcquisitionSharePrice
      contextRef="c20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="4"
      id="Fact_3cd30ebd31c04e40b9691b3eff5105b8"
      unitRef="U003">1.3321</ird:AssetAcquisitionSharePrice>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c20241022to20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="-3"
      id="Fact_17fb274a6a4e43fc9dc78585d9d7fa20"
      unitRef="U001">18843000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <ird:AssetAcquisitionPurchasePriceConsiderationTransferred
      contextRef="c20241022to20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember"
      decimals="-3"
      id="Fact_8c702ea65fe949079e07f7e033d2f355"
      unitRef="U001">25808000</ird:AssetAcquisitionPurchasePriceConsiderationTransferred>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c20241022to20241022_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_a58a784c734c46b8af8c10f5420ed0b8"
      unitRef="U002">1000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c20241022to20241022_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact_eab5809e507142cc9ba0b6ac59744b0c"
      unitRef="U002">1</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="c20250101to20251231"
      id="Text_016dc2dc7037417cafc5d8981b6f3d7c">
&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The fair value of the net assets and IPR&amp;amp;D acquired was as follows
                (in thousands):&lt;/span&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="letter-spacing: normal; width: 100%; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;Cash acquired&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;1,210&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 88%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;Net liabilities assumed&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;(955&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;IPR&amp;amp;D (3)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;28,000&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; font-size: 10pt; width: 88%; padding-bottom: 4px;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;Net assets and IPR&amp;amp;D acquired&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;28,255&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;  &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
                      &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-size: 10pt; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;(3)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
                      &lt;div style="color: rgb(0, 0, 0); text-align: justify; font-size: 10pt;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
                        &lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
                          &lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';"&gt;Represents the Private Opus Acquisition research and development projects which were in-process, but not yet completed, and which the Company may advance post the Opus
                              Acquisition. This includes the development of gene therapies for IRDs.&#160;Current accounting standards require that the fair value of IPR&amp;amp;D projects acquired in an asset acquisition with no alternative future use be charged
                              to expense on the acquisition date. The acquired IPR&amp;amp;D did not have outputs or employees. The fair value of the&lt;span style="letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; IPR&amp;amp;D was recorded at fair value using Level 3 inputs. A Multi-Period Excess Earnings Method (&#x201c;MPEEM&#x201d;)
                                model was applied which incorporates assumptions such as future earnings and margins in connection with the further development and commercialization of IRD therapies, and a discount rate of &lt;span style="text-indent: 0pt;"&gt;20&lt;/span&gt;%.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
                        &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
                      &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <ird:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="c20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember"
      decimals="-3"
      id="Fact_51cdd47cf0df4d27b1213dde59d49473"
      unitRef="U001">1210000</ird:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <ird:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="c20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember"
      decimals="-3"
      id="Fact_c8f3908b00ad4ae2a8060774c7ebbe77"
      unitRef="U001">955000</ird:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <ird:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopmentExpenses
      contextRef="c20241022to20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember"
      decimals="-3"
      id="Fact_876b3eb4978b497091cb6aa51397b83e"
      unitRef="U001">28000000</ird:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopmentExpenses>
    <ird:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="c20241022to20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember"
      decimals="-3"
      id="Fact_862efae5824f4346a11afa692c32bb6d"
      unitRef="U001">28255000</ird:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <ird:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopmentExpensesDiscountRate
      contextRef="c20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember"
      decimals="2"
      id="Fact_4b2bac4a9fd04bb19d9cc57e2327b0b8"
      unitRef="U006">0.20</ird:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopmentExpensesDiscountRate>
    <ird:GainRecordedUponAcquisitionTableTextBlock
      contextRef="c20250101to20251231"
      id="Text_f397b4a9ecf54bd0a6869cd5ae48644f">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-bottom: 12pt;"&gt;The gain recorded upon the close of the Opus Acquisition is recapped below (in
              thousands):&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;Purchase Price&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;25,808&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;Net assets and IPR&amp;amp;D acquired&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;28,255&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; font-size: 10pt; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;Gain recorded upon close of Opus Acquisition&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;2,447&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</ird:GainRecordedUponAcquisitionTableTextBlock>
    <ird:AssetAcquisitionPurchasePriceConsiderationTransferred
      contextRef="c20241022to20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember"
      decimals="-3"
      id="Fact_bd4d6859adae42bd8f5540ce355c032d"
      unitRef="U001">25808000</ird:AssetAcquisitionPurchasePriceConsiderationTransferred>
    <ird:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="c20241022to20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember"
      decimals="-3"
      id="Fact_cfbe42132be04b2a8780c97ffa42f69a"
      unitRef="U001">28255000</ird:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <ird:AssetAcquisitionGainLossOnAcquisitionOfBusiness
      contextRef="c20241022to20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember"
      decimals="-3"
      id="Fact_864f8993c371420cb892da96f0453572"
      unitRef="U001">2447000</ird:AssetAcquisitionGainLossOnAcquisitionOfBusiness>
    <ird:ContingentValueRightEntitledPerEachShareOfCommonStockHeld
      contextRef="c20201105_BusinessAcquisitionAxis_RexahnStockholdersMember"
      decimals="INF"
      id="Fact_23dad48c485f4705ba5e6fdce90037d5"
      unitRef="U007">1</ird:ContingentValueRightEntitledPerEachShareOfCommonStockHeld>
    <ird:PaymentsDueUnderCVRAgreement
      contextRef="c20251231"
      decimals="0"
      id="Fact_df42f271131940d4a75e55cc50e234f8"
      unitRef="U001">0</ird:PaymentsDueUnderCVRAgreement>
    <ird:NumberOfMilestonesAccrued
      contextRef="c20251231"
      decimals="INF"
      id="Fact_73a68a1dea8742f6b2a4d5cf2b177740"
      unitRef="U008">0</ird:NumberOfMilestonesAccrued>
    <ird:NumberOfPotentialMilestones
      contextRef="c20210930"
      decimals="INF"
      id="Fact_98d853f3478e4d06b288e570fb53153e"
      unitRef="U008">0</ird:NumberOfPotentialMilestones>
    <ird:NumberOfPotentialMilestones
      contextRef="c20210630"
      decimals="INF"
      id="Fact_2144f0175c944e7aaab402bd8a7e9ac4"
      unitRef="U008">0</ird:NumberOfPotentialMilestones>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="c20250101to20251231"
      id="Text_f4324b533615435389f491f72b1e967e">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold;"&gt;3.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold;"&gt;Commitments and Contingencies &lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Apexian Sublicense Agreement&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;On January 21, 2020, the Company entered into a sublicense agreement with Apexian Pharmaceuticals, Inc., pursuant to which it obtained exclusive worldwide patent and
          other intellectual property rights. In exchange for the patent and other intellectual rights, the Company agreed to certain milestone payments and royalty payments on future sales (See Note 9 &#x2013; Apexian Sublicense Agreement). As of December 31,
          2025, there was sufficient uncertainty with regard to any future cash milestone payments under the sublicense agreement that no liabilities were recorded related to the sublicense agreement.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-style: italic; font-weight: bold;"&gt;University of Pennsylvania LCA5/RDH12 License Agreement&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;On June 15, 2022, Opus entered into an amended and restated license agreement (the &#x201c;LCA5/RDH12 Agreement&#x201d;) with the Trustees of the
              University of Pennsylvania (&#x201c;Penn&#x201d;) pursuant to which it was granted an exclusive, royalty-bearing license to certain patents and a non-exclusive license to certain information relating to products directed towards treatment or correction of
              mutation of the LCA5 or RDH12 genes. In return for these rights, the Company is obligated to make certain development, regulatory and commercial milestone payments up to a maximum potential aggregate amount of $2.6 million and royalty payments on future net sales of such products. Until the Company is required to pay royalties under the LCA5/RDH12
              Agreement, the Company must pay a &lt;span style="font-style: italic;"&gt;de minimis&lt;/span&gt; annual license maintenance fee to Penn.&#160; The Company is also obligated to make payments on any sublicense income, with such percentage depending on the
              stage of product development, which there was no sublicense income for any of the periods presented. During the year ended December 31, 2025, the first development milestone under the LCA5/RDH12 Agreement specific to LCA5 was satisfied, and
              the amount of $0.1 million was included in research and development expense. &lt;br/&gt;
            &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic; font-weight: bold;"&gt;Iveric Asset Purchase Agreement &#x2013; BEST1 and RHO Programs&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;On December 23, 2022, Opus entered into an asset purchase agreement (the &#x201c;Iveric Agreement&#x201d;) with a subsidiary of Iveric Bio, Inc. (&#x201c;Iveric&#x201d;) pursuant to which the
                Company acquired certain assets, including the BEST1 License (as defined below), relating to the BEST1 and RHO products. In return for these rights, the Company is obligated to make payments to Iveric upon the achievement of specified
                development and commercial milestones, the maximum potential aggregate amount of such payments being $111.7 million. During the
                year ended December 31, 2025, the first development milestone under the Iveric Agreement specific to BEST1 was satisfied, and the amount of $0.4
                million was included in research and development expense.&lt;/span&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-weight: bold; font-style: italic; font-size: 10pt;"&gt;Penn and University of Florida BEST1 License Agreement&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;On
              April 10, 2019, Iveric entered into an exclusive patent license agreement (as amended, the &#x201c;BEST1 License&#x201d;) with Penn and the University of Florida Research Foundation (&#x201c;UF&#x201d;), which agreement was assigned to Opus under the terms of the Iveric
              Agreement.&#160; Under the BEST1 License, Opus received exclusive patent rights and non-exclusive knowhow and data rights with regard to products to treat diseases associated with mutations in the BEST1 gene. In return for these rights, the
              Company is obligated to make payments to Penn upon the achievement of certain clinical, regulatory and commercial milestones, the maximum potential aggregate amount of such payments being $76.4 million.&#160; The Company is also obligated to make royalty payments on future net sales of licensed BEST1 products. Until the Company is required to pay royalties under
              the BEST1 License, the Company must pay a &lt;span style="font-style: italic;"&gt;de minimis&lt;/span&gt; annual license maintenance fee to UF and Penn. The Company must also make payments on any sublicense income, with such percentage depending on the
              stage of product development, which there was no sublicense income during any of the periods presented. In consideration for Penn and UF&#x2019;s consent to the assignment of the BEST1 License to us under the Iveric Agreement, the Company will also
              pay Penn a percentage of each milestone payment that we are required to pay to Iveric under the Iveric Agreement. During the year ended December 31, 2025, the first development milestone under the BEST1 License Agreement was satisfied, and
              the amount of $0.7 million was included in research and development expense.&lt;/span&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic; font-weight: bold;"&gt;Penn and UF RHO License Agreement&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;On June 6, 2018, Iveric entered into an exclusive patent license agreement (the &#x201c;RHO License&#x201d;) by and between Penn and UF pursuant to which
              the Company has exclusive patent rights and non-exclusive knowhow and data rights with regard to products to treat rhodopsin-mediated diseases as a result of the Iveric Agreement as defined above.&#160; In return for these rights, the Company is
              obligated to make development and commercial milestone payments, the maximum potential aggregate amount of such payments being $93.5
              million and royalty payments on future sales of such products. As of December 31, 2025, the Company determined that none of the future obligations under the agreement were probable and therefore no liabilities were recorded related to the
              agreement.&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: left; margin-bottom: 12pt; font-style: italic; font-weight: bold;"&gt;Massachusetts Eye and Ear Infirmary License Agreement&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; margin-bottom: 12pt; font-style: italic; font-weight: bold;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;On November 9, 2021, Opus entered into a license agreement with the Massachusetts Eye
              and Ear Infirmary (&#x201c;MEEI&#x201d;), granting an exclusive worldwide license of MEEI patents for use in the NMNAT1 program for all products and processes including the treatment of retinal disease in humans, and a non-exclusive worldwide license to
              technological information. In return for these rights, the Company is obligated to make development milestone payments, the maximum potential aggregate amount of such payments being $0.4 million and royalty payments on future sales of such products. As of December 31, 2025, the Company determined that none of the future obligations under the agreement
              were probable and therefore no liabilities were recorded related to the agreement.&lt;/span&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none;"&gt;Facility and Equipment Leases&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;On January 1, 2025, the Company relocated its headquarters to Durham, North Carolina. On July 1st, 2025, the Company extended the lease for its headquarters in
          Durham, North Carolina for three months through September 30, 2025, and the lease is currently in place on a month-to-month basis. The
          headquarters lease qualifies for the short-term exception under ASC 842, Leases.&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; The Company also leases additional laboratory space in Durham, North Carolina on a month-to-month basis. Upon the Opus Acquisition, the Company assumed a number of
          equipment leases that expired in &lt;span style="-sec-ix-hidden:Fact_a289e5cb1ce143a0827898c97406573a"&gt;July 2025&lt;/span&gt; and are now on a month-to-month basis. Both the laboratory space and equipment leases
          qualify for the short-term exception under ASC 842, Leases.&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; The rent expense associated with all leases amounted to $0.3
          million and $0.1 million during the years ended December 31, 2025 and 2024, respectively.&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Other&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;In the ordinary course of business, from time to time, the Company may be subject to a broad range of claims and legal proceedings that relate to contractual
          allegations, patent infringement and other claims. In addition, the Company from time to time may be potentially committed to reimburse third parties for costs incurred associated with business development related transactions upon the
          achievement of certain milestones. The Company establishes accruals when applicable for matters and commitments for which it believes losses are probable and can be reasonably estimated.&lt;/div&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ird:FutureMilestoneMethodRevenueNotRecognized
      contextRef="c20220615to20220615_HealthCareOrganizationRevenueSourcesAxis_DevelopmentRegulatoryAndCommercialMilestoneMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_UniversityOfPennsylvaniaLCA5RDH12LicenseAgreementMember"
      decimals="-5"
      id="Fact_d1b052767fef426ca45ae803d4c563b0"
      unitRef="U001">2600000</ird:FutureMilestoneMethodRevenueNotRecognized>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="c20250101to20251231_HealthCareOrganizationRevenueSourcesAxis_DevelopmentRegulatoryAndCommercialMilestoneMember_TypeOfArrangementAxis_UniversityOfPennsylvaniaLCA5RDH12LicenseAgreementMember"
      decimals="-5"
      id="Fact_157c1c5ccdaf48af91e47594b1e7ba15"
      unitRef="U001">100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <ird:FutureMilestoneMethodRevenueNotRecognized
      contextRef="c20221223to20221223_HealthCareOrganizationRevenueSourcesAxis_CommercialMilestonesMember_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_BEST1ProgramMember_TypeOfArrangementAxis_IvericAssetPurchaseAgreementMember"
      decimals="-5"
      id="Fact_e6826fa868a643f88de6b5b43d96921f"
      unitRef="U001">111700000</ird:FutureMilestoneMethodRevenueNotRecognized>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="c20250101to20251231_HealthCareOrganizationRevenueSourcesAxis_CommercialMilestonesMember_SubsidiarySaleOfStockAxis_BEST1ProgramMember_TypeOfArrangementAxis_IvericAssetPurchaseAgreementMember"
      decimals="-5"
      id="Fact_3418c0fe8aef48ba94a8f9f8e542300c"
      unitRef="U001">400000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <ird:FutureMilestoneMethodRevenueNotRecognized
      contextRef="c20190410to20190410_HealthCareOrganizationRevenueSourcesAxis_CommercialMilestonesMember_ProductOrServiceAxis_FirstLicensedProductMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_PennAndUniversityOfFloridaBEST1LicenseAgreementMember"
      decimals="-5"
      id="Fact_aa3392a82da042f2840f9726c9d59ec6"
      unitRef="U001">76400000</ird:FutureMilestoneMethodRevenueNotRecognized>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="c20250101to20251231_HealthCareOrganizationRevenueSourcesAxis_CommercialMilestonesMember_ProductOrServiceAxis_FirstLicensedProductMember_TypeOfArrangementAxis_PennAndUniversityOfFloridaBEST1LicenseAgreementMember"
      decimals="-5"
      id="Fact_b7f99527cdc84479aed1d8f3fe1f020d"
      unitRef="U001">700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <ird:FutureMilestoneMethodRevenueNotRecognized
      contextRef="c20180606to20180606_HealthCareOrganizationRevenueSourcesAxis_DevelopmentRegulatoryAndCommercialMilestoneMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_PennAndUFRHOLicenseAgreementMember"
      decimals="-5"
      id="Fact_33237c3fc0e24ac2ab049069805fa8bb"
      unitRef="U001">93500000</ird:FutureMilestoneMethodRevenueNotRecognized>
    <ird:FutureMilestoneMethodRevenueNotRecognized
      contextRef="c20211109to20211109_HealthCareOrganizationRevenueSourcesAxis_DevelopmentRegulatoryAndCommercialMilestoneMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_MassachusettsEyeAndEarInfirmaryLicenseAgreementMember"
      decimals="-5"
      id="Fact_4e29cb4d7a7b48dabd51c6cd8b2cdbe9"
      unitRef="U001">400000</ird:FutureMilestoneMethodRevenueNotRecognized>
    <us-gaap:LeaseExpirationDate1
      contextRef="c20250701to20250701"
      id="Fact_69b3e72860ec4423acb1204d09cdba12">2025-09-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:OperatingLeaseCost
      contextRef="c20250101to20251231"
      decimals="-5"
      id="Fact_9d4d65b20ddd40bca9db484760d87373"
      unitRef="U001">300000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="c20240101to20241231"
      decimals="-5"
      id="Fact_d6e9501e09964df8b6d29aa3bfde5e31"
      unitRef="U001">100000</us-gaap:OperatingLeaseCost>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="c20250101to20251231"
      id="Text_c445b60d482d4dc0b9318692297addbf">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold;"&gt;4.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold;"&gt;Supplemental Balance Sheet Information&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Accrued Expenses&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Accrued expenses consist of the following (in thousands): &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2025&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;R&amp;amp;D services and supplies&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2,061&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;4,452&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Payroll&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,992&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,481&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Professional services&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;420&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,608&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Other&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;15&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;606&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;4,488&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;8,147&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="c20250101to20251231"
      id="Text_94cbc1daf51a44dc9149b8fdf8dc4c21">
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Accrued expenses consist of the following (in thousands): &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2025&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;R&amp;amp;D services and supplies&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2,061&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;4,452&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Payroll&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,992&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,481&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Professional services&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;420&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,608&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Other&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;15&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;606&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;4,488&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;8,147&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <ird:AccruedResearchAndDevelopmentServicesAndSuppliesCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_e949e909ad734829ba3f86981a6e6835"
      unitRef="U001">2061000</ird:AccruedResearchAndDevelopmentServicesAndSuppliesCurrent>
    <ird:AccruedResearchAndDevelopmentServicesAndSuppliesCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_1bab95bf42f947ef83e64cc24cf57a48"
      unitRef="U001">4452000</ird:AccruedResearchAndDevelopmentServicesAndSuppliesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_2ad19c1136034f2cba0114d2e401b4e8"
      unitRef="U001">1992000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_bfeb5c35ee7f45288918011a979ef907"
      unitRef="U001">1481000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_fc821737fc5440a79ad7e277436bb338"
      unitRef="U001">420000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_dff9f404f8884a1ebb72018f0cfa2735"
      unitRef="U001">1608000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_0fdf84c046584696b0dc2b97eeebf0be"
      unitRef="U001">15000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_e6db1eb78ced4ee1ae58d19e01a1332e"
      unitRef="U001">606000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_1eed18884de64215be82ff76ba764a6a"
      unitRef="U001">4488000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_0e5c2a76f0d64b42ada1e88de86f64f4"
      unitRef="U001">8147000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="c20250101to20251231"
      id="Text_85066f6df5954754a1aa6743ee8da631">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;5.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Related Party Transactions&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Consulting Agreements with &lt;/span&gt;Dr.
























              Pepose &lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;On April 11, 2024, the Company entered into a consulting agreement (the &#x201c;Pepose Consulting Agreement&#x201d;) with Dr. Pepose, a former director of the Company. Pursuant
            to the Pepose Consulting Agreement, Dr. Pepose was paid a monthly consulting fee and received an award of 32,000 RSUs, as well as
            stock options to purchase 48,000 shares of the Company&#x2019;s common stock. The RSUs vested in 12 equal monthly installments that began on May 11, 2024 and concluded on April 11, 2025. On November 21, 2024, the Pepose Consulting Agreement was amended to continue
            through April 11, 2026.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;For the agreements with Dr. Pepose above, the Company incurred related consulting expenses of $0.5 million during each of the years ended December 31, 2025 and 2024. As of December 31, 2025 and 2024, less than $0.1 million of the related consulting expenses were unpaid.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="margin: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; text-align: justify;"&gt;Consulting Agreement with Dr. Jean Bennett&lt;/div&gt;

&lt;div style="margin: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; text-align: justify;"&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In connection
              with Dr. Jean Bennett&#x2019;s appointment as a member of the Board, effective October 22, 2024, she and the Company entered into a consulting agreement (the &#x201c;Bennett Consulting Agreement&#x201d;), pursuant to which Dr. Bennett will provide consulting
              services to the Company for a one-year period. Pursuant to the Bennett Consulting Agreement, Dr. Bennett was granted a restricted
              stock unit award with respect to 100,000 shares of the Company&#x2019;s common stock, which award vested on October 22, 2025. The Company
              incurred no consulting expenses, beyond the stock-based compensation associated with the restricted stock unit award, during
              the years ended December 31, 2025 and 2024. The Bennett Consulting Agreement terminated in accordance with its terms on October 22, 2025.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-weight: bold; font-style: italic;"&gt;March 2025 Subscription Agreements with Dr. George Magrath and Cam Gallagher&lt;/span&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;On March 21, 2025, the Company entered into a subscription agreement with each of Dr. George Magrath, the Company&#x2019;s Chief Executive Officer, and Cam Gallagher, the
            chairman of the Company&#x2019;s board of directors (the &#x201c;Board&#x201d;), in connection with a private offering of our securities. &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Dr. George Magrath and Cam Gallagher participated in the March 2025 subscription agreement with investments of $0.5 million and $1.0 million,
              respectively. For more information, see Note 7 &#x2013; Financings.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-weight: bold; font-style: italic;"&gt;August 2025 Subscription Agreements with Cam Gallagher and Sean Ainsworth&lt;/span&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;On August 25, 2025, the Company entered into subscription agreements pursuant to which the Company agreed to issue and sell in a private placement (the &#x201c;August
            2025 Private Placement&#x201d;) to certain investors 3,138,338 shares of its common stock for gross proceeds of approximately $3.5 million.&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The August 2025 Private Placement was led by Cam Gallagher, Chair of the Company&#x2019;s Board, with an investment of $1.0 million, along with participation by Sean Ainsworth, the lead independent director of the Board, in the amount of $0.1 million, and other investors for the balance of the Private Placement. For more information, see Note 7 &#x2013; Financings.&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Letter Agreement and Strategic Partnership&#x2014;FFB&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"&gt;&lt;br/&gt;
                &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-style: normal; font-weight: normal; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;On August 25,
                  2022, Private Opus entered into a binding letter of agreement (&#x201c;2022 Binding Letter Agreement&#x201d;) with Foundation Fighting Blindness (&#x201c;FFB&#x201d;) and the Jaeb Center for Health Research (the &#x201c;JCHR&#x201d;) to collaborate on natural history studies
                  involving individuals with retinal dystrophies associated with mutations in multiple genes of interest. Under the terms of the 2022 Binding Letter Agreement, FFB and the JCHR had the sole responsibility and authority to design and conduct
                  the study, with input from the Company. Subject to certain conditions, the 2022 Binding Letter Agreement required that the Company provide FFB with a total of $2.0 million of funding to support the study, such amount being payable in an initial installment of $0.4 million at the time of &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;submission of the final study protocol to the Institutional Review Board of the JCHR&lt;/span&gt; and, subject to certain conditions, in four annual installments of $0.4 million on the anniversaries of such
                  submission. On May 27, 2025, the Company entered into a binding letter of agreement (&#x201c;2025 Letter Agreement&#x201d;) with FFB and the JCHR, which superseded and canceled the 2022 Binding Letter Agreement. As of December 31, 2025 a total of $0.4 million was paid by the Company under the 2022 Binding Letter Agreement and no more payments were due under the 2022 Binding Letter Agreement.&lt;br/&gt;
                &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Under the 2025 Letter Agreement, the Company will collaborate with FFB and the JCHR on portions of a study involving individuals with retinal dystrophies associated with mutations in
                    the RDH12 or BEST1 genes (the &#x201c;Study&#x201d;). The term of this 2025 Letter Agreement ends on the date that is two months from the
                    Study&#x2019;s completion. FFB and the JCHR, as its designee, shall have the sole responsibility and authority to design and conduct the Study, with input from the Company.&#160; Under the 2025 Letter Agreement, the Company is obligated to make two payments to FFB: (1) $0.3
                    million on or before June 30, 2025 and (2) $0.3 million on or before January 31, 2027 upon receipt of semi-annual reports
                    from FFB outlining the progress being made in the Study, including visit completion status and publication plans, and the ability for the Company to provide ongoing comments and suggestions regarding possible changes to the Study. Such
                    payments shall constitute the sole compensation paid to FFB in return for Company access to research materials and datasets.&lt;/span&gt;&lt;br/&gt;
                &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
                &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company paid the initial $0.3 million due on or before June 30, 2025 under the 2025
                      Letter Agreement which was recorded as research and development expense. As of December 31, 2025, the Company is required to fund one additional installment in the aggregate of $0.3 million upon receipt of future semi-annual reports.&lt;/span&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;RDF Agreement&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-style: normal; font-weight: normal; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;On June 13, 2025, the Company entered into a funding agreement (the &#x201c;RDF Agreement&#x201d;) with the Foundation Fighting Blindness Retinal Degeneration Fund (&#x201c;RDF&#x201d;), whose sole member is FFB,
                    a significant stockholder of the Company, relating to the Company&#x2019;s program to develop gene therapies to treat patients impacted by retinitis pigmentosa caused by pathogenic variants in the Mer proto-oncogene tyrosine kinase (MERTK)
                    gene (the &#x201c;MERTK Program&#x201d;). The RDF Agreement provides for nondilutive funding by RDF of up to $2.0 million to support the
                    development of the MERTK Program, $1.0 million of which was disbursed to the Company in June 2025 and up to $1.0 million of which may be disbursed to the Company upon achievement of a specified development milestone subject to RDF&#x2019;s receipt of
                    eligible funds.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-style: normal;"&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-style: normal;"&gt;Under the RDF Agreement, the Company is subject to certain diligence obligations to develop and commercialize a
                  product under the MERTK Program. If the Company is unable to achieve certain milestones by certain dates, or otherwise fails to meet its diligence obligations, the Company will be obligated to collaborate with RDF to out-license or
                  otherwise make applicable rights available to a third party.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-style: normal;"&gt;In addition, the Company will pay a milestone payment equal to the total amounts funded by RDF under the RDF
                  Agreement upon the achievement of a regulatory milestone. The Company will also make tiered royalty payments to RDF in low-to-mid single percentages until RDF has received aggregate royalty payments equal to 300% of the amounts funded by RDF under the Agreement.&#160; In the event of a change of control of the Company or a sale or exclusive license of
                  the MERTK Program, RDF will have the option to require the Company to buy out RDF&#x2019;s interest under the Agreement for an amount equal to 100%
                  of the funds disbursed to the Company under the Agreement. The Agreement may be terminated by either party for cause, including material breach or bankruptcy, subject to a cure period.&lt;br/&gt;
                &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; The RDF Agreement was accounted for as debt under ASC 470, Debt. ASC 470 requires interest expense to be recorded under an effective interest rate method. During the year ended December 31, 2025, interest
                      expense was $0.1 million based on an effective rate of interest of 22.3% and was recorded as interest expense in the accompanying consolidated statements of comprehensive loss. The accreted liability in connection with the RDF Agreement was $1.1 million as of December 31, 2025 and was recorded under the funding agreement, related party line item in the accompanying consolidated
                      balance sheets.&lt;/span&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20240411to20240411_AwardTypeAxis_RestrictedStockUnitsRSUMember_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember"
      decimals="0"
      id="Fact_7cd239b89da34f578ea17ebf2dad124e"
      unitRef="U002">32000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20240411to20240411_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember"
      decimals="0"
      id="Fact_e039ed265efd46dda2e9996d7aeaabde"
      unitRef="U002">48000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEqualInstallmentsForAwardsToVest
      contextRef="c20240511to20240511_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember"
      decimals="0"
      id="Fact_9fb2ca161e6f42ceb3b3824320fd4073"
      unitRef="U009">12</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEqualInstallmentsForAwardsToVest>
    <ird:ConsultingExpense
      contextRef="c20240101to20241231_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember"
      decimals="-5"
      id="Fact_a978bc1d3b8b427da52ec85b88612e0a"
      unitRef="U001">500000</ird:ConsultingExpense>
    <ird:ConsultingExpense
      contextRef="c20250101to20251231_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember"
      decimals="-5"
      id="Fact_5e009561ce54470dbade3c4a7643ac14"
      unitRef="U001">500000</ird:ConsultingExpense>
    <us-gaap:OtherLiabilities
      contextRef="c20241231_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember"
      decimals="-5"
      id="Fact_b3417ad97c704b9d908c856926b8e79f"
      unitRef="U001">100000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="c20251231_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember"
      decimals="-5"
      id="Fact_5d50e05161694f53bece8b7d553c0334"
      unitRef="U001">100000</us-gaap:OtherLiabilities>
    <ird:ConsultationServicesReceivablePeriod
      contextRef="c20250101to20251231_TitleOfIndividualAxis_BoardMemberMember"
      id="Fact_96a25635620d423bb42d28636073f00f">P1Y</ird:ConsultationServicesReceivablePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20241022to20241022_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_BoardMemberMember"
      decimals="0"
      id="Fact_62feaaca826e4afdbac3ae7dba84b530"
      unitRef="U002">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <ird:ConsultingExpense
      contextRef="c20240101to20241231_TitleOfIndividualAxis_BoardMemberMember"
      decimals="0"
      id="Fact_ec26b321ea944b27b89b3ba6b8c226a1"
      unitRef="U001">0</ird:ConsultingExpense>
    <ird:ConsultingExpense
      contextRef="c20250101to20251231_TitleOfIndividualAxis_BoardMemberMember"
      decimals="0"
      id="Fact_646bb2151f3044ceb7fafca446a0a7ad"
      unitRef="U001">0</ird:ConsultingExpense>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c20250321to20250321_SubsidiarySaleOfStockAxis_March2025PrivatePlacementMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="-5"
      id="Fact_d91f1489579f4cdf8fff780881a23915"
      unitRef="U001">500000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c20250321to20250321_SubsidiarySaleOfStockAxis_March2025PrivatePlacementMember_TitleOfIndividualAxis_ChairmanOfTheBoardMember"
      decimals="-5"
      id="Fact_f6f2e5a2e5794d518b3401ec16096e29"
      unitRef="U001">1000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20250825to20250825_SubsidiarySaleOfStockAxis_PrivatePlacementMember"
      decimals="0"
      id="Fact_45344424a40b49989416e6a867e3d60e"
      unitRef="U002">3138338</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20250825to20250825_SubsidiarySaleOfStockAxis_PrivatePlacementMember"
      decimals="-5"
      id="Fact_5819d0cb72054ec995357f21ef44b6c7"
      unitRef="U001">3500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20250825to20250825_RelatedPartyTransactionsByRelatedPartyAxis_CamGallagherMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember"
      decimals="-5"
      id="Fact_dc857aad48cb42e5b8d77fe52d5f2038"
      unitRef="U001">1000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20250825to20250825_RelatedPartyTransactionsByRelatedPartyAxis_SeanAinsworthMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember"
      decimals="-5"
      id="Fact_f40346028efd4383bbbdaaac334979df"
      unitRef="U001">100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ird:MaximumAmountFundedToSupportStudy
      contextRef="c20220825_RelatedPartyTransactionAxis_BindingLetterAgreement2022Member_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember"
      decimals="-5"
      id="Fact_ed829acead8f476895505ff3ee8020c0"
      unitRef="U001">2000000</ird:MaximumAmountFundedToSupportStudy>
    <ird:AmountFundedToSupportStudyPayableInInitialInstallment
      contextRef="c20220825_RelatedPartyTransactionAxis_BindingLetterAgreement2022Member_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember"
      decimals="-5"
      id="Fact_3507745526f54d47ac8f0a50e1866786"
      unitRef="U001">400000</ird:AmountFundedToSupportStudyPayableInInitialInstallment>
    <ird:DebtInstrumentNumberOfInstallments
      contextRef="c20220825to20220825_RelatedPartyTransactionAxis_BindingLetterAgreement2022Member_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember"
      decimals="INF"
      id="Fact_6c27e96b9eb1424b81bc35fc8e488769"
      unitRef="U009">4</ird:DebtInstrumentNumberOfInstallments>
    <ird:AmountFundedToSupportStudyPayableInAnnualInstallment
      contextRef="c20220825_RelatedPartyTransactionAxis_BindingLetterAgreement2022Member_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember"
      decimals="-5"
      id="Fact_a1fa9e27725e4c309569a3317ff6d4c9"
      unitRef="U001">400000</ird:AmountFundedToSupportStudyPayableInAnnualInstallment>
    <ird:PaymentOfFinalInstallmentUponTerminationOfAgreement
      contextRef="c20250527to20250527_RelatedPartyTransactionAxis_BindingLetterAgreement2022Member_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember"
      decimals="-5"
      id="Fact_4cbe055f172e4f87bbbb243bd0858fbd"
      unitRef="U001">400000</ird:PaymentOfFinalInstallmentUponTerminationOfAgreement>
    <ird:PaymentsDueRelatedToAmountFundedToSupportStudy
      contextRef="c20250527_RelatedPartyTransactionAxis_BindingLetterAgreement2022Member_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember"
      decimals="0"
      id="Fact_a99319abd8b34be68ce105ba3ffd7033"
      unitRef="U001">0</ird:PaymentsDueRelatedToAmountFundedToSupportStudy>
    <ird:PeriodOfAgreementTerminationAfterStudyCompletion
      contextRef="c20250101to20251231_RelatedPartyTransactionAxis_LetterAgreement2025Member_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember"
      id="Fact_e43a8a2d32c94fe9a5767bfb42476687">P2M</ird:PeriodOfAgreementTerminationAfterStudyCompletion>
    <ird:DebtInstrumentNumberOfInstallments
      contextRef="c20250527to20250527_RelatedPartyTransactionAxis_LetterAgreement2025Member_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember"
      decimals="INF"
      id="Fact_14fd7531429241d3908302a74e3c0f28"
      unitRef="U009">2</ird:DebtInstrumentNumberOfInstallments>
    <ird:AmountFundedToSupportStudyPayableInInitialInstallment
      contextRef="c20250527_RelatedPartyTransactionAxis_LetterAgreement2025Member_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember"
      decimals="-5"
      id="Fact_85a78db2f4644be89ef760fcfe9035c5"
      unitRef="U001">300000</ird:AmountFundedToSupportStudyPayableInInitialInstallment>
    <ird:FinalInstallmentPayableUponReceiptOfSemiAnnualReportsOfStudy
      contextRef="c20250527_RelatedPartyTransactionAxis_LetterAgreement2025Member_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember"
      decimals="-5"
      id="Fact_8362c4aed4b747ab83dc27742611aef9"
      unitRef="U001">300000</ird:FinalInstallmentPayableUponReceiptOfSemiAnnualReportsOfStudy>
    <ird:PaymentOfInitialInstallmentToSupportStudyUnderAgreement
      contextRef="c20250101to20250630_RelatedPartyTransactionAxis_LetterAgreement2025Member_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember"
      decimals="-5"
      id="Fact_370873665435453a958330f8ad684998"
      unitRef="U001">300000</ird:PaymentOfInitialInstallmentToSupportStudyUnderAgreement>
    <ird:PaymentOfAdditionalInstallmentToSupportStudyUnderAgreement
      contextRef="c20250101to20251231_RelatedPartyTransactionAxis_LetterAgreement2025Member_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember"
      decimals="-5"
      id="Fact_6c2c45e647f04aceb81a381aa8f613fa"
      unitRef="U001">300000</ird:PaymentOfAdditionalInstallmentToSupportStudyUnderAgreement>
    <ird:MaximumAmountOfNondilutiveFundingMilestonePayments
      contextRef="c20250613_RelatedPartyTransactionAxis_FoundationFightingBlindnessRetinalDegenerationFundAgreementMember_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember"
      decimals="-5"
      id="Fact_953c7dbef7e646698a29e84c0cc27efb"
      unitRef="U001">2000000</ird:MaximumAmountOfNondilutiveFundingMilestonePayments>
    <ird:MilestonePaymentsReceived
      contextRef="c20250630_RelatedPartyTransactionAxis_FoundationFightingBlindnessRetinalDegenerationFundAgreementMember_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember"
      decimals="-5"
      id="Fact_00c5597570774cff90d13f7aa3dd8c06"
      unitRef="U001">1000000</ird:MilestonePaymentsReceived>
    <ird:MilestonePaymentReceivable
      contextRef="c20251231_RelatedPartyTransactionAxis_FoundationFightingBlindnessRetinalDegenerationFundAgreementMember_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember"
      decimals="-5"
      id="Fact_569a1e1eba2f407f88b101825ba250fd"
      unitRef="U001">1000000</ird:MilestonePaymentReceivable>
    <ird:PercentageOfRoyaltyPaymentObligation
      contextRef="c20250613_RelatedPartyTransactionAxis_FoundationFightingBlindnessRetinalDegenerationFundAgreementMember_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember"
      decimals="2"
      id="Fact_01ab86bc080444cd852f506c95bb68da"
      unitRef="U006">3</ird:PercentageOfRoyaltyPaymentObligation>
    <ird:BuyoutInterestEqualsPercentageOfDisbursedFundsInEventOfChangeOfControlOrSaleOrLicense
      contextRef="c20250613to20250613_RelatedPartyTransactionAxis_FoundationFightingBlindnessRetinalDegenerationFundAgreementMember_RelatedPartyTransactionsByRelatedPartyAxis_FoundationFightingBlindnessMember"
      decimals="2"
      id="Fact_cbe0cf7e071541a793949131b8247299"
      unitRef="U006">1</ird:BuyoutInterestEqualsPercentageOfDisbursedFundsInEventOfChangeOfControlOrSaleOrLicense>
    <us-gaap:InterestExpenseDebt
      contextRef="c20250101to20251231_RelatedPartyTransactionAxis_FoundationFightingBlindnessRetinalDegenerationFundAgreementMember"
      decimals="-5"
      id="Fact_1df1b8f230ce42f29d4b666e76337532"
      unitRef="U001">100000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20251231_RelatedPartyTransactionAxis_FoundationFightingBlindnessRetinalDegenerationFundAgreementMember"
      decimals="3"
      id="Fact_57ad2b526b364ab8b8ee9e8e4ef3489f"
      unitRef="U006">0.223</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="c20251231_RelatedPartyTransactionAxis_FoundationFightingBlindnessRetinalDegenerationFundAgreementMember"
      decimals="-5"
      id="Fact_63380d5376f844bf935ba5d67e10c304"
      unitRef="U001">1100000</us-gaap:LongTermDebtNoncurrent>
    <ird:TemporaryEquityDisclosureTextBlock
      contextRef="c20250101to20251231"
      id="Text_eb90abd2b16842449d517ab000932850">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;6.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Series A preferred stock&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;On October 22,&#160;2024, the Company filed a Certificate of Designation of Preferences, Rights and
              Limitations of the Series A Non-Voting Convertible Preferred Stock with the Secretary of State of the State of Delaware (the &#x201c;Certificate of Designation&#x201d;) in connection with the Opus Acquisition. The Certificate of Designation provides for
              the authorization of 14,146 shares of Series A preferred stock, of which 14,145.374 Series A preferred stock were issued upon close of the Opus Acquisition. &lt;/span&gt;On April 30, 2025, the Company held its 2025 Annual Meeting of Stockholders.
            During the 2025 Annual Meeting, the Company&#x2019;s stockholders voted to approve the conversion of each share of Series A preferred stock into 1,000
            shares of common stock. Subsequently, on May 5, 2025, all shares of Series A preferred stock were converted into 14,145,374 shares
            of common stock.&lt;/div&gt;
</ird:TemporaryEquityDisclosureTextBlock>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c20241022_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact_0922d68b484548b48c2ab49214a74198"
      unitRef="U002">14146</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c20241022_BusinessAcquisitionAxis_OpusGeneticsIncMember_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="3"
      id="Fact_e250aaa86fea4ab5b92da2127480c152"
      unitRef="U002">14145.374</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c20250430_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_b66ae6f05a0c4c128a030da6c5a74d67"
      unitRef="U002">1000</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="c20250505_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_d521eb152bb44a6a910b0054cd83e3f9"
      unitRef="U002">14145374</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <ird:FinancingsTextBlock
      contextRef="c20250101to20251231"
      id="Text_666e9bb292064a44b6dfc8edb5cef412">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;
        &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;7.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Financings&lt;/span&gt;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic; font-weight: bold;"&gt;November 2025 Registered Direct Offering&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; color: rgb(34, 34, 34);"&gt;On November 6, 2025, the Company entered into a securities purchase agreement
        to sell securities in a registered direct offering (the &#x201c;2025 RDO&#x201d;) for gross proceeds of approximately $23.0 million, before deducting
        offering expenses in the amount of approximately $0.1 million.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; color: rgb(34, 34, 34);"&gt;The Company sold an aggregate of 3,827,751 shares of its common stock at a price of $2.09 per
        share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 7,177,033 shares of
        common stock at a purchase price of $2.0899 per pre-funded warrant. Each pre-funded warrant has an exercise price of $0.0001 per share of common stock, will be immediately exercisable subject to certain conditions set forth in each pre-funded warrant, and will not
        expire. The 2025 RDO closed on November 7, 2025.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic; font-weight: bold;"&gt;August 2025 Private Placement&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;On August 25, 2025, the Company entered into subscription agreements pursuant to
          which the Company agreed to issue and sell in the August 2025 Private Placement to certain investors 3,138,338 shares of its common
          stock for gross proceeds of approximately $3.5 million.&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;The August 2025 Private Placement was led by Cam Gallagher, Chair of the Board,
          along with participation by Sean Ainsworth, the lead independent director of the Board, and other investors. See Note 5 &#x2013; Related Party Transactions.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic; font-weight: bold;"&gt;March 2025 Financings&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;On March 21, 2025, the Company entered into an underwriting agreement with
          Craig-Hallum Capital Group, LLC, as the sole underwriter. Pursuant to the underwriting agreement, the Company agreed to issue and sell, in an underwritten public offering (the &#x201c;March 2025 Offering&#x201d;), 12,219,736 shares of common stock and warrants to purchase up to 21,052,631
          shares of common stock (the &#x201c;March 2025 Warrants&#x201d;). Each share of common stock was sold together with one March 2025 Warrant to purchase one
          share of common stock, at a price to the public of $0.95 per share and related March 2025 Warrant. The Company also issued 8,832,895 pre-funded warrants (&#x201c;Pre-Funded Warrants&#x201d;) at a price to the public of $0.9499 per Pre-funded Warrant.&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;On March 21, 2025, the Company entered into a subscription agreement (the
          &#x201c;Subscription Agreement&#x201d;) with each of Dr. George Magrath, the Company&#x2019;s Chief Executive Officer, and Cam Gallagher, the chairman of the Board.&#160; Pursuant to the Subscription Agreement, the Company agreed to issue and sell, in a private offering
          (the &#x201c;March 2025 Private Placement&#x201d;), a total of 392,157 shares of common stock to Mr. Magrath and 784,314 shares of common stock to Mr. Gallagher, as well as 392,157 warrants to purchase shares of common stock to Mr. Magrath and 784,314
          warrants to purchase shares of common stock to Mr. Gallagher (&#x201c;March 2025 Private Placement Warrants&#x201d;). Each March 2025 Private Placement Warrant has an initial exercise price of $1.15, expires on the five-year anniversary of the original issuance date and may be called by the Company 30 days following the release of the Company&#x2019;s OPGx-BEST1 DUO-1001 Cohort 1 data
          upon achievement of a volume weighted average price of our common stock for 30 consecutive trading days of over $1.725 per share and
          the trading average daily volume for such 30 day period exceeds $150,000 per trading day. See Note 5 &#x2013; Related Party Transactions.&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;The combined gross proceeds from the March 2025 Offering and the March 2025
          Private Placement, which both closed on March 24, 2025 (the &#x201c;Closing Date&#x201d;), were approximately $21.5 million, before deducting
          underwriting discounts and commissions and offering expenses payable by the Company in the amount of $1.8 million.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; text-align: justify; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;March 2025
            Warrants&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;The March 2025 Warrants have an initial exercise price equal to $0.95 per share of common stock and are exercisable for five years from the date of issuance. The exercise prices and numbers of shares of common stock issuable upon exercise are subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar
          events affecting the common stock and also upon any distributions of assets, including cash, stock or other property to our stockholders. A holder may not exercise the March 2025 Warrant if, after giving effect to such exercise, the holder
          (together with its affiliates) would beneficially own (as determined in accordance with the terms of the March 2025 Warrants) more than 4.99%
          (or, at the election of the holder, 9.99%) of the outstanding common stock immediately after giving effect to the exercise. Lastly,
          certain volatility provisions in the event of a fundamental transaction precluded the March 2025 Warrants from being considered indexed to the Company&#x2019;s own stock, and as such, were classified on the consolidated balance sheets as warrant
          liabilities.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-size: 10pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;The March 2025 Warrants are callable by the Company in
          certain circumstances. Subject to certain exceptions, in the event that the March 2025 Warrants are outstanding, if, after the Closing Date, (i) the Company has announced OPGx-BEST1 DUO-1001 Cohort 1 data, (ii) the volume weighted average price
          of the common stock for 30 consecutive trading days (&#x201c;Warrant Measurement Period&#x201d;), which 30 consecutive trading day period shall not have commenced until after the initial exercise date) exceeds $1.425 (subject to adjustment), (iii) the trading average daily volume for such Warrant Measurement Period exceeds $150,000 per trading day and (iv) the March 2025 Warrant holder is not in possession of any information that constitutes or might constitute material non-public information which was
          provided by the Company, its subsidiaries or any of its officers, directors, employees, agents or affiliates, then the Company may, within one trading day of the end of such Warrant Measurement Period, upon notice, call for cancellation of all or
          any portion of the March 2025 Warrants for which a notice of exercise has not yet been delivered for consideration equal to $0.001 per
          March 2025 Warrant share.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-size: 10pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;In the event of a fundamental transaction, as defined in
          the Form of Warrant, the holders of the March 2025 Warrants will be entitled to receive upon exercise the kind and amount of securities, cash or other property that the holders would have received had they exercised immediately prior to such
          fundamental transaction. Additionally, as more fully described in the Form of Warrant, in the event of certain fundamental transactions, the holders of the March 2025 Warrants will be entitled to receive consideration in an amount equal to the
          Black Scholes Value of the remaining unexercised portion of the March 2025 Warrants on the date of consummation of such fundamental transaction.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-size: 10pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;The fair value of the March 2025 Warrants at the time of
          issuance was $14.7 million and were recorded in the warrant liabilities line item in the accompanying consolidated balance sheets upon
          issuance.&#160; The fair value change during the year ended year ended December 31, 2025 was an expense of $10.9 million. The fair value of
          these instruments were based on a Monte Carlo simulation incorporating a volatility rate of 72.5% and 80.0% as of December 31, 2025 and March 24, 2025, respectively, a risk free rate of 3.6% and 4.0% as of December 31, 2025 and March 24, 2025, respectively, the
          market price of the Company&#x2019;s common stock at $2.01 and $1.15 per share as of December 31, 2025 and March 24, 2025, respectively, and other factors over a simulated term of 4.2 years and 5.0 years at December 31, 2025 and March 24, 2025,
          respectively. As of December 31, 2025 the transaction costs attributed to the March 2025 Warrants amounted to approximately $1.3
          million and were recorded in the accompanying consolidated statements of comprehensive loss under financing costs.&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-size: 10pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-size: 10pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; During the year ended December 31, 2025, 862,684 March 2025 Warrants were exercised, resulting in the issuance of 862,684
            shares of common stock. Upon exercise, the Company reclassified approximately $1.1 million of warrant fair value from Warrant
            liabilities to Additional paid-in capital.&lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;March 2025 Private
            Placement Warrants&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-size: 10pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;The March 2025 Private Placement Warrants have an initial
          exercise price equal to $1.15 per share of common stock and are exercisable for five years from the date of issuance. The March 2025 Private Placement Warrants are callable by the Company in certain circumstances. Subject to certain exceptions, in the event that the
          March 2025 Private Placement Warrants are outstanding, if, after the Closing Date, (i) the Company announced OPGx-BEST1 DUO-1001 Cohort 1 data, (ii) the volume weighted average price of the common stock for 30 consecutive trading days (the &#x201c;Private Placement Measurement Period&#x201d;, which 30 consecutive trading day period shall not have commenced until after the initial exercise date) exceeds $1.725 (subject to adjustment), (iii) the trading average daily volume for such Private Placement Measurement Period exceeds $150,000 per trading day and (iv) the March 2025 Private Placement Warrant holder is not in possession of any information that constitutes or might constitute material non-public
          information which was provided by the Company, its subsidiaries or any of its officers, directors, employees, agents or affiliates, then the Company may, within one trading day of the end of such Private Placement Measurement Period, upon notice,
          call for cancellation of all or any portion of the March 2025 Private Placement Warrants for which a notice of exercise has not yet been delivered for consideration equal to $0.001 per March 2025 Private Placement Warrant share.&#160; Other terms under the March 2025 Private Placement Warrants are generally identical to the terms of the March 2025 Warrants discussed
          above. Lastly, certain volatility provisions in the event of a fundamental transaction precluded the March 2025 Private Placement Warrants from being considered indexed to the Company&#x2019;s own stock, and as such, were classified on the consolidated
          balance sheets as warrant liabilities.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-size: 10pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;The fair value of the March 2025 Private Placement Warrants
          at the time of issuance was $0.8 million and were recorded in the warrant liabilities line item in the accompanying consolidated
          balance sheets upon issuance. The fair value change during the year ended December 31, 2025 was an expense of $0.6 million. The fair
          value of these instruments were based on a Monte Carlo simulation incorporating a volatility rate of 72.5% and 80.0% as of December 31, 2025 and March 24, 2025, respectively, a risk free rate of 3.6% and 4.0% as of December 31, 2025 and March 24, 2025, respectively, the
          market price of the Company&#x2019;s common stock at $2.01 and $1.15 per share as of December 31, 2025 and March 24, 2025, respectively, and other factors over a simulated term of 4.2 years and 5.0 years as of December 31, 2025 and March 24, 2025,
          respectively. As of December 31, 2025 transaction costs attributed to the March 2025 Private Placement Warrants were&#160;&lt;span style="font-style: italic;"&gt;de minimis&lt;/span&gt;&#160;and were recorded in the accompanying consolidated statements of
          comprehensive loss under financing costs.&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-size: 10pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-size: 10pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;During the year ended December 31, 2025 there were no March 2025 Private Placement Warrants exercised.&lt;br/&gt;
        &lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Pre-Funded
            Warrants&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-size: 10pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Pre-Funded Warrants have an exercise price of $0.0001 per share of common stock and are immediately exercisable and are exercisable at any time until exercised in full. The exercise prices and
          numbers of shares of common stock issuable upon exercise are subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the common stock.&#160; A holder may not exercise the Pre-Funded
          Warrant if, after giving effect to such exercise, the holder (together with its affiliates) would beneficially own (as determined in accordance with the terms of the Pre-Funded Warrants) more than 4.99% (or, at the election of the holder, 9.99%) of the
          outstanding common stock immediately after giving effect to the exercise. In the event of a fundamental transaction, as defined in the Form of Pre-Funded Warrant, the holders of the Pre-Funded Warrants will be entitled to receive upon exercise of
          the Pre-Funded Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants immediately prior to such fundamental transaction.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-size: 10pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Pre-Funded Warrants were recorded in the accompanying
          consolidated balance sheets as Additional paid-in capital.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold; background-color: rgb(255, 255, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;At-The-Market Program&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;Since 2021, the Company has maintained at&#x2011;the&#x2011;market (&#x201c;ATM&#x201d;) equity offering programs (collectively, the &#x201c;ATM Programs&#x201d;) pursuant to sales agreements with
        JonesTrading Institutional Services LLC (&#x201c;JonesTrading&#x201d;) and, more recently, Leerink Partners LLC (&#x201c;Leerink&#x201d;). Under the ATM Programs, shares of our common stock may be offered and sold from time to time at prevailing market prices.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;On March 11, 2021, we entered into a sales agreement with JonesTrading under which we may offer and sell, from time to time at our sole discretion, to or through
        JonesTrading, acting as agent and/or principal, shares of our common stock having an aggregate offering price of up to $40.0 million.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;On January 13, 2025, the Company entered into a new sales
          agreement by and between the Company and Leerink under which we may offer and sell, from time to time at our sole discretion, to or through Leerink, acting as agent and/or principal, shares of our common stock having an aggregate offering price
          of up to $40.0 million. Upon entry into the new sales agreement, the Company terminated its prior ATM program pursuant to the Capital
          on DemandTM Sales Agreement dated March 11, 2021, by and between the Company and JonesTrading.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-size: 10pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;During the years ended December 31, 2025 and 2024, 1,919,412 and 1,608,522 shares of
          common stock were sold under the ATM Programs for aggregate gross proceeds in the amount of $2.3 million and $3.8 million, respectively, before deducting issuance expenses, including the placement agent&#x2019;s fees, legal and accounting expenses, in the amount of $0.3 million and $0.4 million,
          respectively. As of December 31, 2025, the Company had sold an aggregate of 9,573,250 shares of common stock under the ATM Programs
          since their inception, resulting in gross proceeds of $28.7 million and total issuance costs of $1.4 million.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Lincoln Park Purchase Agreement&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-size: 10pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;On August 10, 2023, the Company entered into a common stock
          purchase agreement with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;) for an equity line financing (the &#x201c;Purchase Agreement&#x201d;). The Purchase Agreement provided that, subject to the terms and conditions set forth therein, the Company had the sole
          right, but not the obligation, to direct Lincoln Park to purchase up to $50 million of shares of the Company&#x2019;s common stock from time
          to time over the 30-month term of the Purchase Agreement. Concurrently with entering into the Purchase Agreement, the Company also
          entered into a registration rights agreement with Lincoln Park (the &#x201c;Registration Rights Agreement&#x201d;), pursuant to which the Company agreed to register the resale of the shares of the Company&#x2019;s common stock that had been issued to Lincoln Park
          under the Purchase Agreement pursuant to a registration statement. Lincoln Park has agreed not to cause or engage in any manner whatsoever in any direct or indirect short selling or hedging of the Company&#x2019;s common stock.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-size: 10pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;On April 2, 2025, the Company delivered written notice to
          Lincoln Park of its election to terminate the Purchase Agreement.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;A total of 400,000 shares were issued under the
        Purchase Agreement during the year ended December 31, 2024 for net proceeds of $0.7 million. The Company incurred&#160;&lt;span style="font-style: italic;"&gt;de minimis&lt;/span&gt;&#160;issuance costs during the year ended December 31, 2024. There were no issuances of
        common stock under the Purchase Agreement during the year ended December 31, 2025.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;In addition to the initial commitment shares issued upon the execution of the Purchase Agreement of 246,792, a total of 1,700,000 shares of common stock were sold
        under the Purchase Agreement for gross proceeds through the April 2, 2025 termination date in the amount of $5.2 million and with
        issuance costs in the aggregate of $1.4 million.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;The pricing and settlement provisions in the Purchase Agreement resulted in the recognition of a derivative liability accounted for on a fair value basis under
        the provisions of ASC 815 -&#160;Derivatives and Hedging.&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-style: italic; font-weight: bold;"&gt;Registered Direct Offering&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;On June 4, 2021, the Company entered into a placement agency agreement for a
        registered direct offering (&#x201c;RDO&#x201d;) with A.G.P./Alliance Global Partners (&#x201c;AGP&#x201d;). Pursuant to the terms of the placement agency agreement, AGP on June 8, 2021 sold an aggregate of 3,076,923 shares of the Company&#x2019;s common stock and warrants to purchase 1,538,461
        shares of the Company&#x2019;s common stock (the &#x201c;RDO Warrants&#x201d;) at an offering price of $4.875 per one share and per &lt;span style="-sec-ix-hidden:Fact_d090cab10f4f4fabacc37ae2d3b591d3"&gt;one-half&lt;/span&gt; of each RDO Warrant. The RDO was made pursuant to the Company&#x2019;s 2021 shelf registration.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;The RDO Warrants have an exercise price of $6.09 per share, are exercisable from the initial issuance date of June 8, 2021, and will expire five years following the initial issuance date. As of December 31, 2025, 1,538,461
        RDO Warrants were outstanding and none have been exercised since issuance.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;Subject to limited exceptions, a holder of a RDO Warrant will not have the right to
        exercise any portion of its RDO Warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or, at
        the election of a holder prior to the date of issuance, 9.99%) of the number of shares of the Company&#x2019;s common stock outstanding
        immediately after giving effect to such exercise; provided that upon prior notice to the Company, the holder may increase or decrease the beneficial ownership limitation, provided further that in no event shall the beneficial ownership limitation
        exceed 9.99%.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic; font-weight: bold;"&gt;Pre-Merger Financing&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;On June 17, 2020, the Company, Rexahn and certain investors entered into a
        Securities Purchase Agreement, which was amended and restated in its entirety on June 29, 2020 (as amended and restated, the &#x201c;Securities Purchase Agreement&#x201d;). Pursuant to the Securities Purchase Agreement, the investors invested a total of $21.15 million in cash, including $0.3
        million invested by five directors of the Company prior to the Rexahn Merger and one director of Rexahn upon closing of the Rexahn Merger (the &#x201c;Pre-Merger Financing&#x201d;). The Pre-Merger Financing also included the issuance of Series A Warrants, discussed
        further below, and Series B Warrants that were fully exercised by the first quarter of 2023.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic;"&gt;&lt;span style="text-decoration: underline;"&gt;Series A Warrants&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;The Series A Warrants were issued on November 19, 2020 at an initial exercise price
        of $4.4795 per share, were immediately exercisable upon issuance and had a term of five years from the date of issuance. The Series A Warrants expired unexercised in November 2025.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-style: italic; font-weight: bold;"&gt;Warrant Activity and Summary&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; text-align: justify; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Warrants&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Exercise&lt;/div&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Price Per&lt;/div&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Warrant&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Average Exercise&lt;/div&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Price&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Average Term&lt;/div&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;(Years)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-size: 10pt;"&gt;Outstanding and exercisable at December 31, 2024&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;7,204,299&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;4.48-6.09&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;4.82&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;1.00&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-size: 10pt;"&gt;Issued&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;22,229,102&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;0.95-1.15&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;0.96&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;5.00&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-size: 10pt;"&gt;Exercised&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;(862,684&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;0.95&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;0.95&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-size: 10pt;"&gt;Expired&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;(5,665,838&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;4.48&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;4.48&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-size: 10pt;"&gt;Outstanding and exercisable at December 31, 2025&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;22,904,879&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;0.95-6.09&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;1.31&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;3.98&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;The following table summarizes information about warrants outstanding at December
        31, 2025:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Exercise Price&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Number Outstanding&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Weighted Average&lt;/div&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Remaining Contractual&lt;/div&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;life (Years)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Number Exercisable at&lt;/div&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;December 31,&lt;/div&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;2025&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&lt;br/&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;0.95&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;20,189,947&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;4.23&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;20,189,947&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-size: 10pt;"&gt;*&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;1.15&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;1,176,471&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;4.23&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;1,176,471&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-size: 10pt;"&gt;*&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;6.09&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;1,538,461&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;0.43&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;1,538,461&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-size: 10pt;"&gt;Total&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; padding-bottom: 4px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; padding-bottom: 4px; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;22,904,879&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; padding-bottom: 4px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; padding-bottom: 4px; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; padding-bottom: 4px; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: justify; padding-bottom: 4px; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; padding-bottom: 4px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; padding-bottom: 4px; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;22,904,879&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; padding-bottom: 4px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="text-align: right; vertical-align: top; width: 18pt;"&gt;
                  &lt;div&gt;* &lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="text-align: left; vertical-align: top; width: auto;"&gt;
                  &lt;div&gt;L&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;iability classified warrants in connection with March 2025 Financings&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
       &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255);"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255);"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;The above tables exclude 16,009,928 pre-funded warrants with a nominal exercise price of $0.0001
          per share issued in connection with the 2025 RDO in the amount of 7,177,033 and in connection with the March 2025 Offering in the
          amount of 8,832,895. All of the pre-funded warrants were deemed outstanding common stock for net loss per share purposes (See Note 11
          &#x2013; Net Loss per Share).&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt; &lt;br/&gt;
        &lt;/div&gt;
</ird:FinancingsTextBlock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20251106to20251106_SubsidiarySaleOfStockAxis_November2025RegisteredDirectOfferingMember"
      decimals="-5"
      id="Fact_b54d3da8f51f491fba639ad073ade028"
      unitRef="U001">23000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c20251106to20251106_SubsidiarySaleOfStockAxis_November2025RegisteredDirectOfferingMember"
      decimals="-5"
      id="Fact_d0215c8e4f8142e798d26d9ecb98c162"
      unitRef="U001">100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20251106to20251106_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_November2025RegisteredDirectOfferingMember"
      decimals="0"
      id="Fact_5357a88c44d44181be23fae2d9672d35"
      unitRef="U002">3827751</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c20251106_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_November2025RegisteredDirectOfferingMember"
      decimals="2"
      id="Fact_f6b2d712f3264e72a60c443d38052566"
      unitRef="U003">2.09</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20251106_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_November2025RegisteredDirectOfferingMember"
      decimals="0"
      id="Fact_20547a49b6b14d63b0d34e410dbe85fc"
      unitRef="U002">7177033</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ird:StockSoldPricePerShare
      contextRef="c20251106_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_November2025RegisteredDirectOfferingMember"
      decimals="4"
      id="Fact_9c4035bec8c64c42a08fec4ef63b0fc3"
      unitRef="U003">2.0899</ird:StockSoldPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20251106_FinancialInstrumentAxis_PreFundedRDOWarrantsMember_SubsidiarySaleOfStockAxis_November2025RegisteredDirectOfferingMember"
      decimals="4"
      id="Fact_5aae1c92deee481983842c19c4e82eb7"
      unitRef="U003">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20250825to20250825_SubsidiarySaleOfStockAxis_PrivatePlacementMember"
      decimals="0"
      id="Fact_0ef3a59b86bc4a63a846b6cf9e6e01bf"
      unitRef="U002">3138338</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20250825to20250825_SubsidiarySaleOfStockAxis_PrivatePlacementMember"
      decimals="-5"
      id="Fact_484f7ab2005348b59f179ac3e97ca145"
      unitRef="U001">3500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20250321to20250321_SubsidiarySaleOfStockAxis_UnderwrittenPublicOfferingMember"
      decimals="0"
      id="Fact_c248c857714448f7ba93156e17eb138a"
      unitRef="U002">12219736</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20250321_ClassOfWarrantOrRightAxis_March2025WarrantsMember_RangeAxis_MaximumMember"
      decimals="0"
      id="Fact_e51f76e4703b404bade8abc12763b0c5"
      unitRef="U002">21052631</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ird:NumberOfSecuritiesToPurchaseInEachShareOfCommonStockAndWarrant
      contextRef="c20250321_ClassOfWarrantOrRightAxis_March2025WarrantsMember"
      decimals="INF"
      id="Fact_cdcb766ac3bd465a8309f4180a148d52"
      unitRef="U002">1</ird:NumberOfSecuritiesToPurchaseInEachShareOfCommonStockAndWarrant>
    <ird:StockSoldPricePerShare
      contextRef="c20250321_ClassOfWarrantOrRightAxis_March2025WarrantsMember"
      decimals="INF"
      id="Fact_a37cb6a99b2d49e88b89d136feefcc02"
      unitRef="U003">0.95</ird:StockSoldPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20250321_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember"
      decimals="0"
      id="Fact_a8cd7d2be4a249228f524ece024d1ef1"
      unitRef="U002">8832895</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ird:StockSoldPricePerShare
      contextRef="c20250321_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember"
      decimals="4"
      id="Fact_7755c94536e5441ba27698e9f84942e4"
      unitRef="U003">0.9499</ird:StockSoldPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20250321to20250321_SubsidiarySaleOfStockAxis_PrivateOfferingMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_904adc7de82045a393ed9f7cbbf56133"
      unitRef="U002">392157</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20250321to20250321_SubsidiarySaleOfStockAxis_PrivateOfferingMember_TitleOfIndividualAxis_ChairmanOfTheBoardMember"
      decimals="0"
      id="Fact_e74d51d51a9842228f407b3c6b049620"
      unitRef="U002">784314</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20250321_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember_TitleOfIndividualAxis_ChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_5f3af9cfd4a34febb76b710b9f55ba89"
      unitRef="U002">392157</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20250321_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember_TitleOfIndividualAxis_ChairmanOfTheBoardMember"
      decimals="0"
      id="Fact_50a4b20525bf4e41946adaa926b4daa4"
      unitRef="U002">784314</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ird:StockSoldPricePerShare
      contextRef="c20250321_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember"
      decimals="2"
      id="Fact_3d26c93662ec49c4a2d8aaeaa984f686"
      unitRef="U003">1.15</ird:StockSoldPricePerShare>
    <ird:ThresholdWeightedAveragePricePerShare
      contextRef="c20251231_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember_RangeAxis_MinimumMember"
      decimals="3"
      id="Fact_09802c4826d74aad9056c29de6d09e27"
      unitRef="U003">1.725</ird:ThresholdWeightedAveragePricePerShare>
    <ird:ThresholdOfDailyTradingVolumeDuringMeasurementPeriod
      contextRef="c20250101to20251231_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember_RangeAxis_MinimumMember"
      decimals="0"
      id="Fact_c80d0ffaaa2b49358ec7699ce53b4567"
      unitRef="U001">150000</ird:ThresholdOfDailyTradingVolumeDuringMeasurementPeriod>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="c20250324to20250324_SubsidiarySaleOfStockAxis_March2025FinancingsMember"
      decimals="-5"
      id="Fact_7ae6bb8d650a4c9eaf532ae6a9bf6de3"
      unitRef="U001">21500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <ird:UnderwritingDiscountsCommissionsAndOfferingExpenses
      contextRef="c20250324to20250324_SubsidiarySaleOfStockAxis_March2025FinancingsMember"
      decimals="-5"
      id="Fact_9f333d42fef74af784aaebf91da378c3"
      unitRef="U001">1800000</ird:UnderwritingDiscountsCommissionsAndOfferingExpenses>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20250321_ClassOfWarrantOrRightAxis_March2025WarrantsMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="INF"
      id="Fact_9901d5f42b924ce2ab0e5029cdd19edd"
      unitRef="U003">0.95</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="c20250324_ClassOfWarrantOrRightAxis_March2025WarrantsMember"
      id="Fact_0a48451a764147e1a557278de5b273df">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ird:MinimumPercentageOfBeneficialOwnership
      contextRef="c20250101to20251231_ClassOfWarrantOrRightAxis_March2025WarrantsMember"
      decimals="4"
      id="Fact_7eb263c8c3bb4fb184dcb9a648ed74c0"
      unitRef="U006">0.0499</ird:MinimumPercentageOfBeneficialOwnership>
    <ird:MaximumPercentageOfBeneficialOwnershipLimitation
      contextRef="c20250101to20251231_ClassOfWarrantOrRightAxis_March2025WarrantsMember"
      decimals="4"
      id="Fact_e7307d606593440e81c433ac249fe360"
      unitRef="U006">0.0999</ird:MaximumPercentageOfBeneficialOwnershipLimitation>
    <ird:NumberOfConsecutiveTradingDays
      contextRef="c20250101to20251231_ClassOfWarrantOrRightAxis_March2025WarrantsMember"
      id="Fact_af0c3f9d5c0747069bc6e2a82b95dffa">P30D</ird:NumberOfConsecutiveTradingDays>
    <ird:NumberOfConsecutiveTradingDays
      contextRef="c20250101to20251231_ClassOfWarrantOrRightAxis_March2025WarrantsMember"
      id="Fact_47c15802eb3544e8b37f97031dcbd504">P30D</ird:NumberOfConsecutiveTradingDays>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20251231_ClassOfWarrantOrRightAxis_March2025WarrantsMember_RangeAxis_MinimumMember"
      decimals="INF"
      id="Fact_40b1f61194b14d26ae9fbd6ae20d83b8"
      unitRef="U003">1.425</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ird:ThresholdOfDailyTradingVolumeDuringMeasurementPeriod
      contextRef="c20250101to20251231_ClassOfWarrantOrRightAxis_March2025WarrantsMember_RangeAxis_MinimumMember"
      decimals="0"
      id="Fact_a8a7769759b347189fa25453ee498f7c"
      unitRef="U001">150000</ird:ThresholdOfDailyTradingVolumeDuringMeasurementPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20250321_ClassOfWarrantOrRightAxis_March2025WarrantsMember"
      decimals="INF"
      id="Fact_6fa686e49dd1469cb590a7860e6f1db9"
      unitRef="U003">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DerivativeLiabilities
      contextRef="c20251231_ClassOfWarrantOrRightAxis_March2025WarrantsMember"
      decimals="-5"
      id="Fact_8a2bd97beee540248e56fc312213478b"
      unitRef="U001">14700000</us-gaap:DerivativeLiabilities>
    <ird:FairValueChangeAttributedToDerivativeLiability
      contextRef="c20250101to20251231_ClassOfWarrantOrRightAxis_March2025WarrantsMember"
      decimals="-5"
      id="Fact_5b716eed0259423b80c92ea6629cb23f"
      unitRef="U001">10900000</ird:FairValueChangeAttributedToDerivativeLiability>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20250101to20251231_ClassOfWarrantOrRightAxis_March2025WarrantsMember"
      decimals="3"
      id="Fact_4f85488580ac497aa4d4d64cc6bd1710"
      unitRef="U006">0.725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20250324to20250324_ClassOfWarrantOrRightAxis_March2025WarrantsMember"
      decimals="3"
      id="Fact_96a562b45da5498a9985c5d0b11f7c16"
      unitRef="U006">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20250101to20251231_ClassOfWarrantOrRightAxis_March2025WarrantsMember"
      decimals="3"
      id="Fact_a5d998002d114e6383d17248e6b42280"
      unitRef="U006">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20250324to20250324_ClassOfWarrantOrRightAxis_March2025WarrantsMember"
      decimals="3"
      id="Fact_cd1c8439b36b4262abbd50dc623f77e6"
      unitRef="U006">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharePrice
      contextRef="c20251231_ClassOfWarrantOrRightAxis_March2025WarrantsMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="2"
      id="Fact_0ed3cce026234068b5f96a9ee64a7671"
      unitRef="U003">2.01</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c20250324_ClassOfWarrantOrRightAxis_March2025WarrantsMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="2"
      id="Fact_522c4c8de88e4d26ae359e9cfb3e149f"
      unitRef="U003">1.15</us-gaap:SharePrice>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="c20251231_ClassOfWarrantOrRightAxis_March2025WarrantsMember"
      id="Fact_b251b779eb4e4808b8a4c51f9794d994">P4Y2M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="c20250324_ClassOfWarrantOrRightAxis_March2025WarrantsMember"
      id="Fact_2b0a4278d7814707a718d9f887565c21">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ird:TransactionCostsAllocatedToWarrantLiabilities
      contextRef="c20250101to20251231_ClassOfWarrantOrRightAxis_March2025WarrantsMember"
      decimals="-5"
      id="Fact_9b5a3dcc554241fd82f5b06c44fe8af5"
      unitRef="U001">1300000</ird:TransactionCostsAllocatedToWarrantLiabilities>
    <ird:ClassOfWarrantOrRightExercised
      contextRef="c20250101to20251231_ClassOfWarrantOrRightAxis_March2025WarrantsMember"
      decimals="0"
      id="Fact_919a133d7b7746cc9e5ea464b870b995"
      unitRef="U002">862684</ird:ClassOfWarrantOrRightExercised>
    <ird:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="c20250101to20251231_ClassOfWarrantOrRightAxis_March2025WarrantsMember"
      decimals="0"
      id="Fact_68331bb4fc61491fa0ffa3ac4ef4c44f"
      unitRef="U002">862684</ird:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20251231_ClassOfWarrantOrRightAxis_March2025WarrantsMember"
      decimals="-5"
      id="Fact_1f525e7a6a2f4109908c5d48481e99e5"
      unitRef="U001">1100000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20250321_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="2"
      id="Fact_8ec77828444444f4acdbcc84d4fe39b6"
      unitRef="U003">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="c20250324_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember"
      id="Fact_099652c5ec67411e8950407d1362790f">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ird:NumberOfConsecutiveTradingDays
      contextRef="c20250101to20251231_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember"
      id="Fact_576ca30bdca9464daed0758584e07bc3">P30D</ird:NumberOfConsecutiveTradingDays>
    <ird:NumberOfConsecutiveTradingDays
      contextRef="c20250101to20251231_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember"
      id="Fact_d67fd1bcaa394becac43f58945cd69ad">P30D</ird:NumberOfConsecutiveTradingDays>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20251231_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember_RangeAxis_MaximumMember"
      decimals="3"
      id="Fact_c3dd625120344e40976f60d3be6f2fa5"
      unitRef="U003">1.725</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ird:ThresholdOfDailyTradingVolumeDuringMeasurementPeriod
      contextRef="c20250101to20251231_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember_RangeAxis_MinimumMember"
      decimals="0"
      id="Fact_36bf26108d4f412c8207dd8bdc7fce42"
      unitRef="U001">150000</ird:ThresholdOfDailyTradingVolumeDuringMeasurementPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20250321_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember"
      decimals="INF"
      id="Fact_c4c93905a72e401fbdd465d184abb1d3"
      unitRef="U003">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DerivativeLiabilities
      contextRef="c20251231_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember"
      decimals="-5"
      id="Fact_25b241c9437b4825b6346a5231ae26a7"
      unitRef="U001">800000</us-gaap:DerivativeLiabilities>
    <ird:FairValueChangeAttributedToDerivativeLiability
      contextRef="c20250101to20251231_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember"
      decimals="-5"
      id="Fact_a1073fede70b41e19fdb425a80f6980e"
      unitRef="U001">600000</ird:FairValueChangeAttributedToDerivativeLiability>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20250101to20251231_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember"
      decimals="3"
      id="Fact_fa040d017e064339ba9030c61d370d15"
      unitRef="U006">0.725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20250324to20250324_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember"
      decimals="3"
      id="Fact_6cd4fa1ded314e3e923329c91c9dc888"
      unitRef="U006">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20250101to20251231_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember"
      decimals="3"
      id="Fact_ba97d36399294d9e8012d32a097b4415"
      unitRef="U006">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20250324to20250324_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember"
      decimals="3"
      id="Fact_08ade19f1cca402c98cbf6b4d44388f1"
      unitRef="U006">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharePrice
      contextRef="c20251231_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember_RangeAxis_MinimumMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="2"
      id="Fact_31ed06bcf0404734ba9da48d3a9b1b87"
      unitRef="U003">2.01</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c20250324_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="2"
      id="Fact_095d3052a85f4d9296bfa06f8191df1b"
      unitRef="U003">1.15</us-gaap:SharePrice>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="c20251231_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember"
      id="Fact_95ff66ce5ffb4fb3b6e036fb652a30b2">P4Y2M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="c20250324_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember"
      id="Fact_aae0961b1ca94f259329b92156db5105">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ird:ClassOfWarrantOrRightExercised
      contextRef="c20250101to20251231_ClassOfWarrantOrRightAxis_March2025PrivatePlacementWarrantsMember"
      decimals="INF"
      id="Fact_d42abbb267c345108a58c1694331aea7"
      unitRef="U002">0</ird:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20250321_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember"
      decimals="4"
      id="Fact_fa6ee5a00ec74874a550e21fa4fecce5"
      unitRef="U003">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ird:MinimumPercentageOfBeneficialOwnership
      contextRef="c20250101to20251231_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember"
      decimals="4"
      id="Fact_8164cbff09694465adafc9504f66c9ae"
      unitRef="U006">0.0499</ird:MinimumPercentageOfBeneficialOwnership>
    <ird:MaximumPercentageOfBeneficialOwnershipLimitation
      contextRef="c20250101to20251231_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember"
      decimals="4"
      id="Fact_a0c5e45209dc4c51b52c128d1d8883e3"
      unitRef="U006">0.0999</ird:MaximumPercentageOfBeneficialOwnershipLimitation>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20250311to20250311_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember"
      decimals="-5"
      id="Fact_9edc9a1287e542f19ec2e95ecfbc85ae"
      unitRef="U001">40000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20250113to20250113_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember"
      decimals="-5"
      id="Fact_7c70585994fc47ceb32ab9e51c1839a0"
      unitRef="U001">40000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20250101to20251231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember"
      decimals="0"
      id="Fact_f0078a8810964ca9919cc55ba428badc"
      unitRef="U002">1919412</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20240101to20241231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember"
      decimals="0"
      id="Fact_355a8564a55849a9ae965bcc69792dd6"
      unitRef="U002">1608522</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20250101to20251231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember"
      decimals="-5"
      id="Fact_53e9a46334e64a209cdbdb5483a1e630"
      unitRef="U001">2300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20240101to20241231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember"
      decimals="-5"
      id="Fact_92ae98c2a6034545a8af36188362dd38"
      unitRef="U001">3800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c20250101to20251231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember"
      decimals="-5"
      id="Fact_747f0206323d47a8a624b9bb97cb9e12"
      unitRef="U001">300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c20240101to20241231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember"
      decimals="-5"
      id="Fact_ef2d95143c084cc980f3129a314f161a"
      unitRef="U001">400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20210311to20251231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember"
      decimals="0"
      id="Fact_e0bd0ee82ee14befbf246bb5493664a6"
      unitRef="U002">9573250</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20210311to20251231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember"
      decimals="-5"
      id="Fact_1a4d53a4dd304d32bca6edb257905251"
      unitRef="U001">28700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c20210311to20251231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember"
      decimals="-5"
      id="Fact_ccc8e8b7c84a4bf08f4b122462284a94"
      unitRef="U001">1400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <ird:MaximumAmountToBeSoldUnderCommonStockPurchaseAgreementAmount
      contextRef="c20230810_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_PurchaseAgreementMember"
      decimals="-6"
      id="Fact_f4cb9d6dff06443381997e0915f3ed39"
      unitRef="U001">50000000</ird:MaximumAmountToBeSoldUnderCommonStockPurchaseAgreementAmount>
    <ird:TermOfPurchaseAgreement
      contextRef="c20250101to20251231_SubsidiarySaleOfStockAxis_PurchaseAgreementMember"
      id="Fact_95c667b53ddd4f16b2c169ebf297beb0">P30M</ird:TermOfPurchaseAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20240101to20241231_SubsidiarySaleOfStockAxis_PurchaseAgreementMember"
      decimals="0"
      id="Fact_9b31058e567f41549c2396a36d77bca9"
      unitRef="U002">400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20240101to20241231_SubsidiarySaleOfStockAxis_PurchaseAgreementMember"
      decimals="-5"
      id="Fact_d0ed7e3a8532485fb9892dc9be759051"
      unitRef="U001">700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20250101to20251231_SubsidiarySaleOfStockAxis_PurchaseAgreementMember"
      decimals="INF"
      id="Fact_2ad848c40ba446f59f9a9b4e40945d93"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20230801to20230810_SubsidiarySaleOfStockAxis_PurchaseAgreementMember"
      decimals="0"
      id="Fact_f6eadb3ee21d4f44b3a595fb9a4962e4"
      unitRef="U002">246792</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20230811to20250402_SubsidiarySaleOfStockAxis_PurchaseAgreementMember"
      decimals="0"
      id="Fact_7cf4f785678147bf9a2bba694b553af7"
      unitRef="U002">1700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20230811to20250402_SubsidiarySaleOfStockAxis_PurchaseAgreementMember"
      decimals="-5"
      id="Fact_30ce8569d2ff409196caa873ec6ac094"
      unitRef="U001">5200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c20230811to20250402_SubsidiarySaleOfStockAxis_PurchaseAgreementMember"
      decimals="-5"
      id="Fact_eb270b4bfb6e4ac2a6076eea4448c6f5"
      unitRef="U001">1400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20210608to20210608_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"
      decimals="0"
      id="Fact_aaadcdca472944b3bbe4598b43fc53e5"
      unitRef="U002">3076923</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20210608_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"
      decimals="0"
      id="Fact_03a6fac8ad57410cb7b7d21e7ca4d58e"
      unitRef="U002">1538461</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ird:StockSoldPricePerShare
      contextRef="c20210608_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"
      decimals="3"
      id="Fact_8e7c4c35f4f74da8a64dd10393eb46f9"
      unitRef="U003">4.875</ird:StockSoldPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20210608_FinancialInstrumentAxis_RDOWarrantsMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"
      decimals="2"
      id="Fact_76c2d898495a46b0add9498b57078a41"
      unitRef="U003">6.09</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="c20251231_FinancialInstrumentAxis_RDOWarrantsMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"
      id="Fact_f324969c7f8d459684d2213acf49702d">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20251231_FinancialInstrumentAxis_RDOWarrantsMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"
      decimals="0"
      id="Fact_8ba647f0b38c4aee9dadb2fd8431ca54"
      unitRef="U002">1538461</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ird:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="c20250101to20251231_FinancialInstrumentAxis_RDOWarrantsMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"
      decimals="INF"
      id="Fact_7e31cdc155c54ef6bc1e571f39e0090c"
      unitRef="U002">0</ird:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <ird:MinimumPercentageOfBeneficialOwnership
      contextRef="c20250101to20251231_FinancialInstrumentAxis_RDOWarrantsMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"
      decimals="4"
      id="Fact_ba8cd183b3a044b6b4408de37dd5b2a4"
      unitRef="U006">0.0499</ird:MinimumPercentageOfBeneficialOwnership>
    <ird:MaximumPercentageOfBeneficialOwnershipLimitation
      contextRef="c20250101to20251231_FinancialInstrumentAxis_RDOWarrantsMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"
      decimals="4"
      id="Fact_9811e46a0aff417f9f82653193a3b337"
      unitRef="U006">0.0999</ird:MaximumPercentageOfBeneficialOwnershipLimitation>
    <ird:MaximumPercentageOfBeneficialOwnershipLimitation
      contextRef="c20250101to20251231_FinancialInstrumentAxis_RDOWarrantsMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"
      decimals="4"
      id="Fact_aaad235e9afe45d28723072a82e68979"
      unitRef="U006">0.0999</ird:MaximumPercentageOfBeneficialOwnershipLimitation>
    <ird:ProceedsFromPreMergerFinancing
      contextRef="c20200629to20200629_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember"
      decimals="-4"
      id="Fact_4cbbc63ccad241b0861f621a318bbc10"
      unitRef="U001">21150000</ird:ProceedsFromPreMergerFinancing>
    <ird:ProceedsFromPreMergerFinancing
      contextRef="c20200629to20200629_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Fact_f462a3561212492b8bf76c08e4bc7d20"
      unitRef="U001">300000</ird:ProceedsFromPreMergerFinancing>
    <ird:NumberOfDirectors
      contextRef="c20200629to20200629_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact_62f94cc7b8d54569b73b209e991ce788"
      unitRef="U010">5</ird:NumberOfDirectors>
    <ird:NumberOfDirectors
      contextRef="c20200629to20200629_BusinessAcquisitionAxis_RexahnStockholdersMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact_fa769263fcde4ef288edbadefa635354"
      unitRef="U010">1</ird:NumberOfDirectors>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20201119_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember"
      decimals="4"
      id="Fact_3c46485f67a346d19c6ba80868af416f"
      unitRef="U003">4.4795</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="c20251231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember"
      id="Fact_081c4721dbc84d05aaacf1f6c652f24e">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="c20250101to20251231"
      id="Text_c84dff61bce44f12ad86ed6530324e70">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-style: italic; font-weight: bold;"&gt;Warrant Activity and Summary&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; text-align: justify; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Warrants&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Exercise&lt;/div&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Price Per&lt;/div&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Warrant&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Average Exercise&lt;/div&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Price&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Average Term&lt;/div&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;(Years)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-size: 10pt;"&gt;Outstanding and exercisable at December 31, 2024&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;7,204,299&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;4.48-6.09&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;4.82&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;1.00&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-size: 10pt;"&gt;Issued&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;22,229,102&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;0.95-1.15&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;0.96&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;5.00&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-size: 10pt;"&gt;Exercised&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;(862,684&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;0.95&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;0.95&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-size: 10pt;"&gt;Expired&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;(5,665,838&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;4.48&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;4.48&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-size: 10pt;"&gt;Outstanding and exercisable at December 31, 2025&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;22,904,879&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;0.95-6.09&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;1.31&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-size: 10pt;"&gt;3.98&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;The following table summarizes information about warrants outstanding at December
        31, 2025:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Exercise Price&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Number Outstanding&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Weighted Average&lt;/div&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Remaining Contractual&lt;/div&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;life (Years)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;Number Exercisable at&lt;/div&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;December 31,&lt;/div&gt;
              &lt;div style="text-align: center; font-weight: bold; font-size: 10pt;"&gt;2025&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&lt;br/&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;0.95&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;20,189,947&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;4.23&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;20,189,947&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-size: 10pt;"&gt;*&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;1.15&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;1,176,471&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;4.23&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;1,176,471&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-size: 10pt;"&gt;*&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;6.09&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;1,538,461&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;0.43&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;1,538,461&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-size: 10pt;"&gt;Total&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; padding-bottom: 4px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; padding-bottom: 4px; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;22,904,879&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; padding-bottom: 4px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; padding-bottom: 4px; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; padding-bottom: 4px; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: justify; padding-bottom: 4px; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; padding-bottom: 4px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; padding-bottom: 4px; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="text-align: right; font-size: 10pt;"&gt;22,904,879&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: justify; vertical-align: bottom; padding-bottom: 4px; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="text-align: right; vertical-align: top; width: 18pt;"&gt;
                  &lt;div&gt;* &lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="text-align: left; vertical-align: top; width: auto;"&gt;
                  &lt;div&gt;L&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;iability classified warrants in connection with March 2025 Financings&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;
</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20241231"
      decimals="0"
      id="Fact_155c9e5d35e640bf85250acd67408002"
      unitRef="U002">7204299</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriod
      contextRef="c20241231"
      decimals="0"
      id="Fact_12074e828fcc4045bf6a0e239a25ed50"
      unitRef="U002">7204299</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriod>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodExercisePricePerWarrant
      contextRef="c20241231_RangeAxis_MinimumMember"
      decimals="2"
      id="Fact_e70b52e3ece34d619d25c5de526bd985"
      unitRef="U003">4.48</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodExercisePricePerWarrant>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisePricePerWarrant
      contextRef="c20241231_RangeAxis_MinimumMember"
      decimals="2"
      id="Fact_10fee880ff5346298fe100e89111dc24"
      unitRef="U003">4.48</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisePricePerWarrant>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisePricePerWarrant
      contextRef="c20241231_RangeAxis_MaximumMember"
      decimals="2"
      id="Fact_ae1e453a84e04feaa21d9e9fca97b9de"
      unitRef="U003">6.09</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisePricePerWarrant>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodExercisePricePerWarrant
      contextRef="c20241231_RangeAxis_MaximumMember"
      decimals="2"
      id="Fact_142c62a401374eb7b112454f3e2339f4"
      unitRef="U003">6.09</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodExercisePricePerWarrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c20241231"
      decimals="2"
      id="Fact_cd0eff879c264af48d2e3efa9bf9ba06"
      unitRef="U003">4.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20241231"
      decimals="2"
      id="Fact_580d53cadc104e9695c533bc1f701cf4"
      unitRef="U003">4.82</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="c20240101to20241231"
      id="Fact_e73f4bdc73714a0993a12edad2f94591">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageRemainingContractualTerm
      contextRef="c20240101to20241231"
      id="Fact_70602178bb7448cc88f06e4d5913918b">P1Y</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20250101to20251231"
      decimals="0"
      id="Fact_a6e3ec1254474934a09040488ef80dc6"
      unitRef="U002">22229102</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodExercisePricePerWarrant
      contextRef="c20250101to20251231_RangeAxis_MinimumMember"
      decimals="2"
      id="Fact_26f7674597804612be5c9f872a58c665"
      unitRef="U003">0.95</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodExercisePricePerWarrant>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodExercisePricePerWarrant
      contextRef="c20250101to20251231_RangeAxis_MaximumMember"
      decimals="2"
      id="Fact_43654da1ce924627b0336606068d603f"
      unitRef="U003">1.15</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodExercisePricePerWarrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20250101to20251231"
      decimals="2"
      id="Fact_f469cbf621e34f59bac25c2fd8df0ba7"
      unitRef="U003">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageRemainingContractualTerms
      contextRef="c20250101to20251231"
      id="Fact_dfc91a17d28a4dcfb6e419947e07762f">P5Y</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageRemainingContractualTerms>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod
      contextRef="c20250101to20251231"
      decimals="0"
      id="Fact_450bcaa518b94763a61190aefec92dbc"
      unitRef="U002">862684</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodExercisePricePerWarrant
      contextRef="c20250101to20251231"
      decimals="2"
      id="Fact_8228bd3d29df474b8505c909cdd7b97b"
      unitRef="U003">0.95</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodExercisePricePerWarrant>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20250101to20251231"
      decimals="2"
      id="Fact_98dc6424b64a4685980fa9858884bb35"
      unitRef="U003">0.95</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c20250101to20251231"
      decimals="0"
      id="Fact_451d98dc214c49ca9db955b26ec01504"
      unitRef="U002">5665838</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodExercisePricePerWarrant
      contextRef="c20250101to20251231"
      decimals="2"
      id="Fact_6988499235ed40218a6a8ad0e0570207"
      unitRef="U003">4.48</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodExercisePricePerWarrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c20250101to20251231"
      decimals="2"
      id="Fact_ebf389b6f90e465085a4333970e05a71"
      unitRef="U003">4.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20251231"
      decimals="0"
      id="Fact_441b8949925f43c6b4c2894916316ada"
      unitRef="U002">22904879</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriod
      contextRef="c20251231"
      decimals="0"
      id="Fact_3d15a2a7888644b99bcfb0c747f0e46e"
      unitRef="U002">22904879</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriod>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisePricePerWarrant
      contextRef="c20251231_RangeAxis_MinimumMember"
      decimals="2"
      id="Fact_83f4d476102149f0a6ceca3dbbf01f39"
      unitRef="U003">0.95</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisePricePerWarrant>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodExercisePricePerWarrant
      contextRef="c20251231_RangeAxis_MinimumMember"
      decimals="2"
      id="Fact_0568de8f2b8e4096813f9305f40b6105"
      unitRef="U003">0.95</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodExercisePricePerWarrant>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisePricePerWarrant
      contextRef="c20251231_RangeAxis_MaximumMember"
      decimals="2"
      id="Fact_ece2df3c1e65462bbdb52dbd5eb19cda"
      unitRef="U003">6.09</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisePricePerWarrant>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodExercisePricePerWarrant
      contextRef="c20251231_RangeAxis_MaximumMember"
      decimals="2"
      id="Fact_7b05e32f1ba3407cbbcbea732836e682"
      unitRef="U003">6.09</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodExercisePricePerWarrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c20251231"
      decimals="2"
      id="Fact_a1311a9a56464b2cbdb6a603237c4a58"
      unitRef="U003">1.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20251231"
      decimals="2"
      id="Fact_92cb2eba36eb4450be19b81f88b1bd02"
      unitRef="U003">1.31</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="c20250101to20251231"
      id="Fact_3d70c13a553544b1973c08c1c9190880">P3Y11M23D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageRemainingContractualTerm
      contextRef="c20250101to20251231"
      id="Fact_11b28f42014e42d0a962ba9bd325fba0">P3Y11M23D</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20251231_ClassOfWarrantOrRightAxis_WarrantExercisePriceOneMember"
      decimals="2"
      id="Fact_7ff0933ffe8c4ed498e2dd455c0472af"
      unitRef="U003">0.95</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20251231_ClassOfWarrantOrRightAxis_WarrantExercisePriceOneMember"
      decimals="0"
      id="Fact_83bf5baed0ab416e98c34046e186e4a4"
      unitRef="U002">20189947</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="c20251231_ClassOfWarrantOrRightAxis_WarrantExercisePriceOneMember"
      id="Fact_04cb8b3a7f3d40ed9b771bb3e0581ecd">P4Y2M23D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ird:ClassOfWarrantOrRightExercisable
      contextRef="c20251231_ClassOfWarrantOrRightAxis_WarrantExercisePriceOneMember"
      decimals="0"
      id="Fact_6fa2d48410b74f7cbd3d5483b0fbf22a"
      unitRef="U002">20189947</ird:ClassOfWarrantOrRightExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20251231_ClassOfWarrantOrRightAxis_WarrantExercisePriceTwoMember"
      decimals="2"
      id="Fact_fdfd34bf7da84894aeadf9dfc82f7c6d"
      unitRef="U003">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20251231_ClassOfWarrantOrRightAxis_WarrantExercisePriceTwoMember"
      decimals="0"
      id="Fact_a07bc9f1072d4a7f8e30eac33fc878eb"
      unitRef="U002">1176471</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="c20251231_ClassOfWarrantOrRightAxis_WarrantExercisePriceTwoMember"
      id="Fact_ecec5ccbd5234db3a0d1015f8ccd8d76">P4Y2M23D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ird:ClassOfWarrantOrRightExercisable
      contextRef="c20251231_ClassOfWarrantOrRightAxis_WarrantExercisePriceTwoMember"
      decimals="0"
      id="Fact_cc8bdc979116461e84d809f215cb903f"
      unitRef="U002">1176471</ird:ClassOfWarrantOrRightExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20251231_ClassOfWarrantOrRightAxis_WarrantExercisePriceThreeMember"
      decimals="2"
      id="Fact_6c167752a3194d03a0e9bbafce20f8e0"
      unitRef="U003">6.09</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20251231_ClassOfWarrantOrRightAxis_WarrantExercisePriceThreeMember"
      decimals="0"
      id="Fact_53bc84bb8f5e469eb478fcb0968271bd"
      unitRef="U002">1538461</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="c20251231_ClassOfWarrantOrRightAxis_WarrantExercisePriceThreeMember"
      id="Fact_5ba4101731c54c25bc423caa0ae814b5">P0Y5M4D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ird:ClassOfWarrantOrRightExercisable
      contextRef="c20251231_ClassOfWarrantOrRightAxis_WarrantExercisePriceThreeMember"
      decimals="0"
      id="Fact_288845cf52fe4c68a13db55973078798"
      unitRef="U002">1538461</ird:ClassOfWarrantOrRightExercisable>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20251231"
      decimals="0"
      id="Fact_2380110725d4428987cd5a34f3823fea"
      unitRef="U002">22904879</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ird:ClassOfWarrantOrRightExercisable
      contextRef="c20251231"
      decimals="0"
      id="Fact_5181b765ae3a4bb6a767dd934b091b14"
      unitRef="U002">22904879</ird:ClassOfWarrantOrRightExercisable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20251231_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember"
      decimals="0"
      id="Fact_ca52d99e58534f9aa40270b7e96b4893"
      unitRef="U002">16009928</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20251231_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember"
      decimals="4"
      id="Fact_3b3711c7ae6e48f3becafa5294715cbe"
      unitRef="U003">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20251231_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_SubsidiarySaleOfStockAxis_November2025RegisteredDirectOfferingMember"
      decimals="0"
      id="Fact_36cf389a36394ddbb758d2a4ac14caba"
      unitRef="U002">7177033</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20250321_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_SubsidiarySaleOfStockAxis_March2025FinancingsMember"
      decimals="0"
      id="Fact_f00a3adb254a4bf582070681b74995a3"
      unitRef="U002">8832895</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="c20250101to20251231"
      id="Text_e19d84f56a1547d1939fe9ec7bb5720d">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;8.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Stock-based Compensation&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Stock-based compensation expense was included in general and administrative, and research and development costs as follows in the accompanying consolidated
          statements of comprehensive loss for the year end periods below (in thousands):&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;December 31,&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2025&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2024&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;General and administrative&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2,363&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2,382&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Research and development&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;1,036&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;980&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total stock-based compensation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;3,399&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;3,362&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: normal; background-color: rgb(255, 255, 255); font-variant: normal; text-transform: none;"&gt;Inducement Plan&lt;/div&gt;

&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;On May 22, 2025,
              and August 8, 2025, the Company amended the Opus Genetics, Inc. 2021 Inducement Plan (the &#x201c;Inducement Plan&#x201d;) to adjust the reserve by 700,000
              and 800,000 shares, respectively, to a total of 4,125,258 shares of its common stock. The Inducement Plan is to be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company, as an inducement material
              to the individual&#x2019;s entry into employment with the Company within the meaning of Rule 5635(c)(4) of Nasdaq&#x2019;s continued listing requirements.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none;"&gt;2020 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;In November 2020, the stockholders of the Company approved the 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;) for stock-based awards. Under the 2020 Plan, (i) 1,000,000 new shares of common stock were reserved for issuance and (ii) up to 70,325 additional shares of common stock may be issued, consisting of (A) shares that remain available for the issuance of awards under prior equity plans and (B) shares of
          common stock subject to outstanding stock options or other awards covered by prior equity plans that have been cancelled or expire on or after the date that the 2020 Plan became effective. Under the 2020 Plan, the shares reserved automatically
          increase on January 1 of each year, for a period of not more than ten years from the date the 2020 Plan is approved by the
          stockholders of the Company, commencing on January 1, 2021 and ending on (and including) January 1, 2030, by an amount equal to 5% of
          the shares of common stock outstanding as of December 31st of the preceding calendar year. &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;The 2020 Plan permits the grant of incentive and nonstatutory stock options, appreciation rights, restricted stock, restricted stock units, performance stock and cash awards, and other stock-based awards&lt;/span&gt;. On January 1, 2025, 1,578,733 shares were added to the 2020 Plan as a result of its annual increase provision.&lt;br/&gt;
        &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"&gt;2018 Equity Incentive Plan&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Prior to the 2020 Plan, the Company had adopted a 2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;) in April 2018 under which 1,175,000 shares of the Company&#x2019;s common stock were reserved for issuance to employees, directors and consultants. &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Upon the effective date of the 2020 Plan, no
            additional shares were available for issuance under the 2018 Plan&lt;/span&gt;.&lt;/div&gt;

&lt;div style="font-style: italic;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div style="font-weight: bold; font-style: italic; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Stock Options&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;During the years ended December 31, 2025 and 2024, 3,331,725
            and 1,366,914 stock options were granted to officers, directors, employees and consultants, respectively, generally vesting over a &lt;span style="-sec-ix-hidden:Fact_5ad805ae5165416189740367b2bde6bb"&gt;one&lt;/span&gt; to four year period. The Company
            recognized $1.9 million in stock-based compensation expense related to stock options during each of the years ended December 31,
            2025 and 2024.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;During the years ended December 31, 2025 and 2024, 336,759
            and zero stock options were exercised, respectively, with an intrinsic value of $0.3 million and zero, respectively. &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;"&gt;The following table
            summarizes the Company&#x2019;s stock option plan activity:&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
                &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Number of&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Options&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Average&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Exercise&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Price&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Weighted Average&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Remaining&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Contractual&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Term (years)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Aggregate&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Intrinsic&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Value&lt;sup&gt;(1)&lt;/sup&gt;&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;(in thousands)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Outstanding at December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;4,410,258&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2.98&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;7.81&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2,385&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Granted&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;1,366,914&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2.17&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Exercised&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Forfeited/Cancelled&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(703,436&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;3.58&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Outstanding at December 31, 2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;5,073,736&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2.68&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;7.37&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;124&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Granted&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;3,331,725&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;1.16&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Exercised&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(336,759&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;1.05&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Forfeited/Cancelled&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(813,067&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2.31&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Outstanding at December 31, 2025&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;7,255,635&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2.10&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;7.76&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;3,414&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; width: 52%; padding-bottom: 4px;" valign="bottom"&gt;Vested and expected to vest at December 31, 2025&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;7,255,635&lt;br/&gt;
                &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;2.10&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;7.76&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;3,414&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Vested and exercisable at December 31, 2025&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;3,288,148&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2.84&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;5.96&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;731&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"&gt;(1)&lt;/sup&gt;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The aggregate intrinsic value is
                  calculated as the difference between the exercise price of the underlying options and the fair value of our common stock as of December 31, 2025 and 2024 of $2.01 and $1.19 per share, respectively.&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The
            weighted average fair value per share of options granted during the years ended December 31, 2025 and 2024 was $0.80 and $1.73, respectively. The Company measures the fair value of stock options with service-based vesting criteria to employees, directors and consultants
            on the date of grant using the Black-Scholes option pricing model. The Company does not have adequate history to support an internal calculation of volatility and expected term. As such, the Company has used a weighted average volatility
            considering the volatilities of several guideline companies.&lt;/span&gt; &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;For purposes of
            identifying similar entities (guideline companies), the Company considered characteristics such as industry, length of trading history, and stage of life cycle. The average expected life of the options was based on the contractual term for
            agreements that allow for exercise of vested options through the end of the contractual term upon termination of continuous service, and for all other agreements, was based on the mid&#x2011;point between the vesting date and the end of the
            contractual term according to the &#x201c;simplified method&#x201d; as described in Staff Accounting Bulletin 110. The risk&#x2011;free interest rate is determined by reference to implied yields available from U.S. Treasury securities with a remaining term equal to
            the expected life assumed at the date of grant. The assumed dividend yield was based on the Company&#x2019;s expectation of not paying dividends in the foreseeable future.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The weighted average assumptions used in the Black-Scholes option pricing model are as follows during the years ended December 31, 2025 and 2024:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: middle; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2025&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2024&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Expected stock price volatility&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;75.7&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;98.1&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Expected life of options (years)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;6.0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;5.9&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Expected dividend yield&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Risk free interest rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;3.9&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;4.2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;During the years ended December 31, 2025 and 2024, 1,002,842 and 709,358 stock options vested, respectively.
            The weighted average fair value per share of options vesting during the years ended December 31, 2025 and 2024 was $1.94 and $2.61, respectively. During the years ended December 31, 2025 and 2024, 813,067 and 703,436 stock options were forfeited,
            respectively.&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Restricted Stock Units&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;During the year
              ended December 31, 2025, the Company granted an aggregate of 1,688,361 restricted stock units (&#x201c;RSUs&#x201d;), respectively, to certain
              officers and employees under the 2020 Plan. The weighted average grant date per unit fair value of the RSUs granted during the year ended December 31, 2025 was $1.01. The vesting period of the RSUs range from a &lt;span style="-sec-ix-hidden:Fact_058d91f000234303b1e7e8999ccc8b9c"&gt;one&lt;/span&gt; to four year period with vesting tranches on an annual basis, subject to the recipient&#x2019;s continued service on such dates.&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;During the year ended December 31, 2024, the Company granted an aggregate of 1,025,022 RSUs, respectively, to certain officers and employees under the 2020 Plan. The weighted average grant date per unit fair value of the RSUs granted during the year ended
            December 31, 2024 was $1.78. The vesting period of the RSUs range from a &lt;span style="-sec-ix-hidden:Fact_1ef3378be6904988a15aead682a873b1"&gt;one&lt;/span&gt; to four year period with vesting tranches on an annual basis, subject
            to the recipient&#x2019;s continued service on such dates.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;During the year ended December 31, 2025, 664,734
            RSUs vested and 325,630 RSUs were forfeited. During the year ended December 31, 2024, 314,162 RSUs vested and 119,330 RSUs were forfeited. &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The total expense for the years ended December 31, 2025 and 2024 related to the RSUs was $1.4 million and $1.2 million, respectively. &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;"&gt;A summary of RSU
            activity is as follows for the years ended December 31, 2025 and 2024:&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Number of&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Shares&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Non-vested at December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;801,700&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Granted&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;1,025,022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Forfeited&lt;br/&gt;
                &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(119,330&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Vested&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(314,162&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Non-vested at December 31, 2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;1,393,230&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; width: 88%; white-space: nowrap;" valign="bottom"&gt;Granted&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;1,688,361&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;Forfeited&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(325,630&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;Vested&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;(664,734&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; width: 88%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Non-vested at December 31, 2025&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;2,091,227&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Common Stock Issued for Services&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;The &lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Company granted common stock for services in the amount of 84,243 and 81,234 shares of common
              stock during the years ended December 31, 2025 and 2024, respectively, with a weighted grant date fair value of $1.26 and $3.01 per share, respectively. The common stock was granted to board members who elected to receive their board retainers in the form of stock for
              services. The stock-based compensation related to these services amounted to $0.1 million and $0.2 million during the years ended December 31, 2025 and 2024, respectively&lt;/span&gt;.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;General&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Unrecognized












































































































                stock-based compensation cost was $5.7 million as of December 31, 2025. The unrecognized stock-based compensation cost is
                expected to be recognized over a weighted average period of 1.7 years. As of December 31, 2025, 619,449 shares in the aggregate were available for future issuance under the 2020 Plan and Inducement Plan&lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;.&lt;/span&gt;&lt;/div&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="c20250101to20251231"
      id="Text_ce369da47f764472a9af8d3eda0756be">
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Stock-based compensation expense was included in general and administrative, and research and development costs as follows in the accompanying consolidated
          statements of comprehensive loss for the year end periods below (in thousands):&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;December 31,&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2025&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2024&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;General and administrative&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2,363&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2,382&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Research and development&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;1,036&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;980&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total stock-based compensation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;3,399&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;3,362&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20250101to20251231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact_8c8a82ad8ecc4eb0b05de6708f05d2e4"
      unitRef="U001">2363000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20240101to20241231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact_fb69bb090ea24512b72ccf5730e04cdb"
      unitRef="U001">2382000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20250101to20251231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_7518f3adb6da42699459c9879cfe8bb3"
      unitRef="U001">1036000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20240101to20241231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_63587568a9ed414baf1dfe6165a93a93"
      unitRef="U001">980000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_648cb67a88054ef2b2ff128844a58a39"
      unitRef="U001">3399000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_c8f7f8405f214784a4fbc6fab16748e2"
      unitRef="U001">3362000</us-gaap:AllocatedShareBasedCompensationExpense>
    <ird:CommonStockIncreaseInSharesReservedForFutureIssuance
      contextRef="c20250522_PlanNameAxis_InducementPlanMember"
      decimals="0"
      id="Fact_348fb17cc76d4286a2771248860abaf3"
      unitRef="U002">700000</ird:CommonStockIncreaseInSharesReservedForFutureIssuance>
    <ird:CommonStockIncreaseInSharesReservedForFutureIssuance
      contextRef="c20250808_PlanNameAxis_InducementPlanMember"
      decimals="0"
      id="Fact_9a531c31cd9740619601d6caf0c04a48"
      unitRef="U002">800000</ird:CommonStockIncreaseInSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20250522_PlanNameAxis_InducementPlanMember"
      decimals="0"
      id="Fact_54c8bc8e91674b72ba4e38acb2e60545"
      unitRef="U002">4125258</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20201130_PlanNameAxis_EquityIncentivePlan2020Member"
      decimals="0"
      id="Fact_390d9a29300c4d039aede844842a50e7"
      unitRef="U002">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20201130_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember"
      decimals="0"
      id="Fact_464b4768a1ca4dfaa51a473e8a79322c"
      unitRef="U002">70325</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <ird:MaximumPeriodOfSharesReservedUnderPlan
      contextRef="c20250101to20251231_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember"
      id="Fact_c7d81aec5b754f90b738e6f88ae7ca32">P10Y</ird:MaximumPeriodOfSharesReservedUnderPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="c20250101to20251231_PlanNameAxis_EquityIncentivePlan2020Member"
      decimals="2"
      id="Fact_f04b60c070eb426686ddff6f97d09603"
      unitRef="U006">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <ird:AggregateNumberOfCommonStockReservedForFutureIssuance
      contextRef="c20250101to20250101_PlanNameAxis_EvergreenProvisionPlan2020Member"
      decimals="0"
      id="Fact_9dd619ca6885402ca9cb52aff89f8112"
      unitRef="U002">1578733</ird:AggregateNumberOfCommonStockReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20191231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_20a0c287f0a64c31970dc33ff3fedfb2"
      unitRef="U002">1175000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20201105_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="INF"
      id="Fact_66c5f251df20466e8cd8e66b924a7413"
      unitRef="U002">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20250101to20251231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_698e34195e5546e0866328f3610a3498"
      unitRef="U002">3331725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_3f19764a157440f8b054b984e6c5a62b"
      unitRef="U002">1366914</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="c20250101to20251231_PlanNameAxis_EquityIncentivePlan2018Member_RangeAxis_MaximumMember"
      id="Fact_a77d5d071c90467c80e729d2d404dd1d">P4Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20250101to20251231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="-5"
      id="Fact_5c36586ddc9046bf91a7195d7a4ded45"
      unitRef="U001">1900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="-5"
      id="Fact_471ae6ecae1a4e869fd6a8237877dec1"
      unitRef="U001">1900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20250101to20251231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_f617df2215404d709afeea23e96d8d25"
      unitRef="U002">336759</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="INF"
      id="Fact_3ef0cfed3e5444a2a7ce3cc04754f3e0"
      unitRef="U002">-0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c20251231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="-5"
      id="Fact_df0b62bc34ac4dad92db335592f9ed3a"
      unitRef="U001">300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c20241231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="-3"
      id="Fact_88b67c8e15c14f4cb4ce99b0effa744f"
      unitRef="U001">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="c20250101to20251231"
      id="Text_28c984ccdc3e482885c0eb9898e76a28">&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;"&gt;The following table
            summarizes the Company&#x2019;s stock option plan activity:&lt;/span&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
                &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Number of&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Options&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Weighted&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Average&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Exercise&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Price&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Weighted Average&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Remaining&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Contractual&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Term (years)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Aggregate&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Intrinsic&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Value&lt;sup&gt;(1)&lt;/sup&gt;&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;(in thousands)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Outstanding at December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;4,410,258&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2.98&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;7.81&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2,385&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Granted&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;1,366,914&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2.17&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Exercised&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Forfeited/Cancelled&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(703,436&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;3.58&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Outstanding at December 31, 2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;5,073,736&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2.68&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;7.37&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;124&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Granted&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;3,331,725&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;1.16&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Exercised&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(336,759&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;1.05&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Forfeited/Cancelled&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(813,067&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2.31&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Outstanding at December 31, 2025&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;7,255,635&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2.10&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;7.76&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;3,414&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; width: 52%; padding-bottom: 4px;" valign="bottom"&gt;Vested and expected to vest at December 31, 2025&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;7,255,635&lt;br/&gt;
                &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;2.10&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;7.76&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;3,414&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Vested and exercisable at December 31, 2025&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;3,288,148&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2.84&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;5.96&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;731&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"&gt;(1)&lt;/sup&gt;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The aggregate intrinsic value is
                  calculated as the difference between the exercise price of the underlying options and the fair value of our common stock as of December 31, 2025 and 2024 of $2.01 and $1.19 per share, respectively.&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20231231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_7e6e82b1986a4b338fdeea7ecf60cb53"
      unitRef="U002">4410258</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20231231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_029d6464a3354eceb54bd106e92abc39"
      unitRef="U003">2.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      id="Fact_ebf5f70af2f74d53969a6b5560ad8edd">P7Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c20231231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="-3"
      id="Fact_38c81e4990a94156858e130260ae4948"
      unitRef="U001">2385000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_b2bd9b62e4e04673b9cc7e0a3aa16d16"
      unitRef="U002">1366914</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_80092c6b52564c57ae4576bd41b8d116"
      unitRef="U003">2.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="INF"
      id="Fact_d72a406bbd764adc87871a1c32f233e6"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_044904e437444509870897aea16de975"
      unitRef="U002">703436</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_b2c637b038214d9bb209a8c1131edb80"
      unitRef="U003">3.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_1f94bc36177d4e348b04b2f274555e71"
      unitRef="U002">5073736</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_32012845afc444989e9963e40296a651"
      unitRef="U003">2.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      id="Fact_ed69b5dfaf674605aca13b1469ba605c">P7Y4M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="-3"
      id="Fact_134673f957c0436992877793f9eafd17"
      unitRef="U001">124000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20250101to20251231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_28d2fc96e4174434b43c8135dde31379"
      unitRef="U002">3331725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c20250101to20251231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_0263ea9bfdcc40e191bf168a4d746eb1"
      unitRef="U003">1.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20250101to20251231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_8efef763707e4d48a27ba80ae30cf734"
      unitRef="U002">336759</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c20250101to20251231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_a7cb0ec524b047a380e3810354c0f504"
      unitRef="U003">1.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c20250101to20251231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_5f421e94a0c94ea7a6a2c6e9015fe963"
      unitRef="U002">813067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c20250101to20251231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_e9056558359749579070ec1ef5d56b8e"
      unitRef="U003">2.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20251231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_6ec26114ce0948f090532c6dfd979f53"
      unitRef="U002">7255635</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20251231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_c2ce373931674ef8a882b35bd65c2d30"
      unitRef="U003">2.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="c20250101to20251231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      id="Fact_c61adf9c6b844a62a0f9b52acdce73c6">P7Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c20251231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="-3"
      id="Fact_4dc0d98159294a779910279124bb54a7"
      unitRef="U001">3414000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c20251231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_632a0210ef1849108fcf37d9a497d94a"
      unitRef="U002">7255635</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice
      contextRef="c20251231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_dc456db8443b421bb0cdc8206ad84fd3"
      unitRef="U003">2.1</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm
      contextRef="c20250101to20251231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      id="Fact_bf74c73f3cde461cb01ddc772eaa6aca">P7Y9M3D</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue
      contextRef="c20251231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="-3"
      id="Fact_d9409eb5551b44ada39a396a96ab2c8d"
      unitRef="U001">3414000</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber
      contextRef="c20251231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_a3d37a751b3242d7b337bbab51ce0e2e"
      unitRef="U002">3288148</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="c20251231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_b2d77b187f76469298f38f79b3b00476"
      unitRef="U003">2.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="c20250101to20251231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      id="Fact_efa70ccbbe654006b9a91cbedcde7e97">P5Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="c20251231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="-3"
      id="Fact_b428d88dd24640e09bb40a663afe7d7d"
      unitRef="U001">731000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="c20251231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_fef2580d66ae4a2599e1fc1b071e708d"
      unitRef="U003">2.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="c20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_8d7d6ea7d3294956875e9ab8366cccb6"
      unitRef="U003">1.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="c20250101to20251231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_0fe8f8d6102b4aa695cf8eb7fb476b56"
      unitRef="U003">0.8</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_f96fe9de428545479cdb46e88e9963ad"
      unitRef="U003">1.73</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="c20250101to20251231"
      id="Text_416d0ff8b902480f84750f2d3ed8b433">
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The weighted average assumptions used in the Black-Scholes option pricing model are as follows during the years ended December 31, 2025 and 2024:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: middle; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2025&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2024&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Expected stock price volatility&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;75.7&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;98.1&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Expected life of options (years)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;6.0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;5.9&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Expected dividend yield&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Risk free interest rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;3.9&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;4.2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20250101to20251231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="3"
      id="Fact_3d9bb8271d4545168720fb12365dc8bd"
      unitRef="U006">0.757</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20240101to20241231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="3"
      id="Fact_a655ec8d11a74b6ea110159566a4c90a"
      unitRef="U006">0.981</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20250101to20251231_PlanNameAxis_EquityIncentivePlan2018Member"
      id="Fact_bbaf09a931974542b9c9c52af5edd005">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20240101to20241231_PlanNameAxis_EquityIncentivePlan2018Member"
      id="Fact_887d577d48cc478fa0f29487b9bec01b">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20250101to20251231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_2bd3412ff8994785a3b366f0da2095f2"
      unitRef="U006">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20240101to20241231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_9c1ff2f854f0455781734a02b878fb77"
      unitRef="U006">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20250101to20251231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="3"
      id="Fact_f649ca95af6f4d59b8216417a882a2f9"
      unitRef="U006">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20240101to20241231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="3"
      id="Fact_bfc4a6be97ff4458962c10f8679851cf"
      unitRef="U006">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c20250101to20251231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_059d46fe45ae4c299d759562e9ba0c29"
      unitRef="U002">1002842</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c20240101to20241231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_7b6e13c7bfcc43f6a6d342822f442840"
      unitRef="U002">709358</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="c20250101to20251231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_b6a9a6fca0ee410389ccf44b1b50bcb8"
      unitRef="U003">1.94</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="c20240101to20241231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_07bb9a3a1b7a40a9b218cd0432fc5fd7"
      unitRef="U003">2.61</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="c20250101to20251231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_be6d5c06cf3f4bc69bc50e6575bac3c5"
      unitRef="U002">813067</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="c20240101to20241231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_cbe998dacc9e4a0a8a9ad25fa624f624"
      unitRef="U002">703436</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlan2020Member"
      decimals="0"
      id="Fact_c168e1d5b48d4a459f392432b6bfae19"
      unitRef="U002">1688361</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlan2020Member"
      decimals="2"
      id="Fact_ff1f48124f72411aab910275e4a5d00b"
      unitRef="U003">1.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember"
      id="Fact_99b0b36caadb4dd39fab04091ff2c4ae">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlan2020Member"
      decimals="INF"
      id="Fact_42fee20361104070b568b3569de4732c"
      unitRef="U002">1025022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlan2020Member"
      decimals="2"
      id="Fact_39c77c4bd0894110a2b4f7c13d2ef14f"
      unitRef="U003">1.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember"
      id="Fact_ac16ec89ab594c65b6e89323a0903def">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_147c166e51a7475fbb96459fa8334d0d"
      unitRef="U002">664734</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_7dd53b37a4b14ca5af63008f8f2206fb"
      unitRef="U002">325630</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_2cc8d323f4f14ef8a56585799c4469b6"
      unitRef="U002">314162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_08f949819d644c84ae16965bbcd8a691"
      unitRef="U002">119330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="Fact_c926b20ef4f24a2b86f9c3fadd964691"
      unitRef="U001">1400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="Fact_af1055a48199487c8d885f68274125ef"
      unitRef="U001">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="c20250101to20251231"
      id="Text_91c268caff6c4290bf4cbe0770bac918">&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;"&gt;A summary of RSU
            activity is as follows for the years ended December 31, 2025 and 2024:&lt;/span&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Number of&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Shares&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Non-vested at December 31, 2023&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;801,700&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Granted&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;1,025,022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Forfeited&lt;br/&gt;
                &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(119,330&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Vested&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(314,162&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Non-vested at December 31, 2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;1,393,230&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; width: 88%; white-space: nowrap;" valign="bottom"&gt;Granted&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;1,688,361&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;Forfeited&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(325,630&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;Vested&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;(664,734&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; width: 88%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Non-vested at December 31, 2025&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;2,091,227&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_8b85ffc9bf2c4df397aacceba65ff4b3"
      unitRef="U002">801700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_1605283ea84243f69a1f9ecaa2221f21"
      unitRef="U002">1025022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_1546baae22784efe8edcd9ac2ce1de7d"
      unitRef="U002">119330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_f84dc70038d84e479d2c3b35883821c3"
      unitRef="U002">314162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_4ac9bfde00134cd4a99f90a7ebe7e7c3"
      unitRef="U002">1393230</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact_a8414aea675d4ba88a63617e189d012a"
      unitRef="U002">1688361</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_9c3265ada1a94c02b0ce6ac06b11c9a8"
      unitRef="U002">325630</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_0dc7b4630ea74e28b7e716464465f473"
      unitRef="U002">664734</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact_fd3ed6f36c214664a20fb774da8bf82a"
      unitRef="U002">2091227</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c20250101to20251231"
      decimals="0"
      id="Fact_09cc45a67cb34c399d079988f23ded51"
      unitRef="U002">84243</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c20240101to20241231"
      decimals="0"
      id="Fact_1f4b977431f144dba7a30782d83c00da"
      unitRef="U002">81234</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardServicesGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20250101to20251231"
      decimals="2"
      id="Fact_702f074c5f8c44c7873be93057062a18"
      unitRef="U003">1.26</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardServicesGrantsInPeriodWeightedAverageGrantDateFairValue>
    <ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardServicesGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_6e80f5f6650d4e05b9689b019d4a2140"
      unitRef="U003">3.01</ird:ShareBasedCompensationArrangementByShareBasedPaymentAwardServicesGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="c20250101to20251231"
      decimals="-5"
      id="Fact_649e9fde84454767b11a40d825484ccf"
      unitRef="U001">100000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="c20240101to20241231"
      decimals="-5"
      id="Fact_5bdc2a24049748ebaedc5910e1058fd9"
      unitRef="U001">200000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="c20251231"
      decimals="-5"
      id="Fact_ef2cf37ab5c8444683cc3cc0e038e8c3"
      unitRef="U001">5700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="c20250101to20251231"
      id="Fact_e01d1519123446d293a9ff35fdc20c6e">P1Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <ird:CommonStockCapitalSharesAvailableForFutureIssuance
      contextRef="c20251231_PlanNameAxis_InducementPlanMember"
      decimals="0"
      id="Fact_07add041c9fd418388cb7315a660a0da"
      unitRef="U002">619449</ird:CommonStockCapitalSharesAvailableForFutureIssuance>
    <ird:CommonStockCapitalSharesAvailableForFutureIssuance
      contextRef="c20251231_PlanNameAxis_EvergreenProvisionPlan2020Member"
      decimals="0"
      id="Fact_0238534df7a04c3496f9d9d3d2a54388"
      unitRef="U002">619449</ird:CommonStockCapitalSharesAvailableForFutureIssuance>
    <ird:ApexianSublicenseAgreementTextBlock
      contextRef="c20250101to20251231"
      id="Text_2074a37595f94f3fb91cf9d3e70aaa8f">
&lt;div&gt;  &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;9.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold;"&gt;Apexian Sublicense Agreement&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"&gt;&#160;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;On January 21, 2020, &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;the Company entered into a sublicense agreement (as amended on June 4, 2020,
            the &#x201c;Apexian Sublicense Agreement&#x201d;) with Apexian, pursuant to which it obtained exclusive worldwide patent and other intellectual property rights that constitute a Ref-1 Inhibitor program relating to therapeutic applications to treat disorders
            related to ophthalmic and diabetes mellitus conditions. The lead compound in the Ref-1 Inhibitor program is APX3330, which the Company intends to develop as an oral tablet therapeutic to treat diabetic retinopathy initially, and potentially
            later to treat diabetic macular edema, geographic atrophy and age-related macular degeneration. In connection with the Apexian Sublicense Agreement, the Company issued a total of 891,422 shares of its common stock to Apexian and to certain affiliates of Apexian in calendar year 2020&lt;/span&gt;.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;The &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Company also agreed to make one-time milestone payments
            under the Apexian Sublicense Agreement for each of the first ophthalmic indication and the first diabetes mellitus indication for the development and regulatory milestones, and once for each of several sales milestones. These milestone payments
            include (i) payments for specified developmental and regulatory milestones (including completion of the first Phase 2 trial and the first Phase 3 pivotal trial in the United States, and filing and achieving regulatory approval from the FDA for
            the first New Drug Application for a compound) totaling up to $11 million in the aggregate and (ii) payments for specified sales
            milestones of up to $20 million in the aggregate, which net sales milestone payments are payable once, upon the first achievement of
            such milestone. Lastly, the Company also agreed to make royalty payments equal to a single-digit percentage of its net sales of products associated with the covered patents under the Apexian Sublicense Agreement. If it is not terminated
            pursuant to its terms, the Apexian Sublicense Agreement shall remain in effect until expiration of the last to expire of the covered patents&lt;/span&gt;.&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;None of the milestone
          or royalty payments were triggered or deemed probable as of December 31, 2025.&lt;/div&gt;
</ird:ApexianSublicenseAgreementTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20200101to20201231_RelatedPartyTransactionAxis_ApexianSublicenseAgreementMember"
      decimals="0"
      id="Fact_681d4533a7734a3191eee49bd1d8baf4"
      unitRef="U002">891422</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <ird:FutureMilestoneMethodRevenueNotRecognized
      contextRef="c20250101to20251231_HealthCareOrganizationRevenueSourcesAxis_DevelopmentAndRegulatoryMilestonesMember_RangeAxis_MaximumMember_RelatedPartyTransactionAxis_ApexianSublicenseAgreementMember"
      decimals="-6"
      id="Fact_7e5ea8dedcab4170a4e326fa45a2fd12"
      unitRef="U001">11000000</ird:FutureMilestoneMethodRevenueNotRecognized>
    <ird:FutureMilestoneMethodRevenueNotRecognized
      contextRef="c20250101to20251231_HealthCareOrganizationRevenueSourcesAxis_SalesMilestonesMember_RangeAxis_MaximumMember_RelatedPartyTransactionAxis_ApexianSublicenseAgreementMember"
      decimals="-6"
      id="Fact_4b5feb0796394424a8985f59abd6f2df"
      unitRef="U001">20000000</ird:FutureMilestoneMethodRevenueNotRecognized>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="c20250101to20251231"
      id="Text_b2bdb8e0cda94547911aa84e669ba94b">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;  &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;10.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
              &lt;div style="font-weight: bold;"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;"&gt;License and Collaboration Revenue and Other Funding Agreements&lt;/div&gt;
              &lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Viatris License Agreement&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/span&gt; &lt;/div&gt;

&lt;div style="margin: 0px 0px 0px; font-size: 10pt; text-align: justify;"&gt; &lt;span style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;On November 6, 2022, the
        Company entered into the Viatris License Agreement, pursuant to which it granted Viatris an exclusive, perpetual, sub-licensable license to develop, manufacture, import, export and commercialize (i) PS, for treating (a) reversal of mydriasis, (b)
        night vision disturbances or dim light vision, and (c) presbyopia, and (ii) PS and low dose pilocarpine for treating presbyopia (together, the &#x201c;PS Products&#x201d;) worldwide except for certain countries and jurisdictions in Asia (the &#x201c;Viatris
        Territory&#x201d;). The Company retains the exclusive right to develop, manufacture, have manufactured, import, export and commercialize the PS Products outside of the Viatris Territory. &lt;/span&gt;&lt;/div&gt;

&lt;div style="margin: 0px; font-size: 10pt; text-align: justify; font-family: 'Times New Roman';"&gt;&lt;span style="font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
      &lt;/span&gt;&lt;/div&gt;

&lt;div style="margin: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-transform: none;"&gt; Under the terms of the Viatris License Agreement, the Company
      in partnership with Viatris, plans to develop the PS Products in the United States. Viatris has agreed to reimburse the Company for agreed-to budgeted costs related to the development of the PS Products through FDA approval and then share costs above
      the agreed upon threshold amount of $50.0 million. Viatris will be responsible for developing the PS Products in countries and
      jurisdictions in the Viatris Territory outside of the United States. &lt;span style="color: rgb(0, 0, 0);"&gt;In addition, i&lt;/span&gt;n August 2025, Opus and Viatris entered into a side letter to the Viatris License Agreement providing for the sharing of
      expenses arising in connection with a patent dispute.&lt;/div&gt;

&lt;div style="margin: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-transform: none;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;Pursuant to the Viatris License Agreement, the Company received a one-time
        non-refundable cash payment of $35 million in November 2022 for the exclusive, perpetual, sub-licensable license to develop, manufacture,
        import, export and commercialize the PS Products in the Viatris Territory. In addition, with respect to the PS Products, the Company will be eligible to receive potential additional payments of up to $130 million upon achieving certain specified regulatory or net sales milestones, with the first milestone payment of $10 million already made following approval by the FDA of PS for reversal of mydriasis, which occurred during the third quarter of 2023. The Company will also receive tiered royalties,
        starting at low double-digit royalties up to low 20% royalties, based on the aggregate annual net sales of all PS Products in the United
        States, and will receive low double-digit royalties based on all annual net sales in the Viatris Territory outside of the United States. The royalty payments will continue on a country-by-country basis from the date of the first commercial sale of
        the first PS Product in a country of the Viatris Territory until December 31, 2040.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Viatris License Agreement was accounted for under the provisions of ASC 606. In accordance with the p&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;rovisions under ASC 606, the Company identified two distinct performance obligations at the effective date: &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;(1) the license to its intellectual property and (2) research and
            development services.&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;
      &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company determined that the licenses transferred represented functional intellectual property. As such, the revenue related to the licenses was recognized at the point in time in
        which the license/know-how was delivered to Viatris which occurred during the fourth quarter of 2022. The Company determined that revenue related to the initial research and development services that were constrained to the 120-day non-cancellation period were to be recognized over time as the services were rendered based on an estimated percentage of completion input
        model. &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;The initial research and development services were completed in the first quarter of 2023. Revenue related to the on-going research and development services are based on
        activities completed during the period.&lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"&gt;Recognition of Revenue&lt;/div&gt;

&lt;div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt;Revenue recognized under the Viatris License Agreement during the years ended December 31, 2025 and 2024 was $14.2 million and $11.0 million,
          respectively, related to the output of ongoing research and development services and to a much lesser extent royalty payments.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: italic; font-variant: normal; text-transform: none;"&gt; Regulatory Milestones
          under the Viatris License Agreement &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company has evaluated the regulatory milestones that may be received in connection with the Viatris License Agreement. There is uncertainty that
      the events to obtain the remaining regulatory milestones (aside from the approval by the FDA of RYZUMVI&#xae;) will be achieved given the nature of clinical development and the stage of the development of the PS Products. These remaining regulatory
      milestones will be constrained until it is probable that a significant revenue reversal will not occur.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"&gt;Sales Milestone and Royalty Payments&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Sales milestones and royalties relate predominantly to a license of intellectual property granted to Viatris and are determined by sales or
      usage-based thresholds. The sales milestones and royalties are accounted for under the royalty recognition constraint and are accounted for as constrained variable consideration. The Company applies the royalty recognition constraint for each
      commercial milestone and only recognize revenues for each once a sale of a licensed product (achievement of each) occurs.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Each of the remaining regulatory and sales milestone performance obligations (aside
        from the $10 million milestone payment related to the FDA&#x2019;s approval of PS in the third quarter of 2023) were constrained as of December
        31, 2025 and no revenue was recognized related to these milestones.&lt;br/&gt;
      &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;  &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;A reconciliation of the closing balance of the contract assets and unbilled receivables associated with the Viatris License Agreement is as follows as of December 31,
      2025 and 2024 (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;2025&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2024 &lt;br/&gt;
            &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;Contract Assets and Unbilled Receivables&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance as of beginning of period&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2,209&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;1,407&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
            &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Revenue recognized&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;14,196&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;10,992&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Reclassification to accounts receivable related to &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;costs billed
                under the Viatris License Agreement&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;(15,235&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;(10,190&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;Balance as of end of period&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;1,170&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;2,209&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;  &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-style: italic; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;BioSense License and Assignment&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';"&gt;On March 10, 2020, prior to the Rexahn Merger, Rexahn entered into an amendment to its collaboration and license agreement, (as amended, the
          &#x201c;BioSense License and Assignment Agreement&#x201d;) with BioSense to advance the development and commercialization of the Rexahn RX-3117 drug compound (&#x201c;RX-3117&#x201d;) for all human uses in the Republic of Singapore, China, Hong Kong, Macau, and Taiwan (the
          &#x201c;BioSense Territory&#x201d;).&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Under the BioSense
          License and Assignment Agreement, the Company is eligible to receive additional milestone payments in an aggregate of up to $84.5
          million upon the achievement of development, regulatory and commercial goals and will also be eligible to receive tiered royalties at low double-digit rates on annual net sales in the BioSense Territory. The Company determined that none of the
          milestone payments under the BioSense License and Assignment Agreement were probable of payment as of December 31, 2025, and as a result, no
          revenue related to the milestones was recognized, as the achievement of events entitling the Company to any milestone payments were highly susceptible to factors outside of the Company&#x2019;s control. Future sales-based royalties related to the
          exclusive license to develop RX-3117, if any, will be recognized in the period the underlying sales transaction occurs.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Payments received
          under the BioSense License and Assignment Agreement will be subject to the CVR Agreement described in Note 2 &#x2013; Mergers.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold; font-size: 10pt; text-align: justify; font-family: 'Times New Roman';"&gt;Processa License Agreement&lt;/div&gt;

&lt;div style="font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;On June 16, 2021, the
          Company entered into a license agreement (the &#x201c;Processa License Agreement&#x201d;) with Processa Pharmaceuticals, Inc. (&#x201c;Processa&#x201d;), pursuant to which the Company agreed to grant Processa an exclusive license to develop, manufacture and commercialize
          RX-3117 globally, excluding the BioSense Territory.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Pursuant to the agreement, Processa is obligated to make future payments to the Company upon the achievement of certain development,
            regulatory and commercial milestones. In addition, Processa is obligated to pay the Company mid-single-digit percentage royalties based on annual sales. &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;On June 27, 2025, Processa notified the Company that it would not be
                developing RX-3117 and terminated the Processa License Agreement, effective October 25, 2025 (the &#x201c;Termination Date&#x201d;). No future payments will be received under the Processa License Agreement after the Termination Date and if any future
                payments are received prior to the Termination Date, they will be subject to the CVR Agreement described in Note 2 &#x2013; Mergers.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company determined that none of the milestone payments under the Processa License Agreement were probable of payment as of December 31,
            2025, and as a result, no revenue related to the milestones was recognized.&lt;/div&gt;

&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;SBIR Grant Agreement&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In September 2024, Private Opus received a Small Business Innovation Research (&#x201c;SBIR&#x201d;) grant through the Department of Health and Human
              Services in the amount of $0.9 million to be used on the development of the RHO product. This grant agreement survives the
              acquisition of Private Opus. Direct and allocated indirect costs for development activities are reimbursed on a draw-down basis as development activities are completed. For the year ended December 31, 2025 and 2024, the Company recognized $0.7 million and &lt;span style="-sec-ix-hidden:Fact_75a0e2cc0bbd464db646ff9437462081"&gt;nil&lt;/span&gt;, respectively,
              of other revenue related to the SBIR grant and was recorded as other income, net in the accompanying consolidated statements of comprehensive loss.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="text-align: left; color: rgb(34, 34, 34); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;RDH12 Agreement&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(34, 34, 34);"&gt;On July 22, 2025, the Company, together with its wholly owned subsidiary,
                OPUSTX, LLC (collectively, &#x201c;Opus&#x201d;), entered &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"&gt;into a funding and license agreement (the &#x201c;RDH12 Agreement&#x201d;) with Eyes on the Future (&#x201c;EOTF&#x201d;), and RDH12
                Fund for Sight (the &#x201c;Fund,&#x201d; and together with EOTF, the &#x201c;Funding Parties&#x201d;), charitable organizations, relating to Opus&#x2019; program to develop &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(34, 34, 34);"&gt;gene
                therapies that treat patients with inherited retinal degeneration associated with mutations in the RDH12 gene (the &#x201c;RDH12 Program&#x201d;).The RDH12 Agreement provides for funding by the Funding Parties of up to $1.6 million to support the development of the RDH12 Program. Opus is required to use the funding to conduct development activities in accordance
                with a mutually agreed development plan.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(34, 34, 34); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Under the RDH12 Agreement, Opus is subject to certain diligence obligations to develop a product under the RDH12 Program. If Opus is
              unable to achieve certain milestones by the specified dates, or if certain other events occur (a &#x201c;License Trigger Event&#x201d;), then the Funding Parties may exercise their rights under a non-exclusive, global, royalty-free and fully paid-up
              license granted by Opus to the Funding Parties to develop products under the RDH12 Program.&#160; If the Funding Parties exercise such license rights, then Opus will receive a non-exclusive license under the data and other intellectual property
              generated by the Funding Parties to develop products under the RDH12 Program, and the right to negotiate an exclusive license to such data and intellectual property to commercialize products under the RDH12 Program. The RDH12 Agreement
              includes certain restrictions on Opus&#x2019; ability to out-license rights to the RDH12 Program, and during the term of the RDH12 Agreement, Opus may not grant a third party an exclusive license to develop or commercialize products under the RDH12
              Program in the United States without the prior written consent of the Funding Parties.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(34, 34, 34); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The term of the RDH12 Agreement continues until the earlier of (a) dosing by Opus of three patients in a Phase 1a/2b clinical trial prior
              to a License Trigger Event, and (b) the first commercial sale of a product under the RDH12 Program following receipt of regulatory approval in the United States or certain other European countries.&#160; The RDH12 Agreement will also terminate if
              an exclusive, global licensee of Opus for the RDH12 Program assumes Opus&#x2019; obligations under the RDH12 Agreement. The RDH12 Agreement may be terminated by either party for cause, including material breach or bankruptcy, subject to a cure
              period, or by the Funding Parties for convenience following a License Trigger Event.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Eligible research and development costs under the RDH12 Agreement, as approved by the Funding Parties, are reimbursed on a draw-down basis
              as development activities are completed by the Company.&lt;/div&gt;
</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ird:ViatrisLicenseAndCostSharingAgreement
      contextRef="c20221106to20221106_TypeOfArrangementAxis_ViatrisLicenseAgreementMember"
      decimals="-5"
      id="Fact_7cd4d54ebdf04f279807ad3a2d4b50c8"
      unitRef="U001">50000000</ird:ViatrisLicenseAndCostSharingAgreement>
    <ird:NonRefundableCashPaymentReceived
      contextRef="c20221101to20221130_TypeOfArrangementAxis_ViatrisLicenseAgreementMember"
      decimals="-6"
      id="Fact_d27699320b1b48628b05b4719b992c4d"
      unitRef="U001">35000000</ird:NonRefundableCashPaymentReceived>
    <ird:MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones
      contextRef="c20221106to20221106_TypeOfArrangementAxis_ViatrisLicenseAgreementMember"
      decimals="-6"
      id="Fact_e5a2daf6160041fbab1686f9adf55e89"
      unitRef="U001">130000000</ird:MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones>
    <ird:FirstPotentialMilestonePaymentToBeReceived
      contextRef="c20221106_TypeOfArrangementAxis_ViatrisLicenseAgreementMember"
      decimals="-6"
      id="Fact_d083360dd8034859b6bd411f7b911bd0"
      unitRef="U001">10000000</ird:FirstPotentialMilestonePaymentToBeReceived>
    <ird:MaximumPercentageOfTieredRoyaltiesReceivable
      contextRef="c20251231_TypeOfArrangementAxis_ViatrisLicenseAgreementMember"
      decimals="2"
      id="Fact_2579cafeb86b4a00bf4b001f592167f9"
      unitRef="U006">0.20</ird:MaximumPercentageOfTieredRoyaltiesReceivable>
    <ird:NumberOfPerformanceObligations
      contextRef="c20251231_TypeOfArrangementAxis_ViatrisLicenseAgreementMember"
      decimals="INF"
      id="Fact_9298140a48354a09a3214ee02ff1f6a2"
      unitRef="U011">2</ird:NumberOfPerformanceObligations>
    <ird:NonCancellationPeriodOfConstraintForResearchAndDevelopmentRevenue
      contextRef="c20250101to20251231_TypeOfArrangementAxis_ViatrisLicenseAgreementMember"
      id="Fact_91fc44f113ed4f55b4313860ea28aec5">P120D</ird:NonCancellationPeriodOfConstraintForResearchAndDevelopmentRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20250101to20251231_TypeOfArrangementAxis_ViatrisLicenseAgreementMember"
      decimals="-5"
      id="Fact_ab7e548c99a64335b86afe750fd6df11"
      unitRef="U001">14200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231_TypeOfArrangementAxis_ViatrisLicenseAgreementMember"
      decimals="-5"
      id="Fact_4517965251a041ae8c47a1179426a8bf"
      unitRef="U001">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ird:MilestonePaymentRequiredUnderFDASApproval
      contextRef="c20230930_HealthCareOrganizationRevenueSourcesAxis_SalesMilestonesMember_TypeOfArrangementAxis_ViatrisLicenseAgreementMember"
      decimals="-6"
      id="Fact_c2b5c1c92a194fb89b82d19189f62854"
      unitRef="U001">10000000</ird:MilestonePaymentRequiredUnderFDASApproval>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20250101to20251231_HealthCareOrganizationRevenueSourcesAxis_SalesMilestonesMember_TypeOfArrangementAxis_ViatrisLicenseAgreementMember"
      decimals="-6"
      id="Fact_b3344479220e4820be57380a36d4c94a"
      unitRef="U001">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ird:ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock
      contextRef="c20250101to20251231"
      id="Text_b9374f1b7035421a99606737d320be5d">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;  &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;A reconciliation of the closing balance of the contract assets and unbilled receivables associated with the Viatris License Agreement is as follows as of December 31,
      2025 and 2024 (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;2025&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2024 &lt;br/&gt;
            &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;Contract Assets and Unbilled Receivables&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance as of beginning of period&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2,209&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;1,407&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
            &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Revenue recognized&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;14,196&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;10,992&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
            &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Reclassification to accounts receivable related to &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;costs billed
                under the Viatris License Agreement&lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;(15,235&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;(10,190&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;Balance as of end of period&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" valign="bottom"&gt;1,170&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;2,209&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</ird:ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock>
    <ird:ContractAssetCurrent
      contextRef="c20241231_TypeOfArrangementAxis_ViatrisLicenseAgreementMember"
      decimals="-3"
      id="Fact_5eb17c9aa6214eb8bce4d6493c48f84e"
      unitRef="U001">2209000</ird:ContractAssetCurrent>
    <ird:ContractAssetCurrent
      contextRef="c20231231_TypeOfArrangementAxis_ViatrisLicenseAgreementMember"
      decimals="-3"
      id="Fact_a7d05eb29c7c443096e3dd33caf27864"
      unitRef="U001">1407000</ird:ContractAssetCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20250101to20251231_TypeOfArrangementAxis_ViatrisLicenseAgreementMember"
      decimals="-3"
      id="Fact_b6a4b5fcbc2e403184de79315284912a"
      unitRef="U001">14196000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231_TypeOfArrangementAxis_ViatrisLicenseAgreementMember"
      decimals="-3"
      id="Fact_92d6d55cbc27422bb8cf23be99faed77"
      unitRef="U001">10992000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ird:ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement
      contextRef="c20250101to20251231_ProductOrServiceAxis_LicenseTransferFeeMember_TypeOfArrangementAxis_ViatrisLicenseAgreementMember"
      decimals="-3"
      id="Fact_79e10bbc2a6b445caaaa93a6d5a8dba9"
      unitRef="U001">15235000</ird:ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement>
    <ird:ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement
      contextRef="c20240101to20241231_ProductOrServiceAxis_LicenseTransferFeeMember_TypeOfArrangementAxis_ViatrisLicenseAgreementMember"
      decimals="-3"
      id="Fact_9a82280fdec7427fbddf9d1e486bde7f"
      unitRef="U001">10190000</ird:ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement>
    <ird:ContractAssetCurrent
      contextRef="c20251231_TypeOfArrangementAxis_ViatrisLicenseAgreementMember"
      decimals="-3"
      id="Fact_f65f56e059064e35a66a0dd71c8c4f28"
      unitRef="U001">1170000</ird:ContractAssetCurrent>
    <ird:ContractAssetCurrent
      contextRef="c20241231_TypeOfArrangementAxis_ViatrisLicenseAgreementMember"
      decimals="-3"
      id="Fact_61d77d6714fb44cda396a1297d7fca37"
      unitRef="U001">2209000</ird:ContractAssetCurrent>
    <ird:MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones
      contextRef="c20250101to20251231_TypeOfArrangementAxis_BioSenseLicenseAndAssignmentsAgreementMember"
      decimals="-5"
      id="Fact_c2ba06eaca0e43e2802f977c1520b1fb"
      unitRef="U001">84500000</ird:MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones>
    <ird:MilestonePaymentsAmountReceived
      contextRef="c20250101to20251231_TypeOfArrangementAxis_BioSenseLicenseAndAssignmentsAgreementMember"
      decimals="-3"
      id="Fact_366c4ed30c3a4e858dd8068301d310cc"
      unitRef="U001">0</ird:MilestonePaymentsAmountReceived>
    <ird:MilestonePaymentsAmountReceived
      contextRef="c20250101to20251231_TypeOfArrangementAxis_ProcessaLicenseAgreementMember"
      decimals="-3"
      id="Fact_b113cb51888b4d8f985f4840a0ff2498"
      unitRef="U001">0</ird:MilestonePaymentsAmountReceived>
    <ird:MilestonePaymentsAmountReceived
      contextRef="c20240901to20240930_TypeOfArrangementAxis_SBIRGrantAgreementMember"
      decimals="-5"
      id="Fact_b81114c870944ae78d0a5f8ff76e4dff"
      unitRef="U001">900000</ird:MilestonePaymentsAmountReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20250101to20251231_TypeOfArrangementAxis_SBIRGrantAgreementMember"
      decimals="-5"
      id="Fact_a90f8dcdf3254aa29914bbff8e762cfe"
      unitRef="U001">700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ird:MaximumAmountFundedToSupportStudy
      contextRef="c20250722_TypeOfArrangementAxis_RDH12AgreementMember"
      decimals="-5"
      id="Fact_a8fdbe49b2764fb2a0f96113c8c06cd4"
      unitRef="U001">1600000</ird:MaximumAmountFundedToSupportStudy>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="c20250101to20251231"
      id="Text_b389e89bb99a44f2b22914b55ad571ce">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold;"&gt;11.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold;"&gt;Net loss per share&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.&#160;
            Diluted earnings or loss per share of common stock is computed similarly to basic loss or earnings per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock
            equivalents, if dilutive. The Company&#x2019;s Series A Preferred Stock, warrants, stock options and RSUs, while outstanding, are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the
            warrants, stock options and RSUs. Diluted earnings with respect to the Series A Preferred Stock utilizing the if-converted method was not applicable during the periods outstanding as no conditions required for conversion had occurred. No
            incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the periods presented.&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The following potential common shares were not
            considered in the computation of diluted net loss &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;income &lt;/span&gt;per share as their effect would have been anti-dilutive
            for the year end periods presented below:&lt;/span&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2025&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2024&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Warrants&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;22,904,879&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;7,204,299&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Stock options&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;7,255,635&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5,073,736&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;RSUs&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2,091,227&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,393,230&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="c20250101to20251231"
      id="Text_1e7d9862e0914a08aa475a8026f53290">
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The following potential common shares were not
            considered in the computation of diluted net loss &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;income &lt;/span&gt;per share as their effect would have been anti-dilutive
            for the year end periods presented below:&lt;/span&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2025&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2024&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Warrants&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;22,904,879&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;7,204,299&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Stock options&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;7,255,635&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5,073,736&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;RSUs&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2,091,227&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,393,230&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20250101to20251231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"
      decimals="0"
      id="Fact_916c3e01b72549bdbc85de8648f118ae"
      unitRef="U002">22904879</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"
      decimals="0"
      id="Fact_2098496501524c67b94274468cd34861"
      unitRef="U002">7204299</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20250101to20251231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_58df1a97a89f465986b59f03215423c4"
      unitRef="U002">7255635</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_74ceae9bb6534ecdbc8281efb60777c0"
      unitRef="U002">5073736</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20250101to20251231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockMember"
      decimals="0"
      id="Fact_f4848ca64feb42eca487fb24b719be9f"
      unitRef="U002">2091227</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockMember"
      decimals="0"
      id="Fact_77eb1d51535a488ab4fb43f706e2014d"
      unitRef="U002">1393230</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="c20250101to20251231"
      id="Text_50148989e6f34ac8a68fb7d33b1f8246">
&lt;div&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold;"&gt;12.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold;"&gt;Income Taxes&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The effective tax rate for the years ended December 31, 2025 and 2024 was zero percent.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The tables below represent a reconciliation of the &lt;span style="-sec-ix-hidden:Fact_7b3f3f4f97694e3e8c468e749298a8ce"&gt;U.S.&lt;/span&gt;
          federal statutory income tax rate to effective tax rate. The Company has adopted the guidance in ASU 2023-09 on a prospective basis. The following table reflects the reconciliation rate for 2025 under the new guidance:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt; 2025&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;Tax Expense &lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;Effective Rate&lt;/span&gt; &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="margin-left: 18pt; text-indent: -18pt;"&gt;Income tax (benefit) provision at federal statutory rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(10,414&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(21.0&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)%&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;"&gt;Change in valuation allowance&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;4,594&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;9.3&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;State income tax, net of federal income tax effect (1)&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;3,357&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;6.8&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;Tax credits &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;(848&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;(1.7&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;Nontaxable or nondeductible items: &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div style="margin-left: 18pt; text-indent: -9pt;"&gt;Nondeductible change in warrant liability fair value&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;2,626&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;5.3&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 18pt;"&gt;Stock compensation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;264&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;0.5&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 18pt;"&gt;Other&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;421&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;0.8&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;"&gt;Effective tax rate&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;%&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-size: 10pt;"&gt;(1)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-align: justify; font-size: 10pt;"&gt;
                  &lt;div&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="-sec-ix-hidden:Fact_61ebfbf864f6406981d1e8914baf9657"&gt;North Carolina&lt;/span&gt; makes up the majority (greater than 50%) of the state income tax expense, net of federal income tax effect category.&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
      &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The table below represents a reconciliation of the U.S. federal statutory income tax rate to effective tax rate for the year ended December 31, 2024 under the prior
          guidance.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt; 2024&lt;/span&gt;&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;Effective Rate&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="margin-left: 18pt; text-indent: -18pt;"&gt;Income tax (benefit) provision at federal statutory rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(21.0&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)%&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;"&gt;Valuation allowance&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;26.5&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;State income tax, net of federal benefit&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(4.9&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Private Opus acquisition&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;(11.2&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;"&gt;Stock options&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;0.8&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Acquired IPR&amp;amp;D&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;12.6&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;"&gt;Research and development&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(1.6&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;"&gt;Other&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;(1.2&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;"&gt;Effective tax rate&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;%&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The components of income tax provision (benefit) consisted of the following for the years ended December 31, &lt;span style="font-size: 10pt; color: rgb(0, 0, 0);"&gt;2025

            and 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: middle; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;span style="font-weight: bold; font-family: 'Times New Roman';"&gt; 2025&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: middle; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;span style="font-weight: bold; font-family: 'Times New Roman';"&gt;2024&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;Loss before income taxes:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;(49,591&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;(57,532&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"&gt;Current:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;Federal&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;State&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;Total current tax provision (benefit)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"&gt;Deferred:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;Federal&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;State&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"&gt;Total tax provision (benefit&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities are summarized in the tables below as of December 31, 2025 and 2024 (in thousands):&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-weight: bold; text-align: center;"&gt;2025&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="font-weight: bold; text-align: center;"&gt;2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;Deferred tax assets:&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Federal and state operating loss carryforwards&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;32,248&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;20,342&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Acquired intangibles&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;484&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;547&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Deferral of research and development costs &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;1,451&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;9,582&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Organizational costs&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;4&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;5&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Accruals and other&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;329&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;77&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Stock-based compensation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;1,937&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;2,035&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Research and development credit carryforward &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;2,911&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;2,089&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Transaction costs in connection with Opus Acquisition&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;663&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;753&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Subtotal&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;40,027&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;35,430&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Valuation allowance&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(39,997&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;(35,403&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Total deferred tax assets, net of valuation allowance&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;30&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;27&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;"&gt;Deferred tax liabilities:&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Fixed assets &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(30&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;(27&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Total deferred tax liabilities&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(30&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;(27&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;"&gt;Net deferred tax assets&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;As of December 31, 2025 and 2024, the Company had gross deferred tax assets of approximately $40.0 million and $35.4 million, respectively. Realization of
            the deferred tax assets is primarily dependent upon future taxable income, if any, the amount and timing of which are uncertain. The Company has cumulative pre&#x2011;tax losses and faces significant challenges to becoming profitable in the future.
            Accordingly, the net deferred tax assets have been fully offset by a valuation allowance of $40.0 million and $35.4 million as of December 31, 2025 and 2024, respectively. U.S. net deferred tax assets will continue to require a valuation allowance until the
            Company can demonstrate their realizability through sustained profitability or another source of income.&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;As of December 31, 2025 and 2024, the tax effect of the Company&#x2019;s federal net operating loss carryforwards was approximately $31.5 million and $17.1 million,
          respectively. The Company had federal research credit carryforwards as of December 31, 2025 and 2024 of approximately $2.9 million and
          $2.1 million, respectively. The federal net operating loss carryforwards will not expire and the tax credit carryforwards will begin to
          expire in 2041 if not utilized.&#160; As of December 31, 2025 and 2024, the Company had state net operating loss carryforwards with a tax effect of approximately $0.7 million and $3.3 million, respectively. The Company did not have any state research credit carryforwards as of December 31, 2025 and 2024. The state net operating loss carryforwards will begin to expire
          in 2028.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The Company did not utilize any tax carryforwards or credits during the years ended December 31, 2025 and 2024.&lt;/span&gt;&lt;/span&gt;
        &lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;br/&gt;
            &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&lt;span style="font-size: 10pt;"&gt;Utilization of the net operating loss carryforwards and credits may be subject to a substantial annual limitation due to the ownership
            change limitations provided by Section 382 and Section 383 of the Internal Revenue Code of 1986, as amended, and similar state provisions. Generally, in addition to certain entity reorganizations, the limitation applies when one or more
            &#x201c;5-percent shareholders&#x201d; increase their ownership, in the aggregate, by more than 50 percentage points over a 3 year testing period, or beginning the day after the most recent ownership change, if shorter. The annual limitation may result in
            the expiration of net operating losses and credits before utilization.&lt;br/&gt;
          &lt;/span&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;As a result of the Opus Acquisition, the Company recorded $5.8 million in federal
            and state deferred tax assets, respectively, related largely to any net operating loss carryforwards and research &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;development cost deferrals. The deferred tax assets acquired were fully offset by a
              valuation allowance&lt;span style="background-color: rgb(255, 255, 255);"&gt;.&lt;/span&gt;&lt;/span&gt; The Company has not yet evaluated the impact of Section 382 and Section 383 related to the Opus Acquisition.&lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;As a result of the Merger with Rexhan, the Company recorded deferred tax assets of $10.3 million relating to net operating loss carryforwards which were fully offset by a valuation allowance. The $10.3 million net deferred tax assets recorded in relation to the Merger did not include federal and state net operating loss carryforwards that were estimated to expire under Internal
          Revenue Code Sections 382 as a result of the Merger. The Company has not yet evaluated the impact of Section 382 and Section 383 on its remaining tax attributes that were generated by Opus since the formation of the Company in 2018.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; background-color: rgb(255, 255, 255); text-align: justify;"&gt;The Company recognizes interest and/or penalties related to uncertain tax positions in income tax expense. There
            were no uncertain tax positions as of December 31, 2025 and 2024, and as such, no interest or penalties were recorded to income tax expense.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;The Company&#x2019;s corporate returns are subject to examination beginning with the 2021 tax year for federal income tax purposes and 2020 for state income tax purposes.&lt;/div&gt;
</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c20250101to20251231"
      decimals="0"
      id="Fact_a8a4f3b0d35f4e51b68f8765bdb4c234"
      unitRef="U006">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c20240101to20241231"
      decimals="0"
      id="Fact_234f26e40afe438f88ee2eff8bfba521"
      unitRef="U006">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="c20250101to20251231"
      id="Text_6f01de1444ed4fedb9be6dfa90f28a47">
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The tables below represent a reconciliation of the &lt;span style="-sec-ix-hidden:Fact_7b3f3f4f97694e3e8c468e749298a8ce"&gt;U.S.&lt;/span&gt;
          federal statutory income tax rate to effective tax rate. The Company has adopted the guidance in ASU 2023-09 on a prospective basis. The following table reflects the reconciliation rate for 2025 under the new guidance:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt; 2025&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;Tax Expense &lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;Effective Rate&lt;/span&gt; &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="margin-left: 18pt; text-indent: -18pt;"&gt;Income tax (benefit) provision at federal statutory rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(10,414&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(21.0&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)%&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;"&gt;Change in valuation allowance&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;4,594&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;9.3&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;State income tax, net of federal income tax effect (1)&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;3,357&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;6.8&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;Tax credits &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;(848&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;(1.7&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;Nontaxable or nondeductible items: &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div style="margin-left: 18pt; text-indent: -9pt;"&gt;Nondeductible change in warrant liability fair value&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;2,626&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;5.3&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 18pt;"&gt;Stock compensation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;264&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;0.5&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 18pt;"&gt;Other&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;421&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;0.8&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;"&gt;Effective tax rate&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;%&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-size: 10pt;"&gt;(1)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-align: justify; font-size: 10pt;"&gt;
                  &lt;div&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="-sec-ix-hidden:Fact_61ebfbf864f6406981d1e8914baf9657"&gt;North Carolina&lt;/span&gt; makes up the majority (greater than 50%) of the state income tax expense, net of federal income tax effect category.&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
      &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The table below represents a reconciliation of the U.S. federal statutory income tax rate to effective tax rate for the year ended December 31, 2024 under the prior
          guidance.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt; 2024&lt;/span&gt;&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;Effective Rate&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="margin-left: 18pt; text-indent: -18pt;"&gt;Income tax (benefit) provision at federal statutory rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(21.0&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)%&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;"&gt;Valuation allowance&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;26.5&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;State income tax, net of federal benefit&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(4.9&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Private Opus acquisition&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;(11.2&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;"&gt;Stock options&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;0.8&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Acquired IPR&amp;amp;D&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;12.6&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;"&gt;Research and development&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(1.6&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;"&gt;Other&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;(1.2&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;"&gt;Effective tax rate&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;%&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_e717b9059f5e40cd864da99c8f0047ff"
      unitRef="U001">-10414000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c20250101to20251231"
      decimals="3"
      id="Fact_0dfa3fb5330d4977a5521660fcb37bfa"
      unitRef="U006">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_7871c07cbbab43d78c9f39bf83746ebd"
      unitRef="U001">4594000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c20250101to20251231"
      decimals="3"
      id="Fact_13edf820bcf743d68048d9773fdf2892"
      unitRef="U006">-0.093</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_f72509ad03ba414e9c65925a2c57ac3a"
      unitRef="U001">3357000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="c20250101to20251231"
      decimals="3"
      id="Fact_663c6633920c4cd3a66a6d2e45c34e70"
      unitRef="U006">-0.068</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_dd069e3fed77428cbd68785ecfb1f652"
      unitRef="U001">848000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="c20250101to20251231"
      decimals="3"
      id="Fact_d4f0c18d2261497a915b5435f7224a81"
      unitRef="U006">-0.017</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <ird:EffectiveIncomeTaxRateReconciliationFairValueChangeOfWarrantLabilitiesAmount
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_a65f6585628544d882b86ba0ce77700e"
      unitRef="U001">2626000</ird:EffectiveIncomeTaxRateReconciliationFairValueChangeOfWarrantLabilitiesAmount>
    <ird:EffectiveIncomeTaxRateReconciliationFairValueChangeOfWarrantLabilitiesPercent
      contextRef="c20250101to20251231"
      decimals="3"
      id="Fact_78cf3e167d0648c0abaef6551f55b472"
      unitRef="U006">-0.053</ird:EffectiveIncomeTaxRateReconciliationFairValueChangeOfWarrantLabilitiesPercent>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_caeb6fd696084b70bced3b0c66230808"
      unitRef="U001">264000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="c20250101to20251231"
      decimals="3"
      id="Fact_c7f081797bb04112ab168eab857668a5"
      unitRef="U006">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_169d10b4a91740e3bd16931a479cb749"
      unitRef="U001">421000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="c20250101to20251231"
      decimals="3"
      id="Fact_591a19c91eff4064918da4fcec3a8e62"
      unitRef="U006">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_1d5371aa46e64bf68a59edd0dcc245ca"
      unitRef="U001">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c20250101to20251231"
      decimals="3"
      id="Fact_e27c924807834eae9d6c65f49b908a29"
      unitRef="U006">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c20240101to20241231"
      decimals="3"
      id="Fact_0a6edcf0473b4dc89d0352996e1ac31d"
      unitRef="U006">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c20240101to20241231"
      decimals="3"
      id="Fact_3836dfc1195349b19a7c816922aa07f6"
      unitRef="U006">-0.265</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="c20240101to20241231"
      decimals="3"
      id="Fact_942bcaee26fc48afb2bd3fbb4100f58c"
      unitRef="U006">0.049</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <ird:EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent
      contextRef="c20240101to20241231"
      decimals="3"
      id="Fact_35bc3d714cc444d2bcd2f84f79fafa93"
      unitRef="U006">0.112</ird:EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="c20240101to20241231"
      decimals="3"
      id="Fact_daa121b2e2874848aa3f1a4101e53571"
      unitRef="U006">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <ird:EffectiveIncomeTaxRateReconciliationAcquiredInProcessResearchAndDevelopmentPercent
      contextRef="c20240101to20241231"
      decimals="3"
      id="Fact_f518cd5a89fb46eeb560462f61d31741"
      unitRef="U006">-0.126</ird:EffectiveIncomeTaxRateReconciliationAcquiredInProcessResearchAndDevelopmentPercent>
    <ird:EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentPercent
      contextRef="c20240101to20241231"
      decimals="3"
      id="Fact_19e4dfccf4d441e6b59c385127363762"
      unitRef="U006">0.016</ird:EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="c20240101to20241231"
      decimals="3"
      id="Fact_7b29bff6853b430286d5584bdb6625e1"
      unitRef="U006">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c20240101to20241231"
      decimals="3"
      id="Fact_1b2c536ee68e4e648e64b498e7346241"
      unitRef="U006">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="c20250101to20251231"
      id="Text_1e59f956e9a24ddb9617f363dc094413">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The components of income tax provision (benefit) consisted of the following for the years ended December 31, &lt;span style="font-size: 10pt; color: rgb(0, 0, 0);"&gt;2025

            and 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: middle; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;span style="font-weight: bold; font-family: 'Times New Roman';"&gt; 2025&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: middle; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;span style="font-weight: bold; font-family: 'Times New Roman';"&gt;2024&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;Loss before income taxes:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;(49,591&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;(57,532&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"&gt;Current:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;Federal&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;State&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;Total current tax provision (benefit)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"&gt;Deferred:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;Federal&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;State&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"&gt;Total tax provision (benefit&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_75c040d003664e95b7210d82516adc3c"
      unitRef="U001">-49591000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_7150fe290be94fb68b6e9cb942f9ba7f"
      unitRef="U001">-57532000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_6686c6199475455e8083d98d2473d368"
      unitRef="U001">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_8ce3a92e0f05431ebdf3103d938668fa"
      unitRef="U001">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_d18131ec12554b08ad77c260c7f8a106"
      unitRef="U001">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_9c1a3c9be79c4eb8a855c667fab02746"
      unitRef="U001">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_da14632a04de48c9acc14b1935b9eb19"
      unitRef="U001">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_f9cd066b1f9d4fe48072989496dab567"
      unitRef="U001">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_752e8e3d75f145c3a0c29a653e21182a"
      unitRef="U001">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_aa3930067c984f48b6cf34ced2856af8"
      unitRef="U001">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_7d4e7ce48b774b67925e2b2b5f7c62ac"
      unitRef="U001">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_cf5cc12c53ec4c95adc91bd2759f8d4b"
      unitRef="U001">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_e7f37f9c458a4c3e9963c219d576f017"
      unitRef="U001">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_f551ccbebd7c49b5a421d65b8c73b5d5"
      unitRef="U001">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="c20250101to20251231"
      id="Text_7c7b46a6693c4bb28d230a8db5fa8696">
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities are summarized in the tables below as of December 31, 2025 and 2024 (in thousands):&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="font-weight: bold; text-align: center;"&gt;2025&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="font-weight: bold; text-align: center;"&gt;2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;Deferred tax assets:&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Federal and state operating loss carryforwards&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;32,248&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;20,342&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Acquired intangibles&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;484&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;547&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Deferral of research and development costs &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;1,451&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;9,582&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Organizational costs&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;4&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;5&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Accruals and other&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;329&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;77&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Stock-based compensation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;1,937&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;2,035&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Research and development credit carryforward &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;2,911&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;2,089&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Transaction costs in connection with Opus Acquisition&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;663&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;753&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Subtotal&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;40,027&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;35,430&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Valuation allowance&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(39,997&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;(35,403&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Total deferred tax assets, net of valuation allowance&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;30&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;27&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;"&gt;Deferred tax liabilities:&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Fixed assets &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(30&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;(27&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Total deferred tax liabilities&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(30&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;(27&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;"&gt;Net deferred tax assets&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="c20251231"
      decimals="-3"
      id="Fact_9df18c927b134bcab81d4a6d1b446d44"
      unitRef="U001">32248000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="c20241231"
      decimals="-3"
      id="Fact_a4fe3aeca58f4daba35e03dae7d6667f"
      unitRef="U001">20342000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="c20251231"
      decimals="-3"
      id="Fact_c670fd7a075c46d3857a66c18512a184"
      unitRef="U001">484000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="c20241231"
      decimals="-3"
      id="Fact_41bce7587c99405abc3f4b957d347ea2"
      unitRef="U001">547000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="c20251231"
      decimals="-3"
      id="Fact_969ae03f3554402abff12674573dca08"
      unitRef="U001">1451000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="c20241231"
      decimals="-3"
      id="Fact_f81733933e814a6abf1c69728e042061"
      unitRef="U001">9582000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther
      contextRef="c20251231"
      decimals="-3"
      id="Fact_310487748919426fba98453a158d0afd"
      unitRef="U001">4000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther
      contextRef="c20241231"
      decimals="-3"
      id="Fact_bb9c53765add4cb5ba9b58d63b0ef06f"
      unitRef="U001">5000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="c20251231"
      decimals="-3"
      id="Fact_8336ae5e03184c6eb03e9602addc11b6"
      unitRef="U001">329000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="c20241231"
      decimals="-3"
      id="Fact_61637bef906a4658a5658f23be8ac727"
      unitRef="U001">77000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="c20251231"
      decimals="-3"
      id="Fact_a60aaa9a4dd7473f861c673dae8e184e"
      unitRef="U001">1937000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="c20241231"
      decimals="-3"
      id="Fact_2b99daf689fb452e933fbd87d43a8563"
      unitRef="U001">2035000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <ird:DeferredTaxAssetsResearchAndDevelopment
      contextRef="c20251231"
      decimals="-3"
      id="Fact_4a20b6f5a68d4a03b35e2a404e293960"
      unitRef="U001">2911000</ird:DeferredTaxAssetsResearchAndDevelopment>
    <ird:DeferredTaxAssetsResearchAndDevelopment
      contextRef="c20241231"
      decimals="-3"
      id="Fact_d1bf99af86f9482b85ea89aa10727bb2"
      unitRef="U001">2089000</ird:DeferredTaxAssetsResearchAndDevelopment>
    <ird:DeferredTaxAssetsTransactionCostsAssociatedWithAssetAcquisition
      contextRef="c20251231"
      decimals="-3"
      id="Fact_4838190c0afa4112becfb8f8761d588d"
      unitRef="U001">663000</ird:DeferredTaxAssetsTransactionCostsAssociatedWithAssetAcquisition>
    <ird:DeferredTaxAssetsTransactionCostsAssociatedWithAssetAcquisition
      contextRef="c20241231"
      decimals="-3"
      id="Fact_08ac08da56d24ee9a2ce096e01409774"
      unitRef="U001">753000</ird:DeferredTaxAssetsTransactionCostsAssociatedWithAssetAcquisition>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="c20251231"
      decimals="-3"
      id="Fact_baf0f1a7979f4a3f9db293cc39c442b5"
      unitRef="U001">40027000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="c20241231"
      decimals="-3"
      id="Fact_f146b0ddb32d4fed9e8e26c678cb8112"
      unitRef="U001">35430000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c20251231"
      decimals="-3"
      id="Fact_0964e46b64524eaeabd107301a72a941"
      unitRef="U001">39997000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c20241231"
      decimals="-3"
      id="Fact_4cf342845aa74e99a8680ff19a47debb"
      unitRef="U001">35403000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c20251231"
      decimals="-3"
      id="Fact_79b4ec68e9da463e8f73bee09de073ff"
      unitRef="U001">30000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c20241231"
      decimals="-3"
      id="Fact_a8f97f826ba24b0f91abd87112b1a23d"
      unitRef="U001">27000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="c20251231"
      decimals="-3"
      id="Fact_20f9954941c643ec96c7b7351a180d91"
      unitRef="U001">30000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="c20241231"
      decimals="-3"
      id="Fact_79a6ef20510d4461912e9eb2b9dfa4a2"
      unitRef="U001">27000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="c20251231"
      decimals="-3"
      id="Fact_76eafd1c241e43b480b2ba3d2c803cbf"
      unitRef="U001">30000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="c20241231"
      decimals="-3"
      id="Fact_3efa144f5fe44db89a2500e8bc844e57"
      unitRef="U001">27000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c20251231"
      decimals="-3"
      id="Fact_4d29cb07e04b435dbd149b4209aaaa43"
      unitRef="U001">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c20241231"
      decimals="-3"
      id="Fact_26348c687a70431dbfae734026c597e7"
      unitRef="U001">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="c20251231"
      decimals="-5"
      id="Fact_d46efced64ff45f89e4d57bad54834e3"
      unitRef="U001">40000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="c20241231"
      decimals="-5"
      id="Fact_8c0fdf132b2c47a6894a6081b63a4321"
      unitRef="U001">35400000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c20251231"
      decimals="-5"
      id="Fact_fff6ab95638e40ca92264b11e4544c8f"
      unitRef="U001">40000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c20241231"
      decimals="-5"
      id="Fact_2910c73d5b0b42389446d0b8102d3b88"
      unitRef="U001">35400000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20251231"
      decimals="-5"
      id="Fact_2a3ed2ed82de4ce2a45db7670e93dde8"
      unitRef="U001">31500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20241231"
      decimals="-5"
      id="Fact_faab48f8d49841d1966ed8c57b6074e9"
      unitRef="U001">17100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="c20251231"
      decimals="-5"
      id="Fact_a4353e86b96d407283f061c93a2c1e22"
      unitRef="U001">2900000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="c20241231"
      decimals="-5"
      id="Fact_241d9808b3a34bb2b7ef1e96ffc96a9c"
      unitRef="U001">2100000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="c20251231"
      decimals="-5"
      id="Fact_1bf8b008ea554476b02fac54fec1569e"
      unitRef="U001">700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="c20241231"
      decimals="-5"
      id="Fact_77a08cff72b540378997902b7b9f607b"
      unitRef="U001">3300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <ird:DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal
      contextRef="c20251231"
      decimals="-6"
      id="Fact_8d6b61a4dd0647b290c7dd5ada740374"
      unitRef="U001">0</ird:DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal>
    <ird:DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal
      contextRef="c20241231"
      decimals="-6"
      id="Fact_6886569db375432294199cfe9c6aab5f"
      unitRef="U001">0</ird:DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal>
    <ird:StateAndLocalOperatingLossCarryforwardsTaxEffect
      contextRef="c20240101to20241231"
      decimals="-6"
      id="Fact_7144de81d2bc4d7fa6a7b19429aa23e2"
      unitRef="U001">0</ird:StateAndLocalOperatingLossCarryforwardsTaxEffect>
    <ird:UtilizedFederalResearchCreditCarryforwards
      contextRef="c20240101to20241231"
      decimals="-6"
      id="Fact_3407264d9ed843c6b56b8720b85b8c90"
      unitRef="U001">0</ird:UtilizedFederalResearchCreditCarryforwards>
    <ird:FederalOperatingLossCarryforwardsTaxEffect
      contextRef="c20240101to20241231"
      decimals="-6"
      id="Fact_df1cf253c238480d84d4333a3ce6e380"
      unitRef="U001">0</ird:FederalOperatingLossCarryforwardsTaxEffect>
    <ird:FederalOperatingLossCarryforwardsTaxEffect
      contextRef="c20250101to20251231"
      decimals="-6"
      id="Fact_c444c291f98b4497aa0a2166383d4da3"
      unitRef="U001">0</ird:FederalOperatingLossCarryforwardsTaxEffect>
    <ird:StateAndLocalOperatingLossCarryforwardsTaxEffect
      contextRef="c20250101to20251231"
      decimals="-6"
      id="Fact_b36677f0f0214403b2aba1221670d081"
      unitRef="U001">0</ird:StateAndLocalOperatingLossCarryforwardsTaxEffect>
    <ird:UtilizedFederalResearchCreditCarryforwards
      contextRef="c20250101to20251231"
      decimals="-6"
      id="Fact_455acface53d4b3fb2f267523fd8835b"
      unitRef="U001">0</ird:UtilizedFederalResearchCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="c20251231_BusinessAcquisitionAxis_OpusGeneticsIncMember"
      decimals="-5"
      id="Fact_ce1a786f3ae84f3d9767781f40865fe2"
      unitRef="U001">5800000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="c20251231_BusinessAcquisitionAxis_OpusGeneticsIncMember"
      decimals="-5"
      id="Fact_763a8d2e704c4ebb8984e4cb73dda1f4"
      unitRef="U001">5800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="c20251231_BusinessAcquisitionAxis_RexahnStockholdersMember"
      decimals="-5"
      id="Fact_5bb2a08d16e44d428a5f8bdbb55bc021"
      unitRef="U001">10300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="c20251231_BusinessAcquisitionAxis_RexahnStockholdersMember"
      decimals="-5"
      id="Fact_42abf77cec904272acee2c76248b1ae7"
      unitRef="U001">10300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="c20251231"
      decimals="-6"
      id="Fact_92bbedd7c8ab497cbb0db287d0896a39"
      unitRef="U001">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="c20241231"
      decimals="-6"
      id="Fact_1dd73397d7fb4c6f9d40a71d17729f7c"
      unitRef="U001">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="c20250101to20251231"
      decimals="-6"
      id="Fact_ef2656ad82484f909a7f809eeb921ac2"
      unitRef="U001">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="c20240101to20241231"
      decimals="-6"
      id="Fact_145c91ef9bb84be585a62d79bac29c45"
      unitRef="U001">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="c20250101to20251231"
      id="Text_36390a6c84034e2598bd59693969b64d">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman';"&gt;13.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold; font-family: 'Times New Roman';"&gt;Deferred Compensation Plan &lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Effective October 1, 2021, the Company began offering a 401(k) plan (&#x201c;401K Plan&#x201d;) to its employees.
          All employees are eligible to participate in the 401K Plan. The Company makes matching contributions equal to 100% on the first 3% of compensation that is deferred as an elective deferral and an additional 50% on the next 2% of compensation. The Company&#x2019;s matching contributions are
          made on a monthly basis. During each of the years ended December 31, 2025 and 2024, the Company contributed $0.2 million&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt; to the 401K Plan&lt;/span&gt;.&lt;/span&gt;&lt;/div&gt;
</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="c20211001to20211001_RetirementPlanNameAxis_RetirementPlan401KMember"
      decimals="2"
      id="Fact_3f9cae4e3f3d41e2ae0181933faa1702"
      unitRef="U006">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="c20211001to20211001_RetirementPlanNameAxis_RetirementPlan401KMember"
      decimals="2"
      id="Fact_e0610052319741788f573631946a3d69"
      unitRef="U006">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <ird:DefinedContributionPlanAdditionalEmployerMatchingContribution
      contextRef="c20211001to20211001_RetirementPlanNameAxis_RetirementPlan401KMember"
      decimals="2"
      id="Fact_b19460f63717407fa8169e85877f817f"
      unitRef="U006">0.50</ird:DefinedContributionPlanAdditionalEmployerMatchingContribution>
    <ird:DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred
      contextRef="c20211001to20211001_RetirementPlanNameAxis_RetirementPlan401KMember"
      decimals="2"
      id="Fact_b559d9382e9e4dfca21c6760d6956c1c"
      unitRef="U006">0.02</ird:DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="c20250101to20251231_RetirementPlanNameAxis_RetirementPlan401KMember"
      decimals="-5"
      id="Fact_b0e5286f63c047cb886bbef9f8144507"
      unitRef="U001">200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="c20240101to20241231_RetirementPlanNameAxis_RetirementPlan401KMember"
      decimals="-5"
      id="Fact_3b51168ebb8a4fea90a2db5984cc9766"
      unitRef="U001">200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="c20250101to20251231"
      id="Text_411ca018a91c4245a96f252c899815ab">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold;"&gt;14.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold;"&gt;Subsequent Events&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160; &lt;/div&gt;

&lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;ATM&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Subsequent to December 31, 2025, 1,000,000 shares of common stock were sold under the Leerink ATM for gross proceeds through March 12, 2026 in the amount of $2.3 million, before deducting issuance expenses, including the placement agent&#x2019;s fees, in the amount of $0.1 million.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-style: italic;"&gt;February Private
              Placement&lt;/span&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-style: italic;"&gt; &lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-style: italic;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; On February 13, 2026, the Company
                entered into a securities purchase agreement for a private placement (the &#x201c;February 2026 Private Placement&#x201d;) of 7,374,632 shares
                of Series B Non-Voting Convertible Preferred Stock at a price of $3.39 per share for gross proceeds of $25.0 million, before deducting offering expenses. The private placement closed on February 18, 2026.&lt;/span&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-style: italic;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
              &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-style: italic;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; Subject to Opus Genetics stockholder approval of an increase to the
                  authorized shares of common stock, each share of Series B Non-Voting Convertible Preferred Stock will automatically convert into one
                  share of common stock for an aggregate of 7,374,632 shares of common stock.&lt;/span&gt;&lt;br/&gt;
              &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20260312to20260312_SubsequentEventTypeAxis_SubsequentEventMember_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember"
      decimals="0"
      id="Fact_93a252b22cd6421c98ae999b855033fe"
      unitRef="U002">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20260312to20260312_SubsequentEventTypeAxis_SubsequentEventMember_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember"
      decimals="-5"
      id="Fact_402b6c0d42b6422ca2792c4a2a2d55e9"
      unitRef="U001">2300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c20260312to20260312_SubsequentEventTypeAxis_SubsequentEventMember_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember"
      decimals="-5"
      id="Fact_477b705c9f4f487dacd45322cdad125c"
      unitRef="U001">100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c20260213_StatementClassOfStockAxis_SeriesBPreferredStockMember_SubsequentEventTypeAxis_SubsequentEventMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember"
      decimals="0"
      id="Fact_801e5a4004b54ceaac83cae5be8f8842"
      unitRef="U002">7374632</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c20260213_StatementClassOfStockAxis_SeriesBPreferredStockMember_SubsequentEventTypeAxis_SubsequentEventMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember"
      decimals="INF"
      id="Fact_a2969fab0c7243308bac0cd9fbc5a8cd"
      unitRef="U003">3.39</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20260213to20260213_SubsequentEventTypeAxis_SubsequentEventMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember"
      decimals="-5"
      id="Fact_b04d541b03854169b0096ac2d4012b61"
      unitRef="U001">25000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="c20260213_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="INF"
      id="Fact_74ddd0e4574a4134bdc06da8063de41d"
      unitRef="U002">1</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c20260213_StatementClassOfStockAxis_SeriesBPreferredStockMember_SubsequentEventTypeAxis_SubsequentEventMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember"
      decimals="0"
      id="Fact_8af17046a6474aefaa51d8a235130711"
      unitRef="U002">7374632</us-gaap:PreferredStockConvertibleSharesIssuable>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_f72509ad03ba414e9c65925a2c57ac3a"
          xlink:label="Fact_f72509ad03ba414e9c65925a2c57ac3a"
          xlink:type="locator"/>
        <link:footnote id="Foot_0ef3900c983b49a0a876b9990141211c" xlink:label="Foot_0ef3900c983b49a0a876b9990141211c" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="-sec-ix-hidden:Fact_61ebfbf864f6406981d1e8914baf9657">North Carolina</xhtml:span> makes up the majority (greater than 50%) of the state income tax expense, net of federal income tax effect category.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_f72509ad03ba414e9c65925a2c57ac3a"
          xlink:to="Foot_0ef3900c983b49a0a876b9990141211c"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_b428d88dd24640e09bb40a663afe7d7d"
          xlink:label="Fact_b428d88dd24640e09bb40a663afe7d7d"
          xlink:type="locator"/>
        <link:footnote id="Foot_b060c1ad19c34ed89e1bcfe2db363855" xlink:label="Foot_b060c1ad19c34ed89e1bcfe2db363855" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The aggregate intrinsic value is
                  calculated as the difference between the exercise price of the underlying options and the fair value of our common stock as of December 31, 2025 and 2024 of $2.01 and $1.19 per share, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_b428d88dd24640e09bb40a663afe7d7d"
          xlink:to="Foot_b060c1ad19c34ed89e1bcfe2db363855"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_38c81e4990a94156858e130260ae4948"
          xlink:label="Fact_38c81e4990a94156858e130260ae4948"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_38c81e4990a94156858e130260ae4948"
          xlink:to="Foot_b060c1ad19c34ed89e1bcfe2db363855"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_134673f957c0436992877793f9eafd17"
          xlink:label="Fact_134673f957c0436992877793f9eafd17"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_134673f957c0436992877793f9eafd17"
          xlink:to="Foot_b060c1ad19c34ed89e1bcfe2db363855"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_4dc0d98159294a779910279124bb54a7"
          xlink:label="Fact_4dc0d98159294a779910279124bb54a7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_4dc0d98159294a779910279124bb54a7"
          xlink:to="Foot_b060c1ad19c34ed89e1bcfe2db363855"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_d9409eb5551b44ada39a396a96ab2c8d"
          xlink:label="Fact_d9409eb5551b44ada39a396a96ab2c8d"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_d9409eb5551b44ada39a396a96ab2c8d"
          xlink:to="Foot_b060c1ad19c34ed89e1bcfe2db363855"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_9e00fa25816b49b3b3a94f5ba3c78eaa"
          xlink:label="Fact_9e00fa25816b49b3b3a94f5ba3c78eaa"
          xlink:type="locator"/>
        <link:footnote id="Foot_1d12e29108a345178acfdb768770a45d" xlink:label="Foot_1d12e29108a345178acfdb768770a45d" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">De minimis value</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_9e00fa25816b49b3b3a94f5ba3c78eaa"
          xlink:to="Foot_1d12e29108a345178acfdb768770a45d"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_9e4a671901244d3dbc772db49292d188"
          xlink:label="Fact_9e4a671901244d3dbc772db49292d188"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_9e4a671901244d3dbc772db49292d188"
          xlink:to="Foot_1d12e29108a345178acfdb768770a45d"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_57024ca792b84d5695790322cb307405"
          xlink:label="Fact_57024ca792b84d5695790322cb307405"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_57024ca792b84d5695790322cb307405"
          xlink:to="Foot_1d12e29108a345178acfdb768770a45d"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50fabaf66e0b4b968d0afc4baef8fade"
          xlink:label="Fact_50fabaf66e0b4b968d0afc4baef8fade"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50fabaf66e0b4b968d0afc4baef8fade"
          xlink:to="Foot_1d12e29108a345178acfdb768770a45d"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_834b0fc015cb442180a8d6a9001f9919"
          xlink:label="Fact_834b0fc015cb442180a8d6a9001f9919"
          xlink:type="locator"/>
        <link:footnote id="Foot_d53016f568214dd6ac1ad20791226369" xlink:label="Foot_d53016f568214dd6ac1ad20791226369" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Based on the last reported sale price of the Company&#x2019;s common stock on the Nasdaq Capital Market on October 22, 2024, the
                            closing date of the Opus Acquisition.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_834b0fc015cb442180a8d6a9001f9919"
          xlink:to="Foot_d53016f568214dd6ac1ad20791226369"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_3cd30ebd31c04e40b9691b3eff5105b8"
          xlink:label="Fact_3cd30ebd31c04e40b9691b3eff5105b8"
          xlink:type="locator"/>
        <link:footnote id="Foot_249693f9b70b48eeaedd46db4d2175b1" xlink:label="Foot_249693f9b70b48eeaedd46db4d2175b1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Based on the fair market valuation of the Series A preferred stock that considered the reported sale price of the Company&#x2019;s
                          common stock on the Nasdaq Capital Market on October 22, 2024 on an as converted basis (1,000 shares of common stock
                          for 1 share of preferred stock), the closing date of the Opus Acquisition, as well as the underlying dividend
                          provisions on a discounted cash flow basis.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_3cd30ebd31c04e40b9691b3eff5105b8"
          xlink:to="Foot_249693f9b70b48eeaedd46db4d2175b1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_876b3eb4978b497091cb6aa51397b83e"
          xlink:label="Fact_876b3eb4978b497091cb6aa51397b83e"
          xlink:type="locator"/>
        <link:footnote id="Foot_de76ad53bfb14be28fb1dc9857de2c11" xlink:label="Foot_de76ad53bfb14be28fb1dc9857de2c11" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; font-family: 'Times New Roman';">Represents the Private Opus Acquisition research and development projects which were in-process, but not yet completed, and which the Company may advance post the Opus
                              Acquisition. This includes the development of gene therapies for IRDs.&#160;Current accounting standards require that the fair value of IPR&amp;D projects acquired in an asset acquisition with no alternative future use be charged
                              to expense on the acquisition date. The acquired IPR&amp;D did not have outputs or employees. The fair value of the<xhtml:span style="letter-spacing: normal; text-align: left; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> IPR&amp;D was recorded at fair value using Level 3 inputs. A Multi-Period Excess Earnings Method (&#x201c;MPEEM&#x201d;)
                                model was applied which incorporates assumptions such as future earnings and margins in connection with the further development and commercialization of IRD therapies, and a discount rate of <xhtml:span style="text-indent: 0pt;">20</xhtml:span>%.</xhtml:span></xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_876b3eb4978b497091cb6aa51397b83e"
          xlink:to="Foot_de76ad53bfb14be28fb1dc9857de2c11"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_6fa2d48410b74f7cbd3d5483b0fbf22a"
          xlink:label="Fact_6fa2d48410b74f7cbd3d5483b0fbf22a"
          xlink:type="locator"/>
        <link:footnote id="Foot_2c2f62030bbf4953aac6de2cd10a3f19" xlink:label="Foot_2c2f62030bbf4953aac6de2cd10a3f19" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">L<xhtml:span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">iability classified warrants in connection with March 2025 Financings</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_6fa2d48410b74f7cbd3d5483b0fbf22a"
          xlink:to="Foot_2c2f62030bbf4953aac6de2cd10a3f19"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_cc8bdc979116461e84d809f215cb903f"
          xlink:label="Fact_cc8bdc979116461e84d809f215cb903f"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_cc8bdc979116461e84d809f215cb903f"
          xlink:to="Foot_2c2f62030bbf4953aac6de2cd10a3f19"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
